100070	AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1
100100	PRUNE BELLY SYNDROME; PBS
100300	ADAMS-OLIVER SYNDROME 1; AOS1
100650	ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2
100800	ACHONDROPLASIA; ACH
101000	NEUROFIBROMATOSIS, TYPE II; NF2
101200	APERT SYNDROME
101400	SAETHRE-CHOTZEN SYNDROME; SCS
101600	PFEIFFER SYNDROME
101800	ACRODYSOSTOSIS 1 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS1
101850	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE III; PPKP3
101900	ACROKERATOSIS VERRUCIFORMIS; AKV
102000	ACROLEUKOPATHY, SYMMETRIC
102200	PITUITARY ADENOMA 1, MULTIPLE TYPES; PITA1
102300	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 1; RLS1
102370	ACROMICRIC DYSPLASIA; ACMICD
102480	ACROSIN; ACR
102500	HAJDU-CHENEY SYNDROME; HJCYS
102510	ACROPECTOROVERTEBRAL DYSPLASIA; ACRPV
102530	SPERMATOGENIC FAILURE 6; SPGF6
102565	FILAMIN C; FLNC
102578	ACUTE PROMYELOCYTIC LEUKEMIA, INDUCER OF; PML
102700	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY
102900	ADENOSINE TRIPHOSPHATE, ELEVATED, OF ERYTHROCYTES
103050	ADENYLOSUCCINASE DEFICIENCY; ADSLD
103285	ADULT SYNDROME
103470	ALBINISM, OCULAR, WITH SENSORINEURAL DEAFNESS
103500	TIETZ ALBINISM-DEAFNESS SYNDROME; TADS
103580	PSEUDOHYPOPARATHYROIDISM, TYPE IA; PHP1A
103780	ALCOHOL DEPENDENCE
103900	HYPERALDOSTERONISM, FAMILIAL, TYPE I; HALD1
104000	ALOPECIA AREATA 1; AA1
104100	PALMOPLANTAR KERATODERMA AND CONGENITAL ALOPECIA 1; PPKCA1
104200	ALPORT SYNDROME, AUTOSOMAL DOMINANT
104250	ALPHA-2C-ADRENERGIC RECEPTOR; ADRA2C
104290	ALTERNATING HEMIPLEGIA OF CHILDHOOD 1; AHC1
104300	ALZHEIMER DISEASE; AD
104310	ALZHEIMER DISEASE 2; AD2
104500	AMELOGENESIS IMPERFECTA, TYPE IB; AI1B
104510	AMELOGENESIS IMPERFECTA, TYPE IV; AI4
104530	AMELOGENESIS IMPERFECTA, TYPE IA; AI1A
104770	AMYLOID P COMPONENT, SERUM; APCS
105120	AMYLOIDOSIS, FINNISH TYPE
105150	CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED
105200	AMYLOIDOSIS, FAMILIAL VISCERAL
105210	AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
105250	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1
105400	AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1
105500	AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1
105550	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1
105580	ANAL CANAL CARCINOMA
105600	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3
105650	DIAMOND-BLACKFAN ANEMIA 1; DBA1
105800	ANEURYSM, INTRACRANIAL BERRY, 1; ANIB1
105830	ANGELMAN SYNDROME; AS
106100	ANGIOEDEMA, HEREDITARY, TYPE I; HAE1
106150	ANGIOTENSINOGEN; AGT
106180	ANGIOTENSIN I-CONVERTING ENZYME; ACE
106190	ANHIDROSIS, ISOLATED, WITH NORMAL SWEAT GLANDS; ANHD
106210	ANIRIDIA 1; AN1
106260	ANKYLOBLEPHARON-ECTODERMAL DEFECTS-CLEFT LIP/PALATE
106300	SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1; SPDA1
106600	TOOTH AGENESIS, SELECTIVE, 1; STHAG1
106700	TOTAL ANOMALOUS PULMONARY VENOUS RETURN 1; TAPVR1
107200	ANOSMIA, ISOLATED CONGENITAL; ANIC
107250	ANTERIOR SEGMENT DYSGENESIS 1; ASGD1
107280	SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 3; SERPINA3
107320	ANTIPHOSPHOLIPID SYNDROME, FAMILIAL
107480	TOWNES-BROCKS SYNDROME 1; TBS1
107600	APLASIA CUTIS CONGENITA, NONSYNDROMIC; ACC
107670	APOLIPOPROTEIN A-II; APOA2
107680	APOLIPOPROTEIN A-I; APOA1
107970	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 1; ARVD1
108010	ARTERIOVENOUS MALFORMATIONS OF THE BRAIN
108120	ARTHROGRYPOSIS, DISTAL, TYPE 1A; DA1A
108145	ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5
108300	STICKLER SYNDROME, TYPE I; STL1
108420	SPERMATOGENIC FAILURE 2; SPGF2
108500	EPISODIC ATAXIA, TYPE 2; EA2
108600	SPASTIC ATAXIA 1, AUTOSOMAL DOMINANT; SPAX1
108720	ATELOSTEOGENESIS, TYPE I; AO1
108721	ATELOSTEOGENESIS, TYPE III; AO3
108725	ATHEROSCLEROSIS SUSCEPTIBILITY; ATHS
108770	ATRIAL STANDSTILL 1; ATRST1
108800	ATRIAL SEPTAL DEFECT 1; ASD1
108900	ATRIAL SEPTAL DEFECT 7 WITH OR WITHOUT ATRIOVENTRICULAR CONDUCTION DEFECTS; ASD7
108962	NATRIURETIC PEPTIDE RECEPTOR C; NPR3
108985	SVEINSSON CHORIORETINAL ATROPHY; SCRA
109150	MACHADO-JOSEPH DISEASE; MJD
109200	ALOPECIA, ANDROGENETIC, 1; AGA1
109350	GASTROESOPHAGEAL REFLUX; GER
109400	BASAL CELL NEVUS SYNDROME; BCNS
109543	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2
109560	B-CELL LEUKEMIA/LYMPHOMA 3; BCL3
109565	B-CELL LYMPHOMA 6; BCL6
109630	BETA-1-ADRENERGIC RECEPTOR; ADRB1
109690	BETA-2-ADRENERGIC RECEPTOR; ADRB2
109720	BILIARY CIRRHOSIS, PRIMARY, 1; PBC1
109730	AORTIC VALVE DISEASE 1; AOVD1
109800	BLADDER CANCER
110100	BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPES
110450	BLOOD GROUP, COLTON SYSTEM; CO
110500	BLOOD GROUP, DIEGO SYSTEM; DI
110700	BLOOD GROUP, DUFFY SYSTEM; FY
110800	BLOOD GROUP, I SYSTEM; Ii
110900	BLOOD GROUP--KELL SYSTEM; KEL
111100	FUCOSYLTRANSFERASE 3; FUT3
111150	BLOOD GROUP--LUTHERAN INHIBITOR; INLU
111200	BLOOD GROUP--LUTHERAN SYSTEM; LU
111250	BLOOD GROUP SYSTEM, LANDSTEINER-WIENER; LW
111300	BLOOD GROUP, MN; MN
111380	BLOOD GROUP--OK; OK
111400	BLOOD GROUP, P1PK SYSTEM
111600	BLOOD GROUP, LANGEREIS SYSTEM; LAN
111620	RADIN BLOOD GROUP ANTIGEN; RD
111700	RHESUS BLOOD GROUP, CcEe ANTIGENS; RHCE
111740	BLOOD GROUP, Ss; Ss
111750	BLOOD GROUP--SCIANNA SYSTEM; SC
112010	BLOOD GROUP--WALDNER TYPE; WD
112050	BLOOD GROUP--WRIGHT ANTIGEN; WR
112100	YT BLOOD GROUP ANTIGEN
112240	COLE-CARPENTER SYNDROME 1; CLCRP1
112250	DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS HISTIOCYTOMA; DMSMFH
112310	BOOMERANG DYSPLASIA
112410	HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB
112500	BRACHYDACTYLY, TYPE A1; BDA1
112600	BRACHYDACTYLY, TYPE A2; BDA2
113000	BRACHYDACTYLY, TYPE B1; BDB1
113100	BRACHYDACTYLY, TYPE C; BDC
113200	BRACHYDACTYLY, TYPE D; BDD
113300	BRACHYDACTYLY, TYPE E1; BDE1
113500	BRACHYOLMIA TYPE 3; BCYM3
113520	BRANCHED-CHAIN AMINOTRANSFERASE 1; BCAT1
113530	BRANCHED-CHAIN AMINOTRANSFERASE 2; BCAT2
113620	BRANCHIOOCULOFACIAL SYNDROME; BOFS
113650	BRANCHIOOTORENAL SYNDROME 1; BOR1
113750	ALBINISM, OCULOCUTANEOUS, TYPE VI; OCA6
113800	EPIDERMOLYTIC HYPERKERATOSIS; EHK
113900	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A
113970	BURKITT LYMPHOMA; BL
114000	CAFFEY DISEASE
114200	CAMPTODACTYLY 1; CAMPD1
114290	CAMPOMELIC DYSPLASIA
114300	ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3
114480	BREAST CANCER
114500	COLORECTAL CANCER; CRC
114550	HEPATOCELLULAR CARCINOMA
114580	CANDIDIASIS, FAMILIAL, 1; CANDF1
115080	CARDIAC CONDUCTION DEFECT
115150	CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1
115195	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 2; CMH2
115196	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 3; CMH3
115197	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4; CMH4
115200	CARDIOMYOPATHY, DILATED, 1A; CMD1A
115210	CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 1; RCM1
115300	HYPERCAROTENEMIA AND VITAMIN A DEFICIENCY, AUTOSOMAL DOMINANT; HCVAD
115310	PARAGANGLIOMAS 4; PGL4
115430	CARPAL TUNNEL SYNDROME; CTS1
115470	CAT EYE SYNDROME; CES
115650	CATARACT 32, MULTIPLE TYPES; CTRCT32
115660	CATARACT 7; CTRCT7
115665	CATARACT 8, MULTIPLE TYPES; CTRCT8
115700	CATARACT 4, MULTIPLE TYPES; CTRCT4
115800	CATARACT 29; CTRCT29
115900	CATARACT 42; CTRCT42
116100	CATARACT 20, MULTIPLE TYPES; CTRCT20
116200	CATARACT 1, MULTIPLE TYPES; CTRCT1
116300	CATARACT 30, MULTIPLE TYPES; CTRCT30
116400	CATARACT 41; CTRCT41
116600	CATARACT 6, MULTIPLE TYPES; CTRCT6
116700	CATARACT 13 WITH ADULT i PHENOTYPE; CTRCT13
116800	CATARACT 5, MULTIPLE TYPES; CTRCT5
116860	CEREBRAL CAVERNOUS MALFORMATIONS; CCM
116920	LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD
117000	CENTRAL CORE DISEASE OF MUSCLE; CCD
117100	CENTRALOPATHIC EPILEPSY
117210	SPINOCEREBELLAR ATAXIA 31; SCA31
117300	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2
117360	SPINOCEREBELLAR ATAXIA 29; SCA29
117550	SOTOS SYNDROME 1; SOTOS1
117650	CEREBROCOSTOMANDIBULAR SYNDROME; CCMS
117800	APOCRINE GLAND SECRETION, VARIATION IN
118100	KLIPPEL-FEIL SYNDROME 1, AUTOSOMAL DOMINANT; KFS1
118200	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B
118210	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1
118220	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A
118300	CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS
118400	CHERUBISM
118425	CHLORIDE CHANNEL 1, SKELETAL MUSCLE; CLCN1
118450	ALAGILLE SYNDROME 1; ALGS1
118600	CHONDROCALCINOSIS 2; CCAL2
118700	CHOREA, BENIGN HEREDITARY; BHC
118800	PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1
119100	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1
119300	VAN DER WOUDE SYNDROME 1; VWS1
119500	POPLITEAL PTERYGIUM SYNDROME; PPS
119530	OROFACIAL CLEFT 1; OFC1
119540	CLEFT PALATE, ISOLATED; CPI
119580	BLEPHAROCHEILODONTIC SYNDROME 1; BCDS1
119600	CLEIDOCRANIAL DYSPLASIA; CCD
119800	CLUBFOOT, CONGENITAL, WITH OR WITHOUT DEFICIENCY OF LONG BONES AND/OR MIRROR-IMAGE POLYDACTYLY; CCF
119900	DIGITAL CLUBBING, ISOLATED CONGENITAL
120080	COLCHICINE RESISTANCE
120100	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1
120120	COLLAGEN, TYPE VII, ALPHA-1; COL7A1
120131	COLLAGEN, TYPE IV, ALPHA-4; COL4A4
120140	COLLAGEN, TYPE II, ALPHA-1; COL2A1
120200	COLOBOMA, OCULAR, AUTOSOMAL DOMINANT
120330	PAPILLORENAL SYNDROME; PAPRS
120430	COLOBOMA OF OPTIC NERVE
120433	COLOBOMA, OCULAR, WITH OR WITHOUT HEARING IMPAIRMENT, CLEFT LIP/PALATE, AND/OR MENTAL RETARDATION; COB1
120435	LYNCH SYNDROME I
120502	BRANCHIOOTIC SYNDROME 2
120620	COMPLEMENT COMPONENT RECEPTOR 1; CR1
120790	COMPLEMENT COMPONENT 4, PARTIAL DEFICIENCY OF
120970	CONE-ROD DYSTROPHY 2; CORD2
121050	ARTHROGRYPOSIS, DISTAL, TYPE 9; DA9
121200	SEIZURES, BENIGN FAMILIAL NEONATAL, 1; BFNS1
121201	SEIZURES, BENIGN FAMILIAL NEONATAL, 2; BFNS2
121210	FEBRILE SEIZURES, FAMILIAL, 1; FEB1
121300	COPROPORPHYRIA, HEREDITARY; HCP
121400	CORNEA PLANA 1, AUTOSOMAL DOMINANT; CNA1
121800	SCHNYDER CORNEAL DYSTROPHY; SCCD
121820	CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD
121850	CORNEAL DYSTROPHY, FLECK
121900	CORNEAL DYSTROPHY, GROENOUW TYPE I; CDGG1
122000	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 1; PPCD1
122100	CORNEAL DYSTROPHY, MEESMANN; MECD
122200	CORNEAL DYSTROPHY, LATTICE TYPE I; LCD1
122400	EPITHELIAL RECURRENT EROSION DYSTROPHY; ERED
122470	CORNELIA DE LANGE SYNDROME 1; CDLS1
122600	SPONDYLOCOSTAL DYSOSTOSIS 5; SCDO5
122700	COUMARIN RESISTANCE
122860	CRANIODIAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CDD
122880	CRANIOFACIAL-DEAFNESS-HAND SYNDROME; CDHS
123000	CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CMDD
123100	CRANIOSYNOSTOSIS 1; CRS1
123150	JACKSON-WEISS SYNDROME; JWS
123155	HYDROCEPHALUS, AUTOSOMAL DOMINANT; HDCPH1
123270	CREATINE KINASE, BRAIN TYPE, ECTOPIC EXPRESSION OF; CKBE
123320	CREATINE PHOSPHOKINASE, ELEVATED SERUM
123400	CREUTZFELDT-JAKOB DISEASE; CJD
123500	CROUZON SYNDROME
123700	CUTIS LAXA, AUTOSOMAL DOMINANT 1; ADCL1
123790	BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS
124000	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 1; MC3DN1
124080	CYTOCHROME P450, SUBFAMILY XIB, POLYPEPTIDE 2; CYP11B2
124200	DARIER-WHITE DISEASE; DAR
124480	DEAFNESS, CONGENITAL, WITH ONYCHODYSTROPHY, AUTOSOMAL DOMINANT; DDOD
124500	VOHWINKEL SYNDROME; VOWNKL
124900	DEAFNESS, AUTOSOMAL DOMINANT 1; DFNA1
125250	OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY
125264	DEK ONCOGENE; DEK
125310	CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY, TYPE 1; CADASIL1
125350	FAILURE OF TOOTH ERUPTION, PRIMARY; PFE
125370	DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA
125400	DENTIN DYSPLASIA, TYPE I; DTDP1
125420	DENTIN DYSPLASIA, TYPE II; DTDP2
125480	MAJOR AFFECTIVE DISORDER 1; MAFD1
125490	DENTINOGENESIS IMPERFECTA 1; DGI1
125500	DENTINOGENESIS IMPERFECTA, SHIELDS TYPE III
125520	CAYLER CARDIOFACIAL SYNDROME
125595	DERMATOPATHIA PIGMENTOSA RETICULARIS; DPR
125630	VIBRATORY URTICARIA; VBU
125700	DIABETES INSIPIDUS, NEUROHYPOPHYSEAL
125800	DIABETES INSIPIDUS, NEPHROGENIC, AUTOSOMAL
125850	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY1
125851	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 2; MODY2
125852	DIABETES MELLITUS, INSULIN-DEPENDENT, 2
125853	DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM
125860	NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1
126150	HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HBEGF
126200	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS
126420	TOPOISOMERASE, DNA, I; TOP1
126430	TOPOISOMERASE, DNA, II, ALPHA; TOP2A
126452	DOPAMINE RECEPTOR D4; DRD4
126600	DOYNE HONEYCOMB RETINAL DYSTROPHY; DHRD
126700	BASAL LAMINAR DRUSEN
126800	DUANE RETRACTION SYNDROME 1; DURS1
126900	DUPUYTREN CONTRACTURE
127000	KENNY-CAFFEY SYNDROME, TYPE 2; KCS2
127300	LERI-WEILL DYSCHONDROSTEOSIS; LWD
127400	DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH
127500	DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 1; DUH1
127550	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1; DKCA1
127600	DYSKERATOSIS, HEREDITARY BENIGN INTRAEPITHELIAL; HBID
127700	DYSLEXIA, SUSCEPTIBILITY TO, 1; DYX1
127750	DEMENTIA, LEWY BODY; DLB
128100	DYSTONIA 1, TORSION, AUTOSOMAL DOMINANT; DYT1
128101	DYSTONIA 4, TORSION, AUTOSOMAL DOMINANT; DYT4
128200	EPISODIC KINESIGENIC DYSKINESIA 1; EKD1
128230	DYSTONIA, DOPA-RESPONSIVE; DRD
128235	DYSTONIA 12; DYT12
128700	PREAURICULAR FISTULAE, CONGENITAL
129200	BASAN SYNDROME
129400	RAPP-HODGKIN SYNDROME; RHS
129490	ECTODERMAL DYSPLASIA 10A, HYPOHIDROTIC/HAIR/NAIL TYPE, AUTOSOMAL DOMINANT; ECTD10A
129500	CLOUSTON SYNDROME
129600	ECTOPIA LENTIS 1, ISOLATED, AUTOSOMAL DOMINANT; ECTOL1
129900	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1; EEC1
130000	EHLERS-DANLOS SYNDROME, CLASSIC TYPE, 1; EDSCL1
130010	EHLERS-DANLOS SYNDROME, CLASSIC TYPE, 2; EDSCL2
130050	EHLERS-DANLOS SYNDROME, VASCULAR TYPE; EDSVASC
130060	EHLERS-DANLOS SYNDROME, ARTHROCHALASIA TYPE, 1; EDSARTH1
130070	EHLERS-DANLOS SYNDROME, SPONDYLODYSPLASTIC TYPE, 1; EDSSPD1
130080	EHLERS-DANLOS SYNDROME, PERIODONTAL TYPE, 1; EDSPD1
130600	ELLIPTOCYTOSIS 2; EL2
130650	BECKWITH-WIEDEMANN SYNDROME; BWS
130720	LATERAL MENINGOCELE SYNDROME; LMNS
130900	AMELOGENESIS IMPERFECTA, TYPE IIIA; AI3A
131100	MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1
131200	ENDOMETRIOSIS, SUSCEPTIBILITY TO, 1
131240	ENDOTHELIN 1; EDN1
131300	CAMURATI-ENGELMANN DISEASE; CAEND
131400	EOSINOPHILIA, FAMILIAL
131440	MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA
131705	TRANSIENT BULLOUS DERMOLYSIS OF THE NEWBORN; TBDN
131750	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB
131760	EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA TYPE; EBSDM
131800	EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED
131850	EPIDERMOLYSIS BULLOSA DYSTROPHICA, PRETIBIAL
131900	EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED
131950	EPIDERMOLYSIS BULLOSA SIMPLEX, OGNA TYPE; EBSOG
131960	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MOTTLED PIGMENTATION; EBSMP
132000	EPIDERMOLYSIS BULLOSA WITH CONGENITAL LOCALIZED ABSENCE OF SKIN AND DEFORMITY OF NAILS
132100	PHOTOPAROXYSMAL RESPONSE 1; PPR1
132400	EPIPHYSEAL DYSPLASIA, MULTIPLE, 1; EDM1
132450	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH MYOPIA AND CONDUCTIVE DEAFNESS; EDMMD
132600	PILOMATRIXOMA
132700	CYLINDROMATOSIS, FAMILIAL
132800	MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO; MSSE
132900	AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4
133020	ERYTHERMALGIA, PRIMARY
133100	ERYTHROCYTOSIS, FAMILIAL, 1; ECYT1
133190	SPINOCEREBELLAR ATAXIA 34; SCA34
133200	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1; EKVP1
133239	ESOPHAGEAL CANCER
133430	ESTROGEN RECEPTOR 1; ESR1
133540	COCKAYNE SYNDROME B; CSB
133700	EXOSTOSES, MULTIPLE, TYPE I
133701	EXOSTOSES, MULTIPLE, TYPE II
133780	EXUDATIVE VITREORETINOPATHY 1; EVR1
134600	FANCONI RENOTUBULAR SYNDROME 1; FRTS1
134610	FAMILIAL MEDITERRANEAN FEVER, AUTOSOMAL DOMINANT
134637	FAS CELL SURFACE DEATH RECEPTOR; FAS
134935	FIBROBLAST GROWTH FACTOR RECEPTOR 4; FGFR4
135100	FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP
135150	BIRT-HOGG-DUBE SYNDROME; BHD
135290	DESMOID DISEASE, HEREDITARY
135300	FIBROMATOSIS, GINGIVAL, 1; GINGF1
135400	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA; HTC3
135500	ZIMMERMANN-LABAND SYNDROME 1; ZLS1
135700	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 1; CFEOM1
135750	LAURIN-SANDROW SYNDROME; LSS
135900	COFFIN-SIRIS SYNDROME 1; CSS1
136000	ADERMATOGLYPHIA; ADERM
136120	FISH-EYE DISEASE; FED
136140	FLOATING-HARBOR SYNDROME; FLHS
136520	FOVEAL HYPOPLASIA 1; FVH1
136550	MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1
136570	CHROMOSOME 16p12.1 DELETION SYNDROME, 520-KB
136630	MENTAL RETARDATION, FRA12A TYPE
136680	FRASIER SYNDROME
136760	FRONTONASAL DYSPLASIA 1; FND1
136800	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 1; FECD1
136880	FUNDUS ALBIPUNCTATUS
136900	SORSBY FUNDUS DYSTROPHY; SFD
137100	IMMUNOGLOBULIN A DEFICIENCY 1; IGAD1
137200	NEUROMYOTONIA AND AXONAL NEUROPATHY, AUTOSOMAL RECESSIVE; NMAN
137215	GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC
137241	GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GIPR
137245	LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TYPE
137440	GERSTMANN-STRAUSSLER DISEASE; GSD
137550	MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS
137580	GILLES DE LA TOURETTE SYNDROME; GTS
137600	ANTERIOR SEGMENT DYSGENESIS 4; ASGD4
137750	GLAUCOMA 1, OPEN ANGLE, A; GLC1A
137760	GLAUCOMA, PRIMARY OPEN ANGLE; POAG
137800	GLIOMA SUSCEPTIBILITY 1; GLM1
137920	RENAL CYSTS AND DIABETES SYNDROME; RCAD
137940	HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT SYNDROME; HLTRS
137950	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 1; GFND1
138000	GLOMUVENOUS MALFORMATIONS; GVM
138030	GLUCAGON; GCG
138300	GLUTATHIONE REDUCTASE; GSR
138500	HYPERGLYCINURIA
138800	GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS; MNG1
138900	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1; UAQTL1
139090	GRAY PLATELET SYNDROME; GPS
139190	GROWTH HORMONE-RELEASING HORMONE; GHRH
139210	MYHRE SYNDROME; MYHRS
139300	AROMATASE EXCESS SYNDROME; AEXS
139320	GNAS COMPLEX LOCUS; GNAS
139360	GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-INHIBITING ACTIVITY POLYPEPTIDE 2; GNAI2
139393	GUILLAIN-BARRE SYNDROME, FAMILIAL; GBS
139450	HAIR MORPHOLOGY 2; HRM2
139900	HAND SKILL, RELATIVE; HSR
140000	HAND-FOOT-GENITAL SYNDROME; HFG
140300	HASHIMOTO THYROIDITIS
140350	HAWKINSINURIA
140400	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE II; PFHB2
140600	OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2
140700	HEINZ BODY ANEMIAS
141200	HEMATURIA, BENIGN FAMILIAL; BFH
141500	MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1
141749	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1
141750	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED
142000	HEMOGLOBIN--DELTA LOCUS; HBD
142330	HEPATIC ADENOMAS, FAMILIAL
142335	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 5; HBFQTL5
142340	DIAPHRAGMATIC HERNIA, CONGENITAL
142470	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HBFQTL2
142623	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1
142669	BEUKES HIP DYSPLASIA; BHD
142680	PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT
142690	ACNE INVERSA, FAMILIAL, 1; ACNINV1
142700	DEVELOPMENTAL DYSPLASIA OF THE HIP 1; DDH1
142830	MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B
142858	MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DP BETA-1; HLA-DPB1
142900	HOLT-ORAM SYNDROME; HOS
142910	3-HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE; HMGCR
142945	HOLOPROSENCEPHALY 3; HPE3
142946	HOLOPROSENCEPHALY 4; HPE4
143095	SPONDYLOEPIPHYSEAL DYSPLASIA WITH CONGENITAL JOINT DISLOCATIONS; SEDCJD
143100	HUNTINGTON DISEASE; HD
143200	WAGNER VITREORETINOPATHY; WGVRP
143400	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2; CAKUT2
143465	ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD
143470	HYPERALPHALIPOPROTEINEMIA 1; HALP1
143500	GILBERT SYNDROME
143850	ORTHOSTATIC HYPOTENSIVE DISORDER, STREETEN TYPE
143860	HYPERCHLORHIDROSIS, ISOLATED; HYCHL
143870	HYPERCALCIURIA, ABSORPTIVE, 2; HCA2
143880	HYPERCALCEMIA, INFANTILE, 1; HCINF1
143890	HYPERCHOLESTEROLEMIA, FAMILIAL
144010	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B
144110	HYPERHIDROSIS PALMARIS ET PLANTARIS; HYPRPP
144120	HYPERIMMUNOGLOBULIN G1(A1) SYNDROME
144200	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK
144250	HYPERLIPIDEMIA, FAMILIAL COMBINED; FCHL
144650	HYPERLIPOPROTEINEMIA, TYPE V
144700	RENAL CELL CARCINOMA, NONPAPILLARY; RCC
144750	ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL DOMINANT
144755	HYPEROSTOSIS CRANIALIS INTERNA; HCIN
145000	HYPERPARATHYROIDISM 1; HRPT1
145001	HYPERPARATHYROIDISM 2 WITH JAW TUMORS; HRPT2
145250	HYPERPIGMENTATION WITH OR WITHOUT HYPOPIGMENTATION, FAMILIAL PROGRESSIVE; FPHH
145260	PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A
145410	OPITZ GBBB SYNDROME, TYPE II; GBBB2
145500	HYPERTENSION, ESSENTIAL
145505	ACYL-CoA SYNTHETASE MEDIUM CHAIN FAMILY, MEMBER 3; ACSM3
145600	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1
145650	THYROID HORMONE RESISTANCE, SELECTIVE PITUITARY; PRTH
145680	HYPERTHYROXINEMIA, DYSTRANSTHYRETINEMIC; DTTRH
145701	HYPERTRICHOSIS UNIVERSALIS CONGENITA, AMBRAS TYPE; HTC1
145750	HYPERTRIGLYCERIDEMIA, FAMILIAL
145900	HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS
145980	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1
145981	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2
146000	HYPOCHONDROPLASIA; HCH
146110	HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7
146200	HYPOPARATHYROIDISM, FAMILIAL ISOLATED; FIH
146255	HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; HDR
146300	HYPOPHOSPHATASIA, ADULT
146390	CHROMOSOME 18p DELETION SYNDROME
146450	HYPOSPADIAS 3, AUTOSOMAL; HYSP3
146500	MULTIPLE SYSTEM ATROPHY 1, SUSCEPTIBILITY TO; MSA1
146510	PALLISTER-HALL SYNDROME; PHS
146520	HYPOTRICHOSIS 2; HYPT2
146550	HYPOTRICHOSIS 4; HYPT4
146590	ICHTHYOSIS HYSTRIX, CURTH-MACKLIN TYPE; IHCM
146700	ICHTHYOSIS VULGARIS
146760	Fc FRAGMENT OF IgG, HIGH AFFINITY Ia, RECEPTOR FOR; FCGR1A
146800	ICHTHYOSIS BULLOSA OF SIEMENS; IBS
147050	IgE RESPONSIVENESS, ATOPIC; IGER
147060	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT
147110	IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION GAMMA-2; IGHG2
147250	SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI
147430	MARSILI SYNDROME; MARSIS
147480	CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY, 1; ICP1
147545	INSULIN RECEPTOR SUBSTRATE 1; IRS1
147575	INTERFERON REGULATORY FACTOR 1; IRF1
147630	INSULINOMATOSIS AND DIABETES MELLITUS; INSDM
147660	INTERFERON, ALPHA-1; IFNA1
147750	IVIC SYNDROME
147791	JACOBSEN SYNDROME; JBS
147891	ISCHIOCOXOPODOPATELLAR SYNDROME; ICPPS
147920	KABUKI SYNDROME 1; KABUK1
147950	HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA; HH2
148000	KAPOSI SARCOMA, SUSCEPTIBILITY TO
148050	KBG SYNDROME; KBGS
148190	KERATITIS, HEREDITARY
148200	KERATOENDOTHELIITIS FUGAX HEREDITARIA; KEFH
148210	KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, AUTOSOMAL DOMINANT
148300	KERATOCONUS 1; KTCN1
148350	KERATODERMA, PALMOPLANTAR, WITH DEAFNESS
148370	KERATOLYTIC WINTER ERYTHEMA; KWE
148500	TYLOSIS WITH ESOPHAGEAL CANCER; TOC
148600	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A
148700	PALMOPLANTAR KERATODERMA I, STRIATE, FOCAL, OR DIFFUSE; PPKS1
148820	WAARDENBURG SYNDROME, TYPE 3; WS3
149000	KLIPPEL-TRENAUNAY-WEBER SYNDROME
149200	KNUCKLE PADS, LEUKONYCHIA, AND SENSORINEURAL DEAFNESS
149400	HYPEREKPLEXIA 1; HKPX1
149700	LACRIMAL DUCT DEFECT; LCDD
149730	LACRIMOAURICULODENTODIGITAL SYNDROME; LADD
150200	CHORIONIC SOMATOMAMMOTROPIN HORMONE 1; CSH1
150230	TRICHORHINOPHALANGEAL SYNDROME, TYPE II; TRPS2
150250	LARSEN SYNDROME; LRS
150270	LARYNGEAL ADDUCTOR PARALYSIS; LAP
150400	TOOTH AGENESIS, SELECTIVE, 4; STHAG4
150600	LEGG-CALVE-PERTHES DISEASE; LCPD
150699	LEIOMYOMA, UTERINE; UL
150800	HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC
151050	LENZ-MAJEWSKI HYPEROSTOTIC DWARFISM; LMHD
151100	LEOPARD SYNDROME 1; LPRD1
151200	CHROMOSOME 8q22.1 DUPLICATION SYNDROME
151210	PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, TORRANCE TYPE; PLSDT
151430	B-CELL CLL/LYMPHOMA 2; BCL2
151440	LYMPHOBLASTIC LEUKEMIA-DERIVED SEQUENCE 1; LYL1
151600	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3; NDNC3
151623	LI-FRAUMENI SYNDROME; LFS
151660	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2
152200	APOLIPOPROTEIN(a); LPA
152390	ARACHIDONATE 5-LIPOXYGENASE; ALOX5
152700	SYSTEMIC LUPUS ERYTHEMATOSUS; SLE
152950	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTAL RETARDATION; MCLMR
153100	LYMPHEDEMA, HEREDITARY, IA; LMPH1A
153245	LYMPHOID ENHANCER-BINDING FACTOR 1; LEF1
153400	LYMPHEDEMA-DISTICHIASIS SYNDROME
153480	MOVED TO 158350
153550	CHROMOSOME 5q DELETION SYNDROME
153600	MACROGLOBULINEMIA, WALDENSTROM, SUSCEPTIBILITY TO, 1; WM1
153670	BERNARD-SOULIER SYNDROME, TYPE A2, AUTOSOMAL DOMINANT; BSSA2
153700	MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2
153800	MACULAR DEGENERATION, AGE-RELATED, 2; ARMD2
153880	MACULAR DYSTROPHY, DOMINANT CYSTOID; DCMD
154020	HYPOMAGNESEMIA 2, RENAL; HOMG2
154230	46,XY SEX REVERSAL 4; SRXY4
154275	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 2
154276	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 3
154400	ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1
154500	TREACHER COLLINS SYNDROME 1; TCS1
154700	MARFAN SYNDROME; MFS
154780	MARSHALL SYNDROME; MRSHS
154800	MASTOCYTOSIS, CUTANEOUS; MASTC
155100	MACROTHROMBOCYTOPENIA AND GRANULOCYTE INCLUSIONS WITH OR WITHOUT NEPHRITIS OR SENSORINEURAL HEARING LOSS; MATINS
155240	THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC
155255	MEDULLOBLASTOMA; MDB
155310	VISCERAL MYOPATHY; VSCM
155600	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1
155601	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2; CMM2
155755	MELANOMA-ASTROCYTOMA SYNDROME
155900	MELKERSSON-ROSENTHAL SYNDROME
156200	MENTAL RETARDATION, AUTOSOMAL DOMINANT 1; MRD1
156232	MESOMELIC DYSPLASIA, KANTAPUTRA TYPE; MMDK
156240	MESOTHELIOMA, MALIGNANT; MESOM
156250	METACHONDROMATOSIS; METCDS
156400	METAPHYSEAL CHONDRODYSPLASIA, JANSEN TYPE
156500	METAPHYSEAL CHONDRODYSPLASIA, SCHMID TYPE; MCDS
156510	METAPHYSEAL DYSPLASIA WITH MAXILLARY HYPOPLASIA WITH OR WITHOUT BRACHYDACTYLY; MDMHB
156530	METATROPIC DYSPLASIA
156550	KNIEST DYSPLASIA
156600	MICROCORIA, CONGENITAL
156610	SKIN CREASES, CONGENITAL SYMMETRIC CIRCUMFERENTIAL, 1; CSCSC1
156850	MICROPHTHALMIA, ISOLATED, WITH CATARACT 1; MCOPCT1
157170	HOLOPROSENCEPHALY 2; HPE2
157300	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1
157600	MIRROR MOVEMENTS 1; MRMV1
157640	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1
157700	MITRAL VALVE PROLAPSE 1; MVP1
157800	CARDIOSPONDYLOCARPOFACIAL SYNDROME; CSCF
157900	MOEBIUS SYNDROME; MBS
158000	MONILETHRIX; MNLIX
158105	CHEMOKINE, CC MOTIF, LIGAND 2; CCL2
158170	CHROMOSOME 9p DELETION SYNDROME
158300	ARTHROGRYPOSIS, DISTAL, TYPE 7; DA7
158320	MUIR-TORRE SYNDROME; MRTES
158330	MULLERIAN APLASIA AND HYPERANDROGENISM
158350	COWDEN SYNDROME 1; CWS1
158580	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A
158590	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A
158600	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMAL DOMINANT; SMALED1
158810	BETHLEM MYOPATHY 1; BTHLM1
158900	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1
158901	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2
159000	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A; LGMD1A
159001	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B; LGMD1B
159550	ATAXIA-PANCYTOPENIA SYNDROME; ATXPC
159555	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A
159595	MYELOPROLIFERATIVE SYNDROME, TRANSIENT
159900	DYSTONIA 11, MYOCLONIC; DYT11
159950	SPINAL MUSCULAR ATROPHY WITH PROGRESSIVE MYOCLONIC EPILEPSY; SMAPME
160120	EPISODIC ATAXIA, TYPE 1; EA1
160150	MYOPATHY, CENTRONUCLEAR, 1; CNM1
160500	MYOPATHY, DISTAL, 1; MPD1
160700	MYOPIA 2, AUTOSOMAL DOMINANT; MYP2
160800	MYOTONIA CONGENITA, AUTOSOMAL DOMINANT
160900	MYOTONIC DYSTROPHY 1; DM1
160980	CARNEY COMPLEX, TYPE 1; CNC1
161000	NAEGELI-FRANCESCHETTI-JADASSOHN SYNDROME; NFJS
161200	NAIL-PATELLA SYNDROME; NPS
161400	NARCOLEPSY 1; NRCLP1
161550	NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 2; NPCA2
161800	NEMALINE MYOPATHY 3; NEM3
161900	RENAL FAILURE, PROGRESSIVE, WITH HYPERTENSION; RFH1
161950	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 1; IGAN1
162000	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1
162080	NEURAL RETINA LEUCINE ZIPPER; NRL
162091	SCHWANNOMATOSIS 1; SWNTS1
162100	AMYOTROPHY, HEREDITARY NEURALGIC; HNA
162200	NEUROFIBROMATOSIS, TYPE I; NF1
162210	NEUROFIBROMATOSIS, FAMILIAL SPINAL
162300	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B
162350	CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B
162400	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A
162500	NEUROPATHY, HEREDITARY, WITH LIABILITY TO PRESSURE PALSIES; HNPP
162643	CHEMOKINE, CXC MOTIF, RECEPTOR 4; CXCR4
162800	CYCLIC NEUTROPENIA
162820	NEUTROPHIL MIGRATION; NM
162900	NEVUS, EPIDERMAL
163000	CAPILLARY MALFORMATIONS, CONGENITAL; CMC
163200	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM
163500	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 2; CSNBAD2
163800	SICK SINUS SYNDROME 2; SSS2
163950	NOONAN SYNDROME 1; NS1
164100	NYSTAGMUS 2, CONGENITAL, AUTOSOMAL DOMINANT; NYS2
164200	OCULODENTODIGITAL DYSPLASIA; ODDD
164210	HEMIFACIAL MICROSOMIA; HFM
164230	OBSESSIVE-COMPULSIVE DISORDER; OCD
164280	FEINGOLD SYNDROME 1; FGLDS1
164300	OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD
164400	SPINOCEREBELLAR ATAXIA 1; SCA1
164500	SPINOCEREBELLAR ATAXIA 7; SCA7
164690	V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; ABL2
164750	OMPHALOCELE, AUTOSOMAL
164757	V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; BRAF
164870	V-ERB-B2 AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; ERBB2
165300	OPTIC ATROPHY 3, AUTOSOMAL DOMINANT; OPA3
165500	OPTIC ATROPHY 1; OPA1
165550	OPTIC NERVE HYPOPLASIA, BILATERAL
165720	OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1
165800	SHORT STATURE AND ADVANCED BONE AGE, WITH OR WITHOUT EARLY-ONSET OSTEOARTHRITIS AND/OR OSTEOCHONDRITIS DISSECANS; SSOAOD
166200	OSTEOGENESIS IMPERFECTA, TYPE I; OI1
166210	OSTEOGENESIS IMPERFECTA, TYPE II; OI2
166220	OSTEOGENESIS IMPERFECTA, TYPE IV; OI4
166250	OSTEOGLOPHONIC DYSPLASIA; OGD
166260	GNATHODIAPHYSEAL DYSPLASIA; GDD
166300	MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME; MCTO
166350	OSSEOUS HETEROPLASIA, PROGRESSIVE; POH
166600	OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2
166700	BUSCHKE-OLLENDORFF SYNDROME; BOS
166710	OSTEOPOROSIS
166750	OTODENTAL DYSPLASIA
166760	OTITIS MEDIA, SUSCEPTIBILITY TO; OMS
166780	OTOFACIOCERVICAL SYNDROME 1; OTFCS
166800	OTOSCLEROSIS 1; OTSC1
166900	OVALOCYTOSIS, SOUTHEAST ASIAN; SAO
167000	OVARIAN CANCER
167030	NEPHROLITHIASIS, CALCIUM OXALATE; CAON
167200	PACHYONYCHIA CONGENITA 1; PC1
167210	PACHYONYCHIA CONGENITA 2; PC2
167250	PAGET DISEASE OF BONE 3; PDB3
167320	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 1; IBMPFD1
167800	PANCREATITIS, HEREDITARY; PCTT
167870	PANIC DISORDER 1; PAND1
168000	PARAGANGLIOMAS 1; PGL1
168300	PARAMYOTONIA CONGENITA OF VON EULENBURG; PMC
168360	EMBRYONIC LETHAL, ABNORMAL VISION, DROSOPHILA, HOMOLOG-LIKE 4; ELAVL4
168400	PARASTREMMATIC DWARFISM
168500	PARIETAL FORAMINA 1; PFM1
168550	PARIETAL FORAMINA WITH CLEIDOCRANIAL DYSPLASIA; PFMCCD
168600	PARKINSON DISEASE, LATE-ONSET; PD
168601	PARKINSON DISEASE 1, AUTOSOMAL DOMINANT; PARK1
168605	PERRY SYNDROME
168820	PARAOXONASE 1; PON1
168860	PATELLA APLASIA-HYPOPLASIA; PTLAH
169100	CHAR SYNDROME; CHAR
169150	MACULAR DYSTROPHY, PATTERNED, 1; MDPT1
169400	PELGER-HUET ANOMALY; PHA
169500	LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT; ADLD
169600	BENIGN CHRONIC PEMPHIGUS; BCPM
170100	PROLIDASE DEFICIENCY
170390	ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS
170400	HYPOKALEMIC PERIODIC PARALYSIS, TYPE 1; HOKPP1
170500	HYPERKALEMIC PERIODIC PARALYSIS; HYPP
170650	PERIODONTITIS, AGGRESSIVE, 1
170998	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA; PPARA
171200	THIOUREA TASTING; THIOT
171300	PHEOCHROMOCYTOMA
171400	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A
171720	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1
171860	PHOSPHOFRUCTOKINASE, LIVER TYPE; PFKL
172425	PHOSPHOLIPID TRANSFER PROTEIN; PLTP
172430	ENOLASE 1; ENO1
172471	PHOSPHORYLASE KINASE, TESTIS/LIVER, GAMMA-2; PHKG2
172700	PICK DISEASE OF BRAIN
172800	PIEBALD TRAIT; PBT
172870	PIGMENTED PARAVENOUS CHORIORETINAL ATROPHY; PPCRA
173100	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2
173200	PITYRIASIS RUBRA PILARIS; PRP
173360	SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1; SERPINE1
173470	INTEGRIN, BETA-3; ITGB3
173510	CD36 ANTIGEN; CD36
173600	PNEUMOTHORAX, PRIMARY SPONTANEOUS
173650	KINDLER SYNDROME; KNDLRS
173900	POLYCYSTIC KIDNEY DISEASE 1 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD1
174000	MEDULLARY CYSTIC KIDNEY DISEASE 1; MCKD1
174050	POLYCYSTIC LIVER DISEASE 1 WITH OR WITHOUT KIDNEY CYSTS; PCLD1
174200	POLYDACTYLY, POSTAXIAL, TYPE A1; PAPA1
174300	OROFACIODIGITAL SYNDROME V; OFD5
174500	POLYDACTYLY, PREAXIAL II; PPD2
174700	POLYDACTYLY, PREAXIAL IV
174810	FAMILIAL EXPANSILE OSTEOLYSIS; FEO
174900	JUVENILE POLYPOSIS SYNDROME; JPS
175050	JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME; JPHT
175100	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1
175200	PEUTZ-JEGHERS SYNDROME; PJS
175700	GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS
175780	PORENCEPHALY 1; POREN1
175800	POROKERATOSIS 1, MULTIPLE TYPES; POROK1
175850	POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2
175900	POROKERATOSIS 3, MULTIPLE TYPES; POROK3
176000	PORPHYRIA, ACUTE INTERMITTENT; AIP
176100	PORPHYRIA CUTANEA TARDA
176200	PORPHYRIA VARIEGATA
176270	PRADER-WILLI SYNDROME; PWS
176305	PREAXIAL DEFICIENCY, POSTAXIAL POLYDACTYLY, AND HYPOSPADIAS
176400	PRECOCIOUS PUBERTY, CENTRAL, 1; CPPB1
176410	PRECOCIOUS PUBERTY, MALE-LIMITED
176430	PREMATURE CHROMATID SEPARATION TRAIT; PCS
176450	CURRARINO SYNDROME
176500	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1
176670	HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS
176780	PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO
176797	ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 16; ZBTB16
176807	PROSTATE CANCER
176860	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT; THPH3
176920	PROTEUS SYNDROME
176943	FIBROBLAST GROWTH FACTOR RECEPTOR 2; FGFR2
176960	PROTEIN KINASE C, ALPHA; PRKCA
177000	PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1
177170	PSEUDOACHONDROPLASIA; PSACH
177200	LIDDLE SYNDROME; LIDLS
177650	EXFOLIATION SYNDROME; XFS
177700	GLAUCOMA 1, OPEN ANGLE, P; GLC1P
177735	PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL DOMINANT; PHA1A
177820	PSEUDO-VON WILLEBRAND DISEASE; VWDP
177850	PSEUDOXANTHOMA ELASTICUM, FORME FRUSTE
177900	PSORIASIS 1, SUSCEPTIBILITY TO; PSORS1
178110	ARTHROGRYPOSIS, DISTAL, TYPE 8; DA8
178500	PULMONARY FIBROSIS, IDIOPATHIC; IPF
178600	PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
179010	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 1; IHPS1
179095	UBIQUITIN-CONJUGATING ENZYME E2B; UBE2B
179450	RAGWEED SENSITIVITY
179502	RAP1, GTPase-GDP DISSOCIATION STIMULATOR 1; RAP1GDS1
179620	RAPH BLOOD GROUP SYSTEM
179800	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT
179820	RENIN; REN
179850	DOWLING-DEGOS DISEASE 1; DDD1
180000	RETINAL ARTERIES, TORTUOSITY OF; RATOR
180020	RETINAL CONE DYSTROPHY 1; RCD1
180100	RETINITIS PIGMENTOSA 1; RP1
180104	RETINITIS PIGMENTOSA 9; RP9
180105	RETINITIS PIGMENTOSA 10; RP10
180200	RETINOBLASTOMA; RB1
180295	RHABDOMYOSARCOMA, EMBRYONAL, 2; RMSE2
180300	RHEUMATOID ARTHRITIS; RA
180385	LIM DOMAIN ONLY 2; LMO2
180500	AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1
180550	RING DERMOID OF CORNEA; RDC
180700	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1
180750	ROBINOW-SORAUF SYNDROME
180800	ROUSSY-LEVY HEREDITARY AREFLEXIC DYSTASIA
180849	RUBINSTEIN-TAYBI SYNDROME 1; RSTS1
180860	SILVER-RUSSELL SYNDROME; SRS
180920	APLASIA OF LACRIMAL AND SALIVARY GLANDS; ALSG
181000	SARCOIDOSIS, SUSCEPTIBILITY TO, 1; SS1
181030	SALIVARY GLAND ADENOMA, PLEOMORPHIC
181270	SCALP-EAR-NIPPLE SYNDROME; SENS
181350	EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2
181400	SCAPULOPERONEAL SYNDROME, NEUROGENIC, KAESER TYPE; SCPNK
181405	SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY; SPSMA
181430	SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM
181450	ULNAR-MAMMARY SYNDROME; UMS
181460	SCHISTOSOMA MANSONI INFECTION, SUSCEPTIBILITY/RESISTANCE TO
181500	SCHIZOPHRENIA; SCZD
181600	HURIEZ SYNDROME; HRZ
181800	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 1; IS1
182000	KERATOSIS, SEBORRHEIC
182170	ANEMIA, SIDEROBLASTIC, 4; SIDBA4
182212	SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS
182230	SEPTOOPTIC DYSPLASIA
182250	SINGLETON-MERTEN SYNDROME 1; SGMRT1
182280	SMALL CELL CANCER OF THE LUNG
182290	SMITH-MAGENIS SYNDROME; SMS
182410	SNEDDON SYNDROME
182455	SOMATOSTATIN RECEPTOR 5; SSTR5
182500	SORBITOL DEHYDROGENASE; SORD
182600	SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A
182601	SPASTIC PARAPLEGIA 4, AUTOSOMAL DOMINANT; SPG4
182900	SPHEROCYTOSIS, TYPE 1; SPH1
182920	MYOPATHY, SPHEROID BODY
182940	NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD
182960	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1
182980	SPINAL MUSCULAR ATROPHY, LATE-ONSET, FINKEL TYPE; SMAFK
183086	SPINOCEREBELLAR ATAXIA 6; SCA6
183090	SPINOCEREBELLAR ATAXIA 2; SCA2
183600	SPLIT-HAND/FOOT MALFORMATION 1; SHFM1
183900	SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; SEDC
184095	SPONDYLOEPIPHYSEAL DYSPLASIA, MAROTEAUX TYPE
184100	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL DOMINANT
184250	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK
184252	SPONDYLOMETAPHYSEAL DYSPLASIA, KOZLOWSKI TYPE; SMDK
184255	SPONDYLOMETAPHYSEAL DYSPLASIA, CORNER FRACTURE TYPE; SMDCF
184450	STUTTERING, FAMILIAL PERSISTENT, 1; STUT1
184460	STAPES ANKYLOSIS WITH BROAD THUMBS AND TOES
184500	STEATOCYSTOMA MULTIPLEX
184700	POLYCYSTIC OVARY SYNDROME 1; PCOS1
184840	OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; OSMEDA
184900	STIFF SKIN SYNDROME; SSKS
185000	OVERHYDRATED HEREDITARY STOMATOCYTOSIS; OHST
185020	CRYOHYDROCYTOSIS; CHC
185070	STORMORKEN SYNDROME; STRMK
185100	STRABISMUS, SUSCEPTIBILITY TO
185300	STURGE-WEBER SYNDROME; SWS
185490	SUPEROXIDE DISMUTASE 3; SOD3
185500	SUPRAVALVULAR AORTIC STENOSIS; SVAS
185800	SYMPHALANGISM, PROXIMAL, 1A; SYM1A
185900	CHROMOSOME 2q35 DUPLICATION SYNDROME
186000	SYNPOLYDACTYLY 1; SPD1
186100	SYNDACTYLY, TYPE III
186200	SYNDACTYLY, TYPE IV; SDTY4
186300	SYNDACTYLY, TYPE V; SDTY5
186500	MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1
186550	LIEBENBERG SYNDROME; LBNBG
186570	TARSAL-CARPAL COALITION SYNDROME; TCC
186580	BLAU SYNDROME; BLAUS
186860	T-CELL LEUKEMIA/LYMPHOMA 4; TCL4
186921	LIM DOMAIN ONLY 1; LMO1
186960	T-CELL LEUKEMIA/LYMPHOMA 1A; TCL1A
187011	CHEMOKINE, CC MOTIF, LIGAND 5; CCL5
187260	TELANGIECTASIA, HEREDITARY BENIGN
187300	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 1; HHT1
187370	ARTHROGRYPOSIS, DISTAL, TYPE 10; DA10
187395	TERATOCARCINOMA-DERIVED GROWTH FACTOR 1; TDGF1
187500	TETRALOGY OF FALLOT; TOF
187600	THANATOPHORIC DYSPLASIA, TYPE I; TD1
187601	THANATOPHORIC DYSPLASIA, TYPE II; TD2
187800	BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16
187900	BLEEDING DISORDER, PLATELET-TYPE, 17; BDPLT17
187950	THROMBOCYTHEMIA 1; THCYT1
188000	THROMBOCYTOPENIA 2; THC2
188025	THROMBOCYTOPENIA, PARIS-TROUSSEAU TYPE; TCPT
188030	THROMBOCYTOPENIC PURPURA, AUTOIMMUNE; AITP
188050	THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1
188055	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
188400	DIGEORGE SYNDROME; DGS
188470	THYROID CANCER, NONMEDULLARY, 2; NMTC2
188545	THYROTROPIN-RELEASING HORMONE RECEPTOR; TRHR
188550	THYROID CANCER, NONMEDULLARY, 1; NMTC1
188570	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH
188580	THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 1; TTPP1
188740	TIBIA, HYPOPLASIA OR APLASIA OF, WITH POLYDACTYLY; THYP
188830	PROTEIN KINASE, cAMP-DEPENDENT, REGULATORY, TYPE I, ALPHA; PRKAR1A
188890	TOBACCO ADDICTION, SUSCEPTIBILITY TO
189500	WITKOP SYNDROME
189800	PREECLAMPSIA/ECLAMPSIA 1; PEE1
189980	ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; ABL1
189990	V-MYB AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG; MYB
190100	GENIOSPASM 1; GSM1
190300	TREMOR, HEREDITARY ESSENTIAL, 1; ETM1
190320	TRICHODENTOOSSEOUS SYNDROME; TDO
190330	TRICHOMEGALY; TCMGLY
190350	TRICHORHINOPHALANGEAL SYNDROME, TYPE I; TRPS1
190351	TRICHORHINOPHALANGEAL SYNDROME, TYPE III; TRPS3
190440	TRIGONOCEPHALY 1; TRIGNO1
190685	DOWN SYNDROME
190900	TRITANOPIA
191100	TUBEROUS SCLEROSIS 1; TSC1
191160	TUMOR NECROSIS FACTOR; TNF
191390	INFLAMMATORY BOWEL DISEASE 11; IBD11
191480	UNCOMBABLE HAIR SYNDROME 1; UHS1
191830	RENAL HYPODYSPLASIA/APLASIA 1; RHDA1
191900	MUCKLE-WELLS SYNDROME; MWS
192315	VASCULOPATHY, RETINAL, WITH CEREBRAL LEUKODYSTROPHY; RVCL
192430	VELOCARDIOFACIAL SYNDROME
192500	LONG QT SYNDROME 1; LQT1
192600	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1
192605	VENTRICULAR TACHYCARDIA, FAMILIAL
192950	VERTICAL TALUS, CONGENITAL; CVT
193000	VESICOURETERAL REFLUX 1; VUR1
193003	NYSTAGMUS 4, CONGENITAL, AUTOSOMAL DOMINANT; NYS4
193007	VERTIGO, BENIGN RECURRENT; BRV
193040	VILLIN; VIL
193100	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL DOMINANT; ADHR
193200	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 6; VAMAS6
193220	VITREORETINOCHOROIDOPATHY; VRCP
193230	VITREORETINAL DEGENERATION, SNOWFLAKE TYPE; SVD
193235	VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY; VRNI
193300	VON HIPPEL-LINDAU SYNDROME; VHL
193400	VON WILLEBRAND DISEASE, TYPE 1; VWD1
193500	WAARDENBURG SYNDROME, TYPE 1; WS1
193510	WAARDENBURG SYNDROME, TYPE 2A; WS2A
193520	WATSON SYNDROME; WTSN
193530	WEYERS ACROFACIAL DYSOSTOSIS; WAD
193670	WHIM SYNDROME; WHIMS
193700	ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A
193900	WHITE SPONGE NEVUS 1; WSN1
194050	WILLIAMS-BEUREN SYNDROME; WBS
194070	WILMS TUMOR 1; WT1
194071	WILMS TUMOR 2; WT2
194072	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, AND MENTAL RETARDATION SYNDROME; WAGR
194080	DENYS-DRASH SYNDROME; DDS
194090	WILMS TUMOR 3; WT3
194190	WOLF-HIRSCHHORN SYNDROME; WHS
194200	WOLFF-PARKINSON-WHITE SYNDROME
194300	WOOLLY HAIR, AUTOSOMAL DOMINANT; ADWH
194380	DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIA AND/OR PERINATAL EDEMA; DHS1
200100	ABETALIPOPROTEINEMIA; ABL
200110	ABLEPHARON-MACROSTOMIA SYNDROME; AMS
200150	CHOREOACANTHOCYTOSIS; CHAC
200500	ACHEIROPODY; ACHP
200600	ACHONDROGENESIS, TYPE IA; ACG1A
200610	ACHONDROGENESIS, TYPE II; ACG2
200700	CHONDRODYSPLASIA, GREBE TYPE
200950	ACID PHOSPHATASE DEFICIENCY
200990	ACROCALLOSAL SYNDROME; ACLS
201000	CARPENTER SYNDROME 1; CRPT1
201100	ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ
201250	ACROMESOMELIC DYSPLASIA, HUNTER-THOMPSON TYPE; AMDH
201300	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A
201400	ACTH DEFICIENCY, ISOLATED; IAD
201450	ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD
201470	ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD
201475	ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, DEFICIENCY OF; ACADVLD
201710	LIPOID CONGENITAL ADRENAL HYPERPLASIA; LCAH
201750	ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS; ABS1
201810	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY
201910	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY
202010	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASE DEFICIENCY
202110	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY
202200	GLUCOCORTICOID DEFICIENCY 1; GCCD1
202300	ADRENOCORTICAL CARCINOMA, HEREDITARY; ADCC
202370	PEROXISOME BIOGENESIS DISORDER 2B; PBD2B
202400	AFIBRINOGENEMIA, CONGENITAL
202650	AGNATHIA-OTOCEPHALY COMPLEX; AGOTC
202700	NEUTROPENIA, SEVERE CONGENITAL, 1, AUTOSOMAL DOMINANT; SCN1
203100	ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A
203200	ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2
203290	ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3
203300	HERMANSKY-PUDLAK SYNDROME 1; HPS1
203400	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY
203450	ALEXANDER DISEASE; ALXDRD
203500	ALKAPTONURIA; AKU
203650	ALOPECIA-MENTAL RETARDATION SYNDROME 1; APMR1
203655	ALOPECIA UNIVERSALIS CONGENITA; ALUNC
203700	MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A
203740	ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY
203750	ALPHA-METHYLACETOACETIC ACIDURIA
203780	ALPORT SYNDROME, AUTOSOMAL RECESSIVE
203800	ALSTROM SYNDROME; ALMS
204000	LEBER CONGENITAL AMAUROSIS 1; LCA1
204100	LEBER CONGENITAL AMAUROSIS 2; LCA2
204200	CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3
204300	CEROID LIPOFUSCINOSIS, NEURONAL, 4A, AUTOSOMAL RECESSIVE; CLN4A
204500	CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2
204650	AMELOGENESIS IMPERFECTA, TYPE IC; AI1C
204690	AMELOGENESIS IMPERFECTA, TYPE IG; AI1G
204700	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA1; AI2A1
204750	2-AMINOADIPIC 2-OXOADIPIC ACIDURIA; AMOXAD
204870	CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD
205100	AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE; ALS2
205400	TANGIER DISEASE; TGD
205950	ANEMIA, SIDEROBLASTIC, 2, PYRIDOXINE-REFRACTORY; SIDBA2
206100	ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 1; AHMIO1
206200	IRON-REFRACTORY IRON DEFICIENCY ANEMIA; IRIDA
206500	ANENCEPHALY; ANPH
206700	GILLESPIE SYNDROME; GLSP
206800	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4; NDNC4
206900	MICROPHTHALMIA, SYNDROMIC 3; MCOPS3
206920	MICROPHTHALMIA WITH LIMB ANOMALIES; MLA
207410	ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS; ABS2
207750	APOLIPOPROTEIN C-II DEFICIENCY
207800	ARGININEMIA
207900	ARGININOSUCCINIC ACIDURIA
208000	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1
208050	ARTERIAL TORTUOSITY SYNDROME; ATS
208085	ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 1; ARCS1
208100	ARTHROGRYPOSIS MULTIPLEX CONGENITA, NEUROGENIC TYPE; AMCN
208150	FETAL AKINESIA DEFORMATION SEQUENCE; FADS
208230	ARTHROPATHY, PROGRESSIVE PSEUDORHEUMATOID, OF CHILDHOOD; PPAC
208250	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP
208400	ASPARTYLGLUCOSAMINURIA; AGU
208500	SHORT-RIB THORACIC DYSPLASIA 1 WITH OR WITHOUT POLYDACTYLY; SRTD1
208530	RIGHT ATRIAL ISOMERISM; RAI
208540	RENAL-HEPATIC-PANCREATIC DYSPLASIA 1; RHPD1
208550	ASTHMA, NASAL POLYPS, AND ASPIRIN INTOLERANCE
208900	ATAXIA-TELANGIECTASIA; AT
208920	ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH
209300	ATRANSFERRINEMIA
209500	ATRICHIA WITH PAPULAR LESIONS; APL
209850	AUTISM
209880	CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS
209885	BARBER-SAY SYNDROME; BBRSAY
209900	BARDET-BIEDL SYNDROME 1; BBS1
209920	BARE LYMPHOCYTE SYNDROME, TYPE II
209950	IMMUNODEFICIENCY 27A; IMD27A
210000	BEHR SYNDROME; BEHRS
210100	BETA-AMINOISOBUTYRIC ACIDURIA; BAIBA
210200	3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D
210210	3-METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY; MCC2D
210250	SITOSTEROLEMIA
210370	BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; BCD
210600	SECKEL SYNDROME 1; SCKL1
210710	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1
210720	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II; MOPD2
210750	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 6; SHEP6
210900	BLOOM SYNDROME; BLM
211180	BOWEN-CONRADI SYNDROME; BWCNS
211380	ELSAHY-WATERS SYNDROME; ESWS
211400	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 1; BESC1
211500	FAZIO-LONDE DISEASE
211530	BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1
211600	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 1; PFIC1
211750	C SYNDROME
211800	CALCIFICATION OF JOINTS AND ARTERIES; CALJA
211900	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 1; HFTC1
211980	LUNG CANCER
212050	CANDIDIASIS, FAMILIAL, 2; CANDF2
212065	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A
212066	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A
212070	CARBOXYPEPTIDASE N DEFICIENCY
212093	CARDIAC VALVULAR DEFECT, DEVELOPMENTAL; CVDD
212112	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM
212138	CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD
212140	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP
212200	CARNOSINEMIA
212350	SENGERS SYNDROME
212500	CATARACT 46, JUVENILE-ONSET; CTRCT46
212550	OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY; ODRMD
212720	MARTSOLF SYNDROME
212750	CELIAC DISEASE, SUSCEPTIBILITY TO, 1; CELIAC1
212780	CENANI-LENZ SYNDACTYLY SYNDROME; CLSS
212840	GORDON HOLMES SYNDROME; GDHS
213200	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2
213300	JOUBERT SYNDROME 1; JBTS1
213600	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1
213700	CEREBROTENDINOUS XANTHOMATOSIS; CTX
213980	CRANIOFACIAL DYSMORPHISM, SKELETAL ANOMALIES, AND MENTAL RETARDATION SYNDROME; CFSMR
214100	PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A
214110	PEROXISOME BIOGENESIS DISORDER 2A (ZELLWEGER); PBD2A
214150	CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1
214300	KLIPPEL-FEIL SYNDROME 2, AUTOSOMAL RECESSIVE; KFS2
214400	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A; CMT4A
214450	GRISCELLI SYNDROME, TYPE 1; GS1
214500	CHEDIAK-HIGASHI SYNDROME; CHS
214700	DIARRHEA 1, SECRETORY CHLORIDE, CONGENITAL; DIAR1
214800	CHARGE SYNDROME
214900	CHOLESTASIS-LYMPHEDEMA SYNDROME
214950	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4; CBAS4
215045	CHONDRODYSPLASIA, BLOMSTRAND TYPE; BOCD
215100	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1
215140	GREENBERG DYSPLASIA; GRBGD
215150	OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE; OSMEDB
215300	CHONDROSARCOMA
215400	CHORDOMA, SUSCEPTIBILITY TO; CHDM
215470	BOUCHER-NEUHAUSER SYNDROME; BNHS
215500	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 1; CACD1
215600	CIRRHOSIS, FAMILIAL
215700	CITRULLINEMIA, CLASSIC
216340	YUNIS-VARON SYNDROME; YVS
216360	COACH SYNDROME
216400	COCKAYNE SYNDROME A; CSA
216550	COHEN SYNDROME; COH1
216820	COLOBOMA, OCULAR, AUTOSOMAL RECESSIVE
216900	ACHROMATOPSIA 2; ACHM2
217000	COMPLEMENT COMPONENT 2 DEFICIENCY; C2D
217050	COMPLEMENT COMPONENT 6; C6
217080	JALILI SYNDROME
217085	CONGENITAL HEART DEFECTS, HAMARTOMAS OF TONGUE, AND POLYSYNDACTYLY; CHDTHP
217090	PLASMINOGEN DEFICIENCY, TYPE I
217095	CONOTRUNCAL HEART MALFORMATIONS; CTHM
217300	CORNEA PLANA 2, AUTOSOMAL RECESSIVE; CNA2
217400	CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS; CDPD
217700	CORNEAL ENDOTHELIAL DYSTROPHY; CHED
217800	MACULAR DYSTROPHY, CORNEAL; MCD
218000	AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN
218030	APPARENT MINERALOCORTICOID EXCESS; AME
218040	COSTELLO SYNDROME; CSTLO
218330	CRANIOECTODERMAL DYSPLASIA 1; CED1
218340	TEMTAMY SYNDROME; TEMTYS
218400	CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE; CMDR
218600	BALLER-GEROLD SYNDROME; BGS
218700	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2
218800	CRIGLER-NAJJAR SYNDROME, TYPE I
219000	FRASER SYNDROME 1; FRASRS1
219050	CRYPTORCHIDISM, UNILATERAL OR BILATERAL
219080	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1
219090	PITUITARY ADENOMA 4, ACTH-SECRETING; PITA4
219100	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IA; ARCL1A
219150	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A
219200	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A
219500	CYSTATHIONINURIA
219700	CYSTIC FIBROSIS; CF
219730	VENTRICULOMEGALY WITH CYSTIC KIDNEY DISEASE; VMCKD
219750	CYSTINOSIS, ADULT NONNEPHROPATHIC
219800	CYSTINOSIS, NEPHROPATHIC; CTNS
219900	CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE
220100	CYSTINURIA
220110	MITOCHONDRIAL COMPLEX IV DEFICIENCY
220111	LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC
220120	D-GLYCERIC ACIDURIA
220150	HYPOURICEMIA, RENAL, 1; RHUC1
220200	DANDY-WALKER SYNDROME; DWS
220210	RITSCHER-SCHINZEL SYNDROME 1; RTSC1
220290	DEAFNESS, AUTOSOMAL RECESSIVE 1A; DFNB1A
220400	JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1
220500	DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, AND SEIZURES SYNDROME; DOORS
220600	SPLIT-HAND/FOOT MALFORMATION 1 WITH SENSORINEURAL HEARING LOSS, AUTOSOMAL RECESSIVE; SHFM1D
221200	DEAFNESS AND MYOPIA; DFNMYP
221750	PITUITARY HORMONE DEFICIENCY, COMBINED, 3; CPHD3
221770	POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY; PLOSL
221820	LEUKOENCEPHALOPATHY, HEREDITARY DIFFUSE, WITH SPHEROIDS; HDLS
221900	PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL RECESSIVE; PHPVAR
222100	DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM
222300	WOLFRAM SYNDROME 1; WFS1
222400	DIAPHRAGMATIC HERNIA 2; DIH2
222448	DONNAI-BARROW SYNDROME
222470	TRICHOHEPATOENTERIC SYNDROME 1; THES1
222600	DIASTROPHIC DYSPLASIA; DTD
222700	LYSINURIC PROTEIN INTOLERANCE; LPI
222730	DICARBOXYLIC AMINOACIDURIA; DCBXA
222748	DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD
222765	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2
222800	BISPHOSPHOGLYCERATE MUTASE DEFICIENCY
222900	SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID
223000	LACTASE DEFICIENCY, CONGENITAL
223100	LACTOSE INTOLERANCE, ADULT TYPE
223360	DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL
223800	DYGGVE-MELCHIOR-CLAUSEN DISEASE; DMC
223900	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3
224050	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 1; CAMRQ1
224100	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2
224120	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A
224230	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1; DKCB1
224410	DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE; DDSH
224500	DYSTONIA 2, TORSION, AUTOSOMAL RECESSIVE; DYT2
224690	MEIER-GORLIN SYNDROME 1; MGORS1
224750	SCHOPF-SCHULZ-PASSARGE SYNDROME; SSPS
224900	ECTODERMAL DYSPLASIA 10B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL RECESSIVE; ECTD10B
225060	CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1
225100	ECTOPIA LENTIS 2, ISOLATED, AUTOSOMAL RECESSIVE; ECTOL2
225200	ECTOPIA LENTIS ET PUPILLAE
225250	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 5; CHNG5
225280	ECTODERMAL DYSPLASIA, ECTRODACTYLY, AND MACULAR DYSTROPHY SYNDROME; EEMS
225300	SPLIT-HAND/FOOT MALFORMATION 6; SHFM6
225320	EHLERS-DANLOS SYNDROME, CARDIAC VALVULAR TYPE; EDSCV
225400	EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE, 1; EDSKSCL1
225410	EHLERS-DANLOS SYNDROME, DERMATOSPARAXIS TYPE; EDSDERMS
225500	ELLIS-VAN CREVELD SYNDROME; EVC
225750	AICARDI-GOUTIERES SYNDROME 1; AGS1
225753	PONTOCEREBELLAR HYPOPLASIA, TYPE 4; PCH4
225790	PROLIFERATIVE VASCULOPATHY AND HYDRANENCEPHALY-HYDROCEPHALY SYNDROME; PVHH
226200	ENTEROKINASE DEFICIENCY
226300	COMPLEMENT HYPERACTIVATION, ANGIOPATHIC THROMBOSIS, AND PROTEIN-LOSING ENTEROPATHY; CHAPLE
226400	EPIDERMODYSPLASIA VERRUCIFORMIS; EV
226600	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB
226650	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE
226670	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY; EBSMD
226700	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE
226730	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA
226750	KOHLSCHUTTER-TONZ SYNDROME; KTZS
226900	EPIPHYSEAL DYSPLASIA, MULTIPLE, 4; EDM4
226980	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS
226990	IMMUNODEFICIENCY 32B; IMD32B
227050	TRANSIENT ERYTHROBLASTOPENIA OF CHILDHOOD; TEC
227220	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1
227240	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 5; SHEP5
227260	FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3
227300	FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 1; F5F8D1
227400	FACTOR V DEFICIENCY
227500	FACTOR VII DEFICIENCY
227600	FACTOR X DEFICIENCY
227645	FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC
227646	FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2
227650	FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA
227810	FANCONI-BICKEL SYNDROME; FBS
228000	FARBER LIPOGRANULOMATOSIS; FRBRL
228300	HYPOGONADOTROPIC HYPOGONADISM 23 WITHOUT ANOSMIA; HH23
228520	FIBROCHONDROGENESIS 1; FBCG1
228550	MYOFIBROMATOSIS, INFANTILE, 1; IMF1
228600	HYALINE FIBROMATOSIS SYNDROME; HFS
228900	FIBULAR HYPOPLASIA AND COMPLEX BRACHYDACTYLY
228930	FIBULAR APLASIA OR HYPOPLASIA, FEMORAL BOWING AND POLY-, SYN-, AND OLIGODACTYLY
228960	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY
228980	FLECK RETINA, FAMILIAL BENIGN; FRFB
229050	FOLATE MALABSORPTION, HEREDITARY
229070	HYPOGONADOTROPIC HYPOGONADISM 24 WITHOUT ANOSMIA; HH24
229100	GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY
229200	BRITTLE CORNEA SYNDROME 1; BCS1
229300	FRIEDREICH ATAXIA 1; FRDA
229600	FRUCTOSE INTOLERANCE, HEREDITARY
229700	FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D
229800	FRUCTOSURIA, ESSENTIAL
230000	FUCOSIDOSIS
230200	GALACTOKINASE DEFICIENCY
230350	GALACTOSE EPIMERASE DEFICIENCY
230400	GALACTOSEMIA
230450	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO
230500	GM1-GANGLIOSIDOSIS, TYPE I
230600	GM1-GANGLIOSIDOSIS, TYPE II
230650	GM1-GANGLIOSIDOSIS, TYPE III
230740	GAPO SYNDROME
230800	GAUCHER DISEASE, TYPE I
230900	GAUCHER DISEASE, TYPE II
231000	GAUCHER DISEASE, TYPE III
231005	GAUCHER DISEASE, TYPE IIIC
231050	GELEOPHYSIC DYSPLASIA 1; GPHYSD1
231070	GERODERMA OSTEODYSPLASTICUM; GO
231090	HYDATIDIFORM MOLE, RECURRENT, 1; HYDM1
231095	GHOSAL HEMATODIAPHYSEAL DYSPLASIA; GHDD
231200	BERNARD-SOULIER SYNDROME; BSS
231300	GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A
231530	3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY
231550	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS
231670	GLUTARIC ACIDEMIA I; GA1
231680	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD
231690	GLUTARIC ACIDURIA III; GA3
231900	GLUTATHIONE SYNTHETASE DEFICIENCY OF ERYTHROCYTES, HEMOLYTIC ANEMIA DUE TO; GSSDE
231950	GLUTATHIONURIA
232200	GLYCOGEN STORAGE DISEASE Ia; GSD1A
232220	GLYCOGEN STORAGE DISEASE Ib; GSD1B
232240	GLYCOGEN STORAGE DISEASE Ic; GSD1C
232300	GLYCOGEN STORAGE DISEASE II; GSD2
232400	GLYCOGEN STORAGE DISEASE III; GSD3
232500	GLYCOGEN STORAGE DISEASE IV; GSD4
232600	GLYCOGEN STORAGE DISEASE V; GSD5
232700	GLYCOGEN STORAGE DISEASE VI; GSD6
232800	GLYCOGEN STORAGE DISEASE VII; GSD7
233100	RENAL GLUCOSURIA; GLYS
233300	OVARIAN DYSGENESIS 1; ODG1
233400	PERRAULT SYNDROME 1; PRLTS1
233420	46,XY SEX REVERSAL 7; SRXY7
233650	COMBINED CELLULAR AND HUMORAL IMMUNE DEFECTS WITH GRANULOMAS; CCHIDG
233690	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-NEGATIVE
233700	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE, TYPE I; CDG1
233710	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE, TYPE II; CDG2
233910	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B
234000	FACTOR XII DEFICIENCY
234050	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4
234200	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1
234500	HARTNUP DISORDER; HND
234580	HEIMLER SYNDROME 1; HMLR1
234810	PULMONARY VENOOCCLUSIVE DISEASE 2, AUTOSOMAL RECESSIVE; PVOD2
235000	HEMIHYPERPLASIA, ISOLATED; IH
235200	HEMOCHROMATOSIS, TYPE 1; HFE1
235400	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1; AHUS1
235510	HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1; HKLLS1
235550	HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY; VODI
235555	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2
235700	HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO HEXOKINASE DEFICIENCY
235730	MOWAT-WILSON SYNDROME; MOWS
235800	HISTIDINEMIA
236000	LYMPHOMA, HODGKIN, CLASSIC; CHL
236100	HOLOPROSENCEPHALY 1; HPE1
236200	HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY
236250	HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATE REDUCTASE ACTIVITY
236270	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE
236500	MULTINUCLEATED NEURONS, ANHYDRAMNIOS, RENAL DYSPLASIA, CEREBELLAR HYPOPLASIA, AND HYDRANENCEPHALY; MARCH
236600	HYDROCEPHALUS, CONGENITAL, 1; HYC1
236670	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1
236680	HYDROLETHALUS SYNDROME 1; HLS1
236700	MCKUSICK-KAUFMAN SYNDROME; MKKS
236730	UROFACIAL SYNDROME 1; UFS1
236792	L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA
236800	HYDROXYKYNURENINURIA
237300	CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO
237310	N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY; NAGSD
237450	HYPERBILIRUBINEMIA, ROTOR TYPE; HBLRR
237500	DUBIN-JOHNSON SYNDROME; DJS
237900	HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL; HBLRTFN
238320	LEYDIG CELL HYPOPLASIA, TYPE I
238600	HYPERLIPOPROTEINEMIA, TYPE I
238700	HYPERLYSINEMIA, TYPE I
238970	HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME
239000	PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5
239100	VAN BUCHEM DISEASE; VBCH
239200	HYPERPARATHYROIDISM, NEONATAL SEVERE; NSHPT
239300	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 1; HPMRS1
239500	HYPERPROLINEMIA, TYPE I; HYRPRO1
239510	HYPERPROLINEMIA, TYPE II; HYRPRO2
239850	CANTU SYNDROME
240300	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLE METAPHYSEAL DYSPLASIA; APS1
240400	HYPOASCORBEMIA
240500	IMMUNODEFICIENCY, COMMON VARIABLE, 2; CVID2
240600	GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A
240800	HYPOGLYCEMIA, LEUCINE-INDUCED; LIH
240900	HYPOINSULINEMIC HYPOGLYCEMIA WITH HEMIHYPERTROPHY; HIHGHH
241080	WOODHOUSE-SAKATI SYNDROME
241200	BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2
241410	HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRDS
241500	HYPOPHOSPHATASIA, INFANTILE
241510	HYPOPHOSPHATASIA, CHILDHOOD
241520	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 1; ARHR1
241530	HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA, HEREDITARY; HHRH
241550	HYPOPLASTIC LEFT HEART SYNDROME 1; HLHS1
241600	IMMUNODEFICIENCY 43; IMD43
241800	HYPOTHALAMIC HAMARTOMAS
241850	HYPOTHYROIDISM, THYROIDAL OR ATHYROIDAL, WITH SPIKY HAIR AND CLEFT PALATE
242100	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 2; ARCI2
242300	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1
242500	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4B; ARCI4B
242600	IMINOGLYCINURIA
242840	VICI SYNDROME; VICIS
242860	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 1; ICF1
242900	SCHIMKE IMMUNOOSSEOUS DYSPLASIA; SIOD
243000	INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL RECESSIVE; CIP
243060	SPERMATOGENIC FAILURE 5; SPGF5
243150	GASTROINTESTINAL DEFECTS AND IMMUNODEFICIENCY SYNDROME; GIDID
243300	CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 1; BRIC1
243310	BARAITSER-WINTER SYNDROME 1; BRWS1
243400	ACETYLATION, SLOW
243500	ISOVALERIC ACIDEMIA; IVA
243605	STROMME SYNDROME; STROMS
243700	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE
243800	JOHANSON-BLIZZARD SYNDROME; JBS
244200	HYPOGONADOTROPIC HYPOGONADISM 3 WITH OR WITHOUT ANOSMIA; HH3
244400	CILIARY DYSKINESIA, PRIMARY, 1; CILD1
244450	KAUFMAN OCULOCEREBROFACIAL SYNDROME; KOS
244460	KENNY-CAFFEY SYNDROME, TYPE 1; KCS1
245000	PAPILLON-LEFEVRE SYNDROME; PALS
245010	HAIM-MUNK SYNDROME; HMS
245050	SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD
245150	KEUTEL SYNDROME; KTLS
245200	KRABBE DISEASE
245300	KURU, SUSCEPTIBILITY TO
245340	ERYTHROCYTE LACTATE TRANSPORTER DEFECT
245348	PYRUVATE DEHYDROGENASE E2 DEFICIENCY; PDHDD
245349	PYRUVATE DEHYDROGENASE E3-BINDING PROTEIN DEFICIENCY; PDHXD
245400	MITOCHONDRIAL DNA DEPLETION SYNDROME 9 (ENCEPHALOMYOPATHIC TYPE WITH METHYLMALONIC ACIDURIA); MTDPS9
245480	SPECIFIC GRANULE DEFICIENCY 1; SGD1
245570	EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION; FESD
245590	GROWTH HORMONE INSENSITIVITY WITH IMMUNODEFICIENCY
245600	MULTIPLE JOINT DISLOCATIONS, SHORT STATURE, AND CRANIOFACIAL DYSMORPHISM WITH OR WITHOUT CONGENITAL HEART DEFECTS; JDSCD
245660	LARYNGOONYCHOCUTANEOUS SYNDROME; LOCS
245800	LAURENCE-MOON SYNDROME; LNMS
245900	LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY
246200	DONOHUE SYNDROME
246300	LEPROSY, SUSCEPTIBILITY TO, 3; LPRS3
246450	3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD
246560	SPLIT-HAND/FOOT MALFORMATION 3; SHFM3
246650	LIPASE DEFICIENCY, COMBINED
246700	CHYLOMICRON RETENTION DISEASE; CMRD
246900	DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD
247100	LIPOID PROTEINOSIS OF URBACH AND WIETHE
247200	MILLER-DIEKER LISSENCEPHALY SYNDROME; MDLS
247420	LUTHERAN NULL
247640	LYMPHOBLASTIC LEUKEMIA, ACUTE, WITH LYMPHOMATOUS FEATURES; LALL
248000	MACROCEPHALY/MEGALENCEPHALY SYNDROME, AUTOSOMAL RECESSIVE; MGCPH
248190	HYPOMAGNESEMIA 5, RENAL, WITH OR WITHOUT OCULAR INVOLVEMENT; HOMG5
248200	STARGARDT DISEASE 1; STGD1
248250	HYPOMAGNESEMIA 3, RENAL; HOMG3
248300	MAL DE MELEDA; MDM
248310	PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL
248340	3MC SYNDROME 3; 3MC3
248360	MALONYL-CoA DECARBOXYLASE DEFICIENCY
248370	MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY; MADA
248390	TREACHER COLLINS SYNDROME 3; TCS3
248450	MANITOBA OCULOTRICHOANAL SYNDROME; MOTA
248500	MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA
248510	MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB
248600	MAPLE SYRUP URINE DISEASE; MSUD
248700	MARDEN-WALKER SYNDROME; MWKS
248800	MARINESCO-SJOGREN SYNDROME; MSS
248900	MAST SYNDROME
249000	MECKEL SYNDROME, TYPE 1; MKS1
249100	FAMILIAL MEDITERRANEAN FEVER; FMF
249270	THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA
249400	MELANOSIS, NEUROCUTANEOUS; NCMS
249420	FRANK-TER HAAR SYNDROME; FTHS
249500	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 1; MRT1
249700	LANGER MESOMELIC DYSPLASIA; LMD
249900	METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY
250100	METACHROMATIC LEUKODYSTROPHY; MLD
250220	SPONDYLOMETAPHYSEAL DYSPLASIA, SEDAGHATIAN TYPE; SMDS
250250	CARTILAGE-HAIR HYPOPLASIA; CHH
250400	METAPHYSEAL DYSPLASIA, SPAHR TYPE; MDST
250410	RETINITIS PIGMENTOSA WITH OR WITHOUT SKELETAL ANOMALIES; RPSKA
250460	METAPHYSEAL DYSPLASIA WITHOUT HYPOTRICHOSIS; MDWH
250620	3-HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD
250790	METHEMOGLOBINEMIA AND AMBIGUOUS GENITALIA; METAG
250800	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE
250850	METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY
250940	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG
250950	3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1
251000	METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY
251100	METHYLMALONIC ACIDURIA, cblA TYPE
251110	METHYLMALONIC ACIDURIA, cblB TYPE
251120	METHYLMALONYL-CoA EPIMERASE DEFICIENCY
251200	MICROCEPHALY 1, PRIMARY, AUTOSOMAL RECESSIVE; MCPH1
251230	MICROCEPHALY-MICROMELIA SYNDROME; MIMIS
251255	JAWAD SYNDROME; JWDS
251260	NIJMEGEN BREAKAGE SYNDROME; NBS
251270	MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 1; MCCRP1
251280	MICROCEPHALY, SEIZURES, SPASTICITY, AND BRAIN CALCIFICATIONS; MISSBC
251290	PSEUDO-TORCH SYNDROME 1; PTORCH1
251300	GALLOWAY-MOWAT SYNDROME 1; GAMOS1
251450	DESBUQUOIS DYSPLASIA 1; DBQD1
251600	MICROPHTHALMIA, ISOLATED 1; MCOP1
251750	MICROSPHEROPHAKIA AND/OR MEGALOCORNEA, WITH ECTOPIA LENTIS AND WITH OR WITHOUT SECONDARY GLAUCOMA; MSPKA
251850	DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2
251880	MITOCHONDRIAL DNA DEPLETION SYNDROME 3 (HEPATOCEREBRAL TYPE); MTDPS3
251950	MITOCHONDRIAL MYOPATHY WITH LACTIC ACIDOSIS; MMLA
252010	MITOCHONDRIAL COMPLEX I DEFICIENCY
252011	MITOCHONDRIAL COMPLEX II DEFICIENCY
252150	MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP A; MOCODA
252160	MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP B; MOCODB
252270	MONOSOMY 7 OF BONE MARROW
252350	MOYAMOYA DISEASE 1; MYMY1
252500	MUCOLIPIDOSIS II ALPHA/BETA
252600	MUCOLIPIDOSIS III ALPHA/BETA
252605	MUCOLIPIDOSIS III GAMMA
252650	MUCOLIPIDOSIS IV; ML4
252900	MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A
252920	MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B
252930	MUCOPOLYSACCHARIDOSIS, TYPE IIIC; MPS3C
252940	MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D
253000	MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A
253010	MUCOPOLYSACCHARIDOSIS, TYPE IVB; MPS4B
253200	MUCOPOLYSACCHARIDOSIS, TYPE VI; MPS6
253220	MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7
253250	MULIBREY NANISM
253260	BIOTINIDASE DEFICIENCY
253270	HOLOCARBOXYLASE SYNTHETASE DEFICIENCY
253280	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3
253290	MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE; LMPS
253300	SPINAL MUSCULAR ATROPHY, TYPE I; SMA1
253310	LETHAL CONGENITAL CONTRACTURE SYNDROME 1; LCCS1
253400	SPINAL MUSCULAR ATROPHY, TYPE III; SMA3
253550	SPINAL MUSCULAR ATROPHY, TYPE II; SMA2
253600	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A
253601	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B
253700	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C
253800	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4
254090	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1
254110	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2H; LGMD2H
254130	MIYOSHI MUSCULAR DYSTROPHY 1; MMD1
254210	MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6
254300	MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10
254450	MYELOFIBROSIS
254500	MYELOMA, MULTIPLE
254600	MYELOPEROXIDASE DEFICIENCY; MPOD
254770	EPILEPSY, MYOCLONIC JUVENILE; EJM
254780	MYOCLONIC EPILEPSY OF LAFORA
254800	MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG
254900	EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE; EPM4
254940	CAREY-FINEMAN-ZITER SYNDROME; CFZS
255100	LIPID STORAGE MYOPATHY DUE TO FLAVIN ADENINE DINUCLEOTIDE SYNTHETASE DEFICIENCY; LSMFLAD
255110	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, MYOPATHIC, STRESS-INDUCED
255120	CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY
255125	MYOPATHY WITH LACTIC ACIDOSIS, HEREDITARY; HML
255160	MYOPATHY, MYOSIN STORAGE, AUTOSOMAL RECESSIVE; MSMB
255200	MYOPATHY, CENTRONUCLEAR, 2; CNM2
255310	MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION; CFTD
255320	MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA
255500	MYOPIA 18, AUTOSOMAL RECESSIVE; MYP18
255600	MYOSCLEROSIS, AUTOSOMAL RECESSIVE
255700	MYOTONIA CONGENITA, AUTOSOMAL RECESSIVE
255800	SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1
255960	MYXOMA, INTRACARDIAC
255995	MYOPATHY, CONGENITAL, BAILEY-BLOCH; MYPBB
256000	LEIGH SYNDROME; LS
256030	NEMALINE MYOPATHY 2; NEM2
256040	PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 1; PRAAS1
256050	ATELOSTEOGENESIS, TYPE II; AO2
256100	NEPHRONOPHTHISIS 1; NPHP1
256300	NEPHROTIC SYNDROME, TYPE 1; NPHS1
256370	NEPHROTIC SYNDROME, TYPE 4; NPHS4
256450	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1
256500	NETHERTON SYNDROME; NETH
256520	NEU-LAXOVA SYNDROME 1; NLS1
256540	GALACTOSIALIDOSIS; GSL
256550	NEURAMINIDASE DEFICIENCY
256600	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A
256700	NEUROBLASTOMA, SUSCEPTIBILITY TO
256730	CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1
256731	CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5
256800	INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA
256810	MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6
256840	NEUROPATHY, HEREDITARY SENSORY, WITH SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE
256850	GIANT AXONAL NEUROPATHY 1, AUTOSOMAL RECESSIVE; GAN1
257200	NIEMANN-PICK DISEASE, TYPE A
257220	NIEMANN-PICK DISEASE, TYPE C1; NPC1
257270	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B; CSNB1B
257300	MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1; MVA1
257320	LISSENCEPHALY 2; LIS2
257550	OCULAR MOTOR APRAXIA
257850	OCULODENTODIGITAL DYSPLASIA, AUTOSOMAL RECESSIVE
257920	3MC SYNDROME 1; 3MC1
257980	ODONTOONYCHODERMAL DYSPLASIA; OODD
258100	OGUCHI DISEASE 1
258315	OMODYSPLASIA 1; OMOD1
258450	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1
258480	OPSISMODYSPLASIA; OPSMD
258500	OPTIC ATROPHY 6; OPA6
258501	3-METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3
258660	NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY, SUSCEPTIBILITY TO
258860	OROFACIODIGITAL SYNDROME IV; OFD4
258870	GYRATE ATROPHY OF CHOROID AND RETINA; GACR
258900	OROTIC ACIDURIA
259050	PRIMROSE SYNDROME; PRIMS
259100	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1
259420	OSTEOGENESIS IMPERFECTA, TYPE III; OI3
259440	OSTEOGENESIS IMPERFECTA, TYPE IX; OI9
259450	BRUCK SYNDROME 1; BRKS1
259500	OSTEOGENIC SARCOMA
259600	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA
259700	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1; OPTB1
259710	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 2; OPTB2
259720	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 5; OPTB5
259730	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3
259770	OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG
259775	RAINE SYNDROME; RNS
259900	HYPEROXALURIA, PRIMARY, TYPE I; HP1
260000	HYPEROXALURIA, PRIMARY, TYPE II; HP2
260005	5-OXOPROLINASE DEFICIENCY; OPLAHD
260300	PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK15
260350	PANCREATIC CANCER
260370	PANCREATIC AGENESIS 1; PAGEN1
260400	SHWACHMAN-DIAMOND SYNDROME 1; SDS1
260500	PAPILLOMA OF CHOROID PLEXUS; CPP
260540	PARKINSON-DEMENTIA SYNDROME
260565	PEHO SYNDROME; PEHO
260600	LEUKODYSTROPHY, HYPOMYELINATING, 3; HLD3
260660	COUSIN SYNDROME
260800	PENTOSURIA; PNTSU
260920	HYPER-IgD SYNDROME; HIDS
261000	INTRINSIC FACTOR DEFICIENCY; IFD
261100	MEGALOBLASTIC ANEMIA 1
261500	EOSINOPHIL PEROXIDASE DEFICIENCY; EPXD
261515	D-BIFUNCTIONAL PROTEIN DEFICIENCY
261540	PETERS-PLUS SYNDROME
261550	PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS
261600	PHENYLKETONURIA; PKU
261630	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C
261640	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A
261650	PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, MITOCHONDRIAL; PCKDM
261670	GLYCOGEN STORAGE DISEASE X; GSD10
261680	PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, CYTOSOLIC; PCKDC
261740	GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL
261750	GLYCOGEN STORAGE DISEASE IXb; GSD9B
261800	PIERRE ROBIN SYNDROME; PRBNS
262000	BJORNSTAD SYNDROME; BJS
262190	PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATIC ABNORMALITIES
262300	ACHROMATOPSIA 3; ACHM3
262400	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A
262500	LARON SYNDROME
262600	PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2
262650	KOWARSKI SYNDROME
262700	PITUITARY HORMONE DEFICIENCY, COMBINED, 4; CPHD4
262850	ALPHA-2-PLASMIN INHIBITOR DEFICIENCY
262890	SCOTT SYNDROME; SCTS
263200	POLYCYSTIC KIDNEY DISEASE 4 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD4
263210	GILLESSEN-KAESBACH-NISHIMURA SYNDROME; GIKANIS
263300	POLYCYTHEMIA VERA; PV
263400	ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2
263450	POLYDACTYLY, POSTAXIAL, TYPE A5; PAPA5
263520	SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6
263570	POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN
263650	POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE
263700	PORPHYRIA, CONGENITAL ERYTHROPOIETIC
263750	POSTAXIAL ACROFACIAL DYSOSTOSIS; POADS
263800	GITELMAN SYNDROME; GTLMNS
264070	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D
264080	PROGESTERONE RESISTANCE
264300	17-BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY
264350	PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1B
264470	PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY
264600	PSEUDOVAGINAL PERINEOSCROTAL HYPOSPADIAS; PPSH
264700	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A
264800	PSEUDOXANTHOMA ELASTICUM; PXE
265000	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS
265050	3MC SYNDROME 2; 3MC2
265100	PULMONARY ALVEOLAR MICROLITHIASIS
265120	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1
265380	ALVEOLAR CAPILLARY DYSPLASIA WITH MISALIGNMENT OF PULMONARY VEINS; ACDMPV
265450	PULMONARY VENOOCCLUSIVE DISEASE 1, AUTOSOMAL DOMINANT; PVOD1
265800	PYCNODYSOSTOSIS
265900	PYLE DISEASE; PYL
266100	EPILEPSY, PYRIDOXINE-DEPENDENT; EPD
266120	URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO
266130	GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD
266140	PYROPOIKILOCYTOSIS, HEREDITARY; HPP
266150	PYRUVATE CARBOXYLASE DEFICIENCY
266200	PYRUVATE KINASE DEFICIENCY OF RED CELLS
266265	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C
266280	RAPADILINO SYNDROME
266300	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2
266500	REFSUM DISEASE, CLASSIC
266510	PEROXISOME BIOGENESIS DISORDER 3B; PBD3B
266600	INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 1; IBD1
266900	SENIOR-LOKEN SYNDROME 1; SLSN1
266920	SHORT-RIB THORACIC DYSPLASIA 9 WITH OR WITHOUT POLYDACTYLY; SRTD9
267000	PERLMAN SYNDROME; PRLMNS
267010	MECKEL SYNDROME, TYPE 7; MKS7
267300	RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS
267430	RENAL TUBULAR DYSGENESIS; RTD
267500	RETICULAR DYSGENESIS
267700	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1
267750	KNOBLOCH SYNDROME 1; KNO1
268100	ENHANCED S-CONE SYNDROME; ESCS
268130	REVESZ SYNDROME
268150	RH-NULL, REGULATOR TYPE; RHNR
268200	MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE
268210	RHABDOMYOSARCOMA, EMBRYONAL, 1; RMSE1
268220	RHABDOMYOSARCOMA 2; RMS2
268300	ROBERTS SYNDROME; RBS
268305	ROBIN SEQUENCE WITH CLEFT MANDIBLE AND LIMB ANOMALIES
268310	ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS
268400	ROTHMUND-THOMSON SYNDROME; RTS
268700	SACCHAROPINURIA
268800	SANDHOFF DISEASE
268900	SARCOSINEMIA; SARCOS
269000	SC PHOCOMELIA SYNDROME
269150	SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME
269160	SCHIZENCEPHALY
269250	SCHNECKENBECKEN DYSPLASIA; SHNKND
269400	ANTERIOR SEGMENT DYSGENESIS 7; ASGD7
269500	SCLEROSTEOSIS 1; SOST1
269600	SEA-BLUE HISTIOCYTE DISEASE
269700	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2
269840	IMMUNODEFICIENCY 48; IMD48
269880	SHORT SYNDROME
269920	INFANTILE SIALIC ACID STORAGE DISEASE; ISSD
269921	SIALURIA
270100	HETEROTAXY, VISCERAL, 5, AUTOSOMAL; HTX5
270200	SJOGREN-LARSSON SYNDROME; SLS
270300	PEELING SKIN SYNDROME 1; PSS1
270400	SMITH-LEMLI-OPITZ SYNDROME; SLOS
270420	DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, WITH OR WITHOUT OTHER CONGENITAL ANOMALIES; DIAR3
270450	INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO; IGF1RES
270550	SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS
270685	SPASTIC PARAPLEGIA 17, AUTOSOMAL DOMINANT; SPG17
270700	SPASTIC PARAPLEGIA 15, AUTOSOMAL RECESSIVE; SPG15
270750	SPASTIC PARAPLEGIA 23; SPG23
270800	SPASTIC PARAPLEGIA 5A, AUTOSOMAL RECESSIVE; SPG5A
270960	SPERMATOGENIC FAILURE 4; SPGF4
270970	SPHEROCYTOSIS, TYPE 3; SPH3
271150	SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4
271245	MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7
271250	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 3; SCAR3
271400	ASPLENIA, ISOLATED CONGENITAL; ICAS
271640	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, TYPE 1, WITH OR WITHOUT FRACTURES; SEMDJL1
271665	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE
271700	SPONDYLOPERIPHERAL DYSPLASIA
271900	CANAVAN DISEASE
271930	STRIATONIGRAL DEGENERATION, INFANTILE; SNDI
271980	SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD
272120	SUDDEN INFANT DEATH SYNDROME
272200	MULTIPLE SULFATASE DEFICIENCY; MSD
272300	SULFITE OXIDASE DEFICIENCY, ISOLATED; ISOD
272430	CRISPONI/COLD-INDUCED SWEATING SYNDROME 1; CISS1
272440	FILIPPI SYNDROME; FLPIS
272460	SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT
272750	GM2-GANGLIOSIDOSIS, AB VARIANT
272800	TAY-SACHS DISEASE; TSD
273300	TESTICULAR GERM CELL TUMOR; TGCT
273395	TETRAAMELIA SYNDROME 1; TETAMS1
273750	THREE M SYNDROME 1; 3M1
273800	GLANZMANN THROMBASTHENIA; GT
273900	THROMBOCYTOPENIA 3; THC3
274000	THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME; TAR
274150	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP
274270	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY
274300	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL RECESSIVE; GRTH
274400	THYROID DYSHORMONOGENESIS 1; TDH1
274500	THYROID DYSHORMONOGENESIS 2A; TDH2A
274600	PENDRED SYNDROME; PDS
274700	THYROID DYSHORMONOGENESIS 3; TDH3
274800	THYROID DYSHORMONOGENESIS 4; TDH4
274900	THYROID DYSHORMONOGENESIS 5; TDH5
275000	GRAVES DISEASE, SUSCEPTIBILITY TO, 1; GRD1
275100	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4
275120	THYROTROPIN-RELEASING HORMONE DEFICIENCY
275210	RESTRICTIVE DERMOPATHY, LETHAL
275220	TIBIAL HEMIMELIA
275350	TRANSCOBALAMIN II DEFICIENCY
275355	SQUAMOUS CELL CARCINOMA, HEAD AND NECK; HNSCC
275400	OLIVER-MCFARLANE SYNDROME; OMCS
275630	CHANARIN-DORFMAN SYNDROME; CDS
275900	SPASTIC PARAPLEGIA 20, AUTOSOMAL RECESSIVE; SPG20
276300	MISMATCH REPAIR CANCER SYNDROME; MMRCS
276400	TWINNING, DIZYGOTIC
276600	TYROSINEMIA, TYPE II; TYRSN2
276700	TYROSINEMIA, TYPE I; TYRSN1
276710	TYROSINEMIA, TYPE III; TYRSN3
276820	ULNA AND FIBULA, ABSENCE OF, WITH SEVERE LIMB DEFICIENCY
276880	UROCANASE DEFICIENCY; UROCD
276900	USHER SYNDROME, TYPE I; USH1
276901	USHER SYNDROME, TYPE IIA; USH2A
276902	USHER SYNDROME, TYPE IIIA; USH3A
276904	USHER SYNDROME, TYPE IC; USH1C
276950	VACTERL ASSOCIATION WITH HYDROCEPHALUS
277170	OROFACIODIGITAL SYNDROME VI; OFD6
277180	VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF; CBAVD
277300	SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1
277380	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE; MAHCF
277400	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC
277410	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD
277440	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A
277450	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1
277460	VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED
277470	PONTOCEREBELLAR HYPOPLASIA, TYPE 2A; PCH2A
277480	VON WILLEBRAND DISEASE, TYPE 3; VWD3
277580	WAARDENBURG SYNDROME, TYPE 4A; WS4A
277590	WEAVER SYNDROME; WVS
277600	WEILL-MARCHESANI SYNDROME 1; WMS1
277700	WERNER SYNDROME; WRN
277900	WILSON DISEASE
277950	WINCHESTER SYNDROME; WNCHRS
278000	LYSOSOMAL ACID LIPASE DEFICIENCY
278150	HYPOTRICHOSIS 8; HYPT8
278250	WRINKLY SKIN SYNDROME; WSS
278300	XANTHINURIA, TYPE I; XAN1
278700	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA
278720	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC
278730	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD
278740	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E
278750	XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV
278760	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF
278780	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG
278800	DE SANCTIS-CACCHIONE SYNDROME
278850	46,XX SEX REVERSAL 2; SRXX2
280000	COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, MENTAL RETARDATION, AND EAR ANOMALIES SYNDROME; CHIME
300000	OPITZ GBBB SYNDROME, TYPE I; GBBB1
300004	CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA
300009	DENT DISEASE 1
300018	46,XY SEX REVERSAL 2; SRXY2
300029	RETINITIS PIGMENTOSA 3; RP3
300030	DEAFNESS, X-LINKED 3; DFNX3
300046	MENTAL RETARDATION, X-LINKED 23; MRX23
300047	MENTAL RETARDATION, X-LINKED 20; MRX20
300048	INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED
300049	PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1
300055	MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13
300062	MENTAL RETARDATION, X-LINKED 14; MRX14
300066	DEAFNESS, X-LINKED 4; DFNX4
300067	LISSENCEPHALY, X-LINKED, 1; LISX1
300068	ANDROGEN INSENSITIVITY SYNDROME; AIS
300071	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A; CSNB2A
300076	IMMUNONEUROLOGIC DISORDER, X-LINKED
300082	COGNITIVE FUNCTION 1, SOCIAL; CGF1
300085	CONE-ROD DYSTROPHY, X-LINKED, 2; CORDX2
300087	X INACTIVATION, FAMILIAL SKEWED, 1; SXI1
300088	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 9; EIEE9
300100	ADRENOLEUKODYSTROPHY; ALD
300106	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, X-LINKED; SEMDX
300114	MENTAL RETARDATION, X-LINKED 49; MRX49
300115	MENTAL RETARDATION, X-LINKED 50; MRX50
300123	MENTAL RETARDATION, X-LINKED, WITH PANHYPOPITUITARISM
300125	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 2
300143	MENTAL RETARDATION, X-LINKED 21; MRX21
300147	PROSTATE CANCER, HEREDITARY, X-LINKED 1; HPCX1
300148	MEHMO SYNDROME; MEHMO
300155	RETINITIS PIGMENTOSA 24; RP24
300166	MICROPHTHALMIA, SYNDROMIC 2; MCOPS2
300194	AMME COMPLEX
300200	ADRENAL HYPOPLASIA, CONGENITAL; AHC
300209	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 2; SGBS2
300210	MENTAL RETARDATION, X-LINKED 58; MRX58
300211	EPISODIC MUSCLE WEAKNESS, X-LINKED; EMWX
300215	LISSENCEPHALY, X-LINKED, 2; LISX2
300218	MENTAL RETARDATION, X-LINKED, SYNDROMIC 7; MRXS7
300228	TESTICULAR GERM CELL TUMOR 1; TGCT1
300238	MENTAL RETARDATION, X-LINKED, SYNDROMIC 11; MRXS11
300243	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHRISTIANSON TYPE; MRXSCH
300244	TERMINAL OSSEOUS DYSPLASIA; TOD
300245	PTOSIS, HEREDITARY CONGENITAL 2
300257	DANON DISEASE
300260	LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL
300261	ARMFIELD X-LINKED MENTAL RETARDATION SYNDROME; MRXSA
300262	ABIDI X-LINKED MENTAL RETARDATION SYNDROME; MRXSAB
300263	SIDERIUS X-LINKED MENTAL RETARDATION SYNDROME; MRXSSD
300265	ZIC FAMILY, MEMBER 3; ZIC3
300266	SPASTIC PARAPLEGIA 16, X-LINKED; SPG16
300271	MENTAL RETARDATION, X-LINKED 72; MRX72
300273	GOITER, MULTINODULAR 2; MNG2
300280	URUGUAY FACIOCARDIOMUSCULOSKELETAL SYNDROME; FCMSU
300291	ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY
300299	NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX
300301	ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNODEFICIENCY, OSTEOPETROSIS, AND LYMPHEDEMA; OLEDAID
300310	AGAMMAGLOBULINEMIA, X-LINKED, TYPE 2; AGMX2
300321	FG SYNDROME 2; FGS2
300322	LESCH-NYHAN SYNDROME; LNS
300323	KELLEY-SEEGMILLER SYNDROME
300324	MENTAL RETARDATION, X-LINKED 53; MRX53
300331	THROMBOCYTHEMIA, X-LINKED; THCYTX
300350	CHORDIN-LIKE 1; CHRDL1
300352	CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1
300354	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC
300355	MENTAL RETARDATION, X-LINKED 73; MRX73
300367	THROMBOCYTOPENIA, X-LINKED, WITH OR WITHOUT DYSERYTHROPOIETIC ANEMIA; XLTDA
300373	OSTEOPATHIA STRIATA WITH CRANIAL SCLEROSIS; OSCS
300376	MUSCULAR DYSTROPHY, BECKER TYPE; BMD
300387	MENTAL RETARDATION, X-LINKED 63; MRX63
300388	POLYMICROGYRIA, BILATERAL PERISYLVIAN, X-LINKED; BPPX
300400	SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1
300419	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED; MRXARX
300422	FG SYNDROME 4; FGS4
300423	MENTAL RETARDATION, X-LINKED, SYNDROMIC, HEDERA TYPE; MRXSH
300424	RETINITIS PIGMENTOSA 23; RP23
300425	AUTISM, SUSCEPTIBILITY TO, X-LINKED 1; AUTSX1
300428	MENTAL RETARDATION, X-LINKED 2; MRX2
300433	MENTAL RETARDATION, X-LINKED 81; MRX81
300434	STOCCO DOS SANTOS X-LINKED MENTAL RETARDATION SYNDROME; SDSX
300436	MENTAL RETARDATION, X-LINKED 46; MRX46
300438	HSD10 MITOCHONDRIAL DISEASE; HSD10MD
300448	ALPHA-THALASSEMIA MYELODYSPLASIA SYNDROME; ATMDS
300454	MENTAL RETARDATION, X-LINKED 77; MRX77
300455	RETINITIS PIGMENTOSA, X-LINKED, AND SINORESPIRATORY INFECTIONS, WITH OR WITHOUT DEAFNESS
300471	CUBITUS VALGUS WITH MENTAL RETARDATION AND UNUSUAL FACIES
300472	CORPUS CALLOSUM, AGENESIS OF, WITH MENTAL RETARDATION, OCULAR COLOBOMA, AND MICROGNATHIA
300475	DEAFNESS, DYSTONIA, AND CEREBRAL HYPOMYELINATION; DDCH
300476	CONE-ROD DYSTROPHY, X-LINKED, 3; CORDX3
300486	MENTAL RETARDATION, X-LINKED, WITH CEREBELLAR HYPOPLASIA AND DISTINCTIVE FACIAL APPEARANCE
300488	MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 1; MENOQ1
300489	SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED 3; SMAX3
300491	EPILEPSY, X-LINKED, WITH VARIABLE LEARNING DISABILITIES AND BEHAVIOR DISORDERS
300494	ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 1; ASPGX1
300495	AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2
300496	AUTISM, SUSCEPTIBILITY TO, X-LINKED 3; AUTSX3
300497	ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 2; ASPGX2
300498	MENTAL RETARDATION, X-LINKED 45; MRX45
300500	ALBINISM, OCULAR, TYPE I; OA1
300504	MENTAL RETARDATION, X-LINKED 52; MRX52
300505	MENTAL RETARDATION, X-LINKED 84; MRX84
300510	OVARIAN DYSGENESIS 2; ODG2
300511	PREMATURE OVARIAN FAILURE 2A; POF2A
300514	FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB
300518	MENTAL RETARDATION, X-LINKED 82; MRX82
300519	MENTAL RETARDATION, X-LINKED, SYNDROMIC, MARTIN-PROBST TYPE; MRXSMP
300523	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS
300534	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CLAES-JENSEN TYPE; MRXSCJ
300539	NEPHROGENIC SYNDROME OF INAPPROPRIATE ANTIDIURESIS; NSIAD
300554	HYPOPHOSPHATEMIC RICKETS, X-LINKED RECESSIVE
300555	DENT DISEASE 2
300558	MENTAL RETARDATION, X-LINKED 30; MRX30
300559	GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D
300577	MENTAL RETARDATION, X-LINKED 91; MRX91
300578	CHROMOSOME Xp11.3 DELETION SYNDROME
300580	MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION, X-LINKED; CFTDX
300582	SHORT STATURE, IDIOPATHIC, X-LINKED; ISS
300584	IMMUNODEFICIENCY WITHOUT ANHIDROTIC ECTODERMAL DYSPLASIA
300589	NYSTAGMUS 5, CONGENITAL, X-LINKED; NYS5
300590	CORNELIA DE LANGE SYNDROME 2; CDLS2
300600	ALAND ISLAND EYE DISEASE; AIED
300604	PREMATURE OVARIAN FAILURE 2B; POF2B
300607	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 8; EIEE8
300612	BROOKS-WISNIEWSKI-BROWN SYNDROME
300614	DEAFNESS, X-LINKED 5; DFNX5
300615	BRUNNER SYNDROME; BRNRS
300622	TN POLYAGGLUTINATION SYNDROME; TNPS
300623	FRAGILE X TREMOR/ATAXIA SYNDROME; FXTAS
300624	FRAGILE X SYNDROME; FXS
300633	HYPOSPADIAS 1, X-LINKED; HYSP1
300635	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2; XLP2
300636	IMMUNODEFICIENCY 33; IMD33
300640	INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 2; IPD2
300643	ROLANDIC EPILEPSY, MENTAL RETARDATION, AND SPEECH DYSPRAXIA, X-LINKED; RESDX
300645	IMMUNODEFICIENCY 34; IMD34
300650	ALBINISM, OCULAR, WITH LATE-ONSET SENSORINEURAL DEAFNESS; OASD
300652	ANGIOMA SERPIGINOSUM, X-LINKED
300653	PHOSPHOGLYCERATE KINASE 1 DEFICIENCY
300659	MENTAL RETARDATION, X-LINKED 93; MRX93
300660	LEUKOENCEPHALOPATHY WITH METAPHYSEAL CHONDRODYSPLASIA; LKMCD
300661	PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY
300672	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2; EIEE2
300673	ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS
300676	MENTAL RETARDATION, X-LINKED, SYNDROMIC 14; MRXS14
300695	SCAPULOPERONEAL MYOPATHY, X-LINKED DOMINANT; SPM
300696	MYOPATHY, X-LINKED, WITH POSTURAL MUSCLE ATROPHY; XMPMA
300699	MENTAL RETARDATION, X-LINKED, SYNDROMIC, WU TYPE; MRXSW
300700	ALBINISM-DEAFNESS SYNDROME; ADFN
300703	SPINOCEREBELLAR ATAXIA, X-LINKED 5; SCAX5
300705	CHROMOSOME Xp11.22 DUPLICATION SYNDROME
300706	MENTAL RETARDATION, X-LINKED, SYNDROMIC, TURNER TYPE; MRXST
300707	TOE SYNDACTYLY, TELECANTHUS, AND ANOGENITAL AND RENAL MALFORMATIONS; STAR
300709	MENTAL RETARDATION, X-LINKED, SYNDROMIC 9; MRXS9
300712	CRANIOFACIOSKELETAL SYNDROME
300716	MENTAL RETARDATION, X-LINKED 95; MRX95
300717	REDUCING BODY MYOPATHY, X-LINKED 1A, SEVERE, WITH INFANTILE OR EARLY CHILDHOOD ONSET; RBMX1A
300718	REDUCING BODY MYOPATHY, X-LINKED 1B, WITH LATE CHILDHOOD OR ADULT ONSET; RBMX1B
300719	DEAFNESS, CATARACT, RETINITIS PIGMENTOSA, AND SPERM ABNORMALITIES
300749	MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA; MICPCH
300750	SPASTIC PARAPLEGIA 34, X-LINKED; SPG34
300751	ANEMIA, SIDEROBLASTIC, 1; SIDBA1
300752	PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP
300755	AGAMMAGLOBULINEMIA, X-LINKED; XLA
300758	HYPOSPADIAS 2, X-LINKED; HYSP2
300770	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 4; SMDP4
300778	CORNEAL DYSTROPHY, LISCH EPITHELIAL; LECD
300779	CORNEAL DYSTROPHY, ENDOTHELIAL, X-LINKED; XECD
300799	MENTAL RETARDATION, X-LINKED, SYNDROMIC, RAYMOND TYPE; MRXSR
300801	CHROMOSOME Xp11.23-p11.22 DUPLICATION SYNDROME
300802	MENTAL RETARDATION, X-LINKED 96; MRX96
300803	MENTAL RETARDATION, X-LINKED 97; MRX97
300804	JOUBERT SYNDROME 10; JBTS10
300807	THROMBOPHILIA, X-LINKED, DUE TO FACTOR IX DEFECT; THPH8
300813	SARCOMA, SYNOVIAL
300814	NYSTAGMUS 6, CONGENITAL, X-LINKED; NYS6
300816	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 6; COXPD6
300818	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1
300830	AUTISM, SUSCEPTIBILITY TO, X-LINKED 4; AUTSX4
300831	CK SYNDROME
300833	46,XX SEX REVERSAL 3; SRXX3
300834	MACULAR DEGENERATION, X-LINKED ATROPHIC
300835	ANEMIA, X-LINKED, WITH OR WITHOUT NEUTROPENIA AND/OR PLATELET ABNORMALITIES; XLANP
300842	MCLEOD SYNDROME; MCLDS
300843	BORNHOLM EYE DISEASE; BED
300844	MENTAL RETARDATION, X-LINKED 19; MRX19
300845	MOYAMOYA DISEASE 4 WITH SHORT STATURE, HYPERGONADOTROPIC HYPOGONADISM, AND FACIAL DYSMORPHISM; MYMY4
300847	AUTISM, SUSCEPTIBILITY TO, X-LINKED 5; AUTSX5
300848	MENTAL RETARDATION, X-LINKED 89; MRX89
300849	MENTAL RETARDATION, X-LINKED 41; MRX41
300850	MENTAL RETARDATION, X-LINKED 90; MRX90
300851	MENTAL RETARDATION, X-LINKED 92; MRX92
300852	MENTAL RETARDATION, X-LINKED 88; MRX88
300853	IMMUNODEFICIENCY, X-LINKED, WITH MAGNESIUM DEFECT, EPSTEIN-BARR VIRUS INFECTION, AND NEOPLASIA; XMEN
300854	RENAL CELL CARCINOMA, Xp11-ASSOCIATED; RCCX1
300855	OGDEN SYNDROME; OGDNS
300857	AMYOTROPHIC LATERAL SCLEROSIS 15 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS15
300858	MENTAL RETARDATION, X-LINKED, SYNDROMIC 17; MRXS17
300860	MENTAL RETARDATION, X-LINKED, SYNDROMIC, NASCIMENTO TYPE; MRXSN
300861	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHUDLEY-SCHWARTZ TYPE; MRXSCS
300863	CHONDRODYSPLASIA WITH PLATYSPONDYLY, DISTINCTIVE BRACHYDACTYLY, HYDROCEPHALY, AND MICROPHTHALMIA
300864	CEREBRAL-CEREBELLAR-COLOBOMA SYNDROME, X-LINKED
300867	KABUKI SYNDROME 2; KABUK2
300868	MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2
300869	CHROMOSOME Xq27.3-q28 DUPLICATION SYNDROME
300872	AUTISM, SUSCEPTIBILITY TO, X-LINKED 6; AUTSX6
300882	CORNELIA DE LANGE SYNDROME 5; CDLS5
300884	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 36; EIEE36
300886	MENTAL RETARDATION, X-LINKED, SYNDROMIC 32; MRXS32
300887	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 2; LSDMCA2
300888	HYPOTHYROIDISM, CENTRAL, AND TESTICULAR ENLARGEMENT; CHTE
300894	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 5; NBIA5
300895	OHDO SYNDROME, X-LINKED; OHDOX
300896	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm; CDG2M
300905	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 6; CMTX6
300908	ANEMIA, NONSPHEROCYTIC HEMOLYTIC, DUE TO G6PD DEFICIENCY
300909	ANGIOEDEMA INDUCED BY ACE INHIBITORS, SUSCEPTIBILITY TO; AEACEI
300910	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 18; BMND18
300911	PARKINSONISM WITH SPASTICITY, X-LINKED; XPDS
300912	MENTAL RETARDATION, X-LINKED 98; MRX98
300914	DEAFNESS, X-LINKED 6; DFNX6
300915	MICROPHTHALMIA, SYNDROMIC 13; MCOPS13
300918	PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTIC PLAQUES, X-LINKED
300919	MENTAL RETARDATION, X-LINKED 99; MRX99
300923	MENTAL RETARDATION, X-LINKED 100; MRX100
300928	MENTAL RETARDATION, X-LINKED 101; MRX101
300932	THYROXINE-BINDING GLOBULIN QUANTITATIVE TRAIT LOCUS; TBGQTL
300934	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iy; CDG1Y
300942	CHROMOSOME Xq26.3 DUPLICATION SYNDROME
300943	PITUITARY ADENOMA 2, GROWTH HORMONE-SECRETING; PITA2
300946	DIAMOND-BLACKFAN ANEMIA 14 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA14
300952	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 3; LSDMCA3
300953	TRICHOTHIODYSTROPHY 5, NONPHOTOSENSITIVE; TTD5
300957	MENTAL RETARDATION, X-LINKED 12; MRX12
300958	MENTAL RETARDATION, X-LINKED 102; MRX102
300960	MEND SYNDROME; MEND
300963	RITSCHER-SCHINZEL SYNDROME 2; RTSC2
300966	MENTAL RETARDATION, X-LINKED, SYNDROMIC 33; MRXS33
300967	MENTAL RETARDATION, X-LINKED, SYNDROMIC 34; MRXS34
300968	MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED; MRXS99F
300971	BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5
300972	IMMUNODEFICIENCY 47; IMD47
300978	MENTAL RETARDATION, X-LINKED 61; MRX61
300979	Xq25 DUPLICATION SYNDROME
300982	MENTAL RETARDATION, X-LINKED 103; MRX103
300983	MENTAL RETARDATION, X-LINKED 104; MRX104
300984	MENTAL RETARDATION, X-LINKED 105; MRX105
300985	VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF, X-LINKED; CBAVDX
300986	MENTAL RETARDATION, X-LINKED, SYNDROMIC, BAIN TYPE; MRXSB
300988	IMMUNODEFICIENCY 50; IMD50
300989	MEESTER-LOEYS SYNDROME; MRLS
300990	MIDFACE HYPOPLASIA, HEARING IMPAIRMENT, ELLIPTOCYTOSIS, AND NEPHROCALCINOSIS; MFHIEN
300991	CILIARY DYSKINESIA, PRIMARY, 36, X-LINKED; CILD36
300997	MENTAL RETARDATION, X-LINKED 106; MRX106
300998	MENTAL RETARDATION, X-LINKED, SYNDROMIC, 35; MRXS35
301000	WISKOTT-ALDRICH SYNDROME; WAS
301006	GALLOWAY-MOWAT SYNDROME 2, X-LINKED; GAMOS2
301008	MENTAL RETARDATION, X-LINKED, SYNDROMIC, HOUGE TYPE; MRXSHG
301010	MYOPIA 26, X-LINKED, FEMALE-LIMITED; MYP26
301013	MENTAL RETARDATION, X-LINKED 107; MRX107
301014	OSTEOGENESIS IMPERFECTA, TYPE XIX; OI19
301015	HEMOLYTIC ANEMIA, CONGENITAL, X-LINKED
301040	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX
301050	ALPORT SYNDROME, X-LINKED; ATS
301200	AMELOGENESIS IMPERFECTA, TYPE IE; AI1E
301201	AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 2
301220	PIGMENTARY DISORDER, RETICULATE, WITH SYSTEMIC MANIFESTATIONS, X-LINKED; PDR
301310	ANEMIA, SIDEROBLASTIC, AND SPINOCEREBELLAR ATAXIA; ASAT
301500	FABRY DISEASE
301590	MICROPHTHALMIA, SYNDROMIC 4; MCOPS4
301830	SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2
301835	ARTS SYNDROME; ARTS
301845	BAZEX SYNDROME; BZX
301900	BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS
302045	CARDIOMYOPATHY, DILATED, 3B; CMD3B
302060	BARTH SYNDROME; BTHS
302200	CATARACT 40; CTRCT40
302350	NANCE-HORAN SYNDROME; NHS
302500	SPINOCEREBELLAR ATAXIA, X-LINKED 1; SCAX1
302800	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1
302801	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 2; CMTX2
302802	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 3; CMTX3
302905	ABRUZZO-ERICKSON SYNDROME; ABERS
302950	CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1
302960	CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2
303100	CHOROIDEREMIA; CHM
303110	CHOROIDEREMIA, DEAFNESS, AND MENTAL RETARDATION
303350	MASA SYNDROME
303400	CLEFT PALATE WITH OR WITHOUT ANKYLOGLOSSIA, X-LINKED; CPX
303600	COFFIN-LOWRY SYNDROME; CLS
303700	BLUE CONE MONOCHROMACY; BCM
303800	COLORBLINDNESS, PARTIAL, DEUTAN SERIES; CBD
303900	COLORBLINDNESS, PARTIAL, PROTAN SERIES; CBP
304020	CONE-ROD DYSTROPHY, X-LINKED, 1; CORDX1
304050	AICARDI SYNDROME; AIC
304100	CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED
304110	CRANIOFRONTONASAL SYNDROME; CFNS
304120	OTOPALATODIGITAL SYNDROME, TYPE II; OPD2
304150	OCCIPITAL HORN SYNDROME; OHS
304340	PETTIGREW SYNDROME; PGS
304400	DEAFNESS, X-LINKED 2; DFNX2
304500	DEAFNESS, X-LINKED 1; DFNX1
304700	MOHR-TRANEBJAERG SYNDROME; MTS
304730	DERMOIDS OF CORNEA; CND
304790	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED; IPEX
304800	DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED
305000	DYSKERATOSIS CONGENITA, X-LINKED; DKCX
305100	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED
305390	EXUDATIVE VITREORETINOPATHY 2, X-LINKED; EVR2
305400	AARSKOG-SCOTT SYNDROME; AAS
305435	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HBFQTL3
305450	OPITZ-KAVEGGIA SYNDROME; OKS
305600	FOCAL DERMAL HYPOPLASIA; FDH
305620	FRONTOMETAPHYSEAL DYSPLASIA 1; FMD1
306000	GLYCOGEN STORAGE DISEASE IXa1; GSD9A1
306400	GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CDGX
306700	HEMOPHILIA A; HEMA
306900	HEMOPHILIA B; HEMB
306955	HETEROTAXY, VISCERAL, 1, X-LINKED; HTX1
306995	HOMOSEXUALITY 1; HMS1
307000	HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS
307030	GLYCEROL KINASE DEFICIENCY; GKD
307150	HYPERTRICHOSIS, CONGENITAL GENERALIZED; HTC2
307200	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3
307700	HYPOPARATHYROIDISM, X-LINKED; HYPX
307800	HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR
308050	CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS
308100	ICHTHYOSIS, X-LINKED; XLI
308205	IFAP SYNDROME WITH OR WITHOUT BRESHECK SYNDROME
308230	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1
308240	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1
308300	INCONTINENTIA PIGMENTI; IP
308350	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1
308700	HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1
308800	KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, X-LINKED; KFSDX
308905	LEBER OPTIC ATROPHY, SUSCEPTIBILITY TO
308990	PROTEINURIA, LOW MOLECULAR WEIGHT, WITH HYPERCALCIURIA AND NEPHROCALCINOSIS
309000	LOWE OCULOCEREBRORENAL SYNDROME; OCRL
309120	SPERMATOGENIC FAILURE, X-LINKED, 2; SPGFX2
309200	MAJOR AFFECTIVE DISORDER 2; MAFD2
309350	MELNICK-NEEDLES SYNDROME; MNS
309400	MENKES DISEASE
309500	RENPENNING SYNDROME 1; RENS1
309510	PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS
309520	LUJAN-FRYNS SYNDROME
309530	MENTAL RETARDATION, X-LINKED 1; MRX1
309541	METHYLMALONIC ACIDEMIA AND HOMOCYSTEINEMIA, cblX TYPE
309545	MENTAL RETARDATION, X-LINKED, SYNDROMIC 12; MRXS12
309548	MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH FRAGILE SITE FRAXE
309549	MENTAL RETARDATION, X-LINKED 9; MRX9
309555	MENTAL RETARDATION WITH OPTIC ATROPHY, DEAFNESS, AND SEIZURES
309580	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1
309583	MENTAL RETARDATION, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE; MRXSSR
309585	WILSON-TURNER X-LINKED MENTAL RETARDATION SYNDROME; WTS
309610	PRIETO X-LINKED MENTAL RETARDATION SYNDROME; PRS
309620	MENTAL RETARDATION, SKELETAL DYSPLASIA, AND ABDUCENS PALSY; MRSD
309630	METACARPAL 4-5 FUSION; MF4
309800	MICROPHTHALMIA, SYNDROMIC 1; MCOPS1
309801	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1
309900	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2
310200	MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD
310300	EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1
310400	MYOPATHY, CENTRONUCLEAR, X-LINKED; CNMX
310440	MYOPATHY, X-LINKED, WITH EXCESSIVE AUTOPHAGY; MEAX
310460	MYOPIA 1, X-LINKED; MYP1
310468	NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN
310490	COWCHOCK SYNDROME; COWCK
310500	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A
310600	NORRIE DISEASE; ND
310700	NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1
311050	OPTIC ATROPHY 2; OPA2
311070	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5
311200	OROFACIODIGITAL SYNDROME I; OFD1
311250	ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO
311300	OTOPALATODIGITAL SYNDROME, TYPE I; OPD1
311360	PREMATURE OVARIAN FAILURE 1; POF1
311510	WAISMAN SYNDROME; WSMN
311900	TARP SYNDROME; TARPS
312000	PANHYPOPITUITARISM, X-LINKED; PHPX
312060	PROPERDIN DEFICIENCY, X-LINKED; CFPD
312080	PELIZAEUS-MERZBACHER DISEASE; PMD
312170	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD
312300	ANDROGEN INSENSITIVITY, PARTIAL; PAIS
312600	RETINITIS PIGMENTOSA 2; RP2
312612	RETINITIS PIGMENTOSA 6; RP6
312700	RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1
312750	RETT SYNDROME; RTT
312863	COMBINED IMMUNODEFICIENCY, X-LINKED; CIDX
312870	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1
312920	SPASTIC PARAPLEGIA 2, X-LINKED; SPG2
313000	SPATIAL VISUALIZATION, APTITUDE FOR
313200	SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1
313350	SPLIT-HAND/FOOT MALFORMATION 2; SHFM2
313400	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, X-LINKED; SEDT
313500	TOOTH AGENESIS, SELECTIVE, X-LINKED, 1; STHAGX1
313850	THORACOABDOMINAL SYNDROME; THAS
313900	THROMBOCYTOPENIA 1; THC1
314050	THROMBOCYTOPENIA WITH BETA-THALASSEMIA, X-LINKED; XLTT
314250	DYSTONIA 3, TORSION, X-LINKED; DYT3
314300	TORTICOLLIS, KELOIDS, CRYPTORCHIDISM, AND RENAL DYSPLASIA; TKCR
314390	VACTERL ASSOCIATION, X-LINKED, WITH OR WITHOUT HYDROCEPHALUS; VACTERLX
314400	CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1
314580	WIEACKER-WOLFF SYNDROME; WRWF
400003	DELETED IN AZOOSPERMIA; DAZ
400004	RETINITIS PIGMENTOSA, Y-LINKED; RPY
400043	DEAFNESS, Y-LINKED 1; DFNY1
400044	46,XY SEX REVERSAL 1; SRXY1
400045	46,XX SEX REVERSAL 1; SRXX1
415000	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2
425500	HAIRY EARS, Y-LINKED
600001	HEART DEFECTS, CONGENITAL, AND OTHER CONGENITAL ANOMALIES; HDCA
600002	EIKEN SYNDROME
600008	NICOTINAMIDE N-METHYLTRANSFERASE; NNMT
600020	MAX-INTERACTING PROTEIN 1; MXI1
600059	RETINITIS PIGMENTOSA 13; RP13
600060	DEAFNESS, AUTOSOMAL RECESSIVE 2; DFNB2
600072	FATAL FAMILIAL INSOMNIA; FFI
600081	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B; VDDR1B
600089	PANCREATIC BETA CELL AGENESIS WITH NEONATAL DIABETES MELLITUS
600098	RELATED RAS VIRAL ONCOGENE HOMOLOG 2; RRAS2
600101	DEAFNESS, AUTOSOMAL DOMINANT 2A; DFNA2A
600105	RETINITIS PIGMENTOSA 12; RP12
600110	STARGARDT DISEASE 3; STGD3
600116	PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; PARK2
600118	WARBURG MICRO SYNDROME 1; WARBM1
600121	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 3; RCDP3
600131	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 1; ECA1
600132	RETINITIS PIGMENTOSA 14; RP14
600138	RETINITIS PIGMENTOSA 11; RP11
600142	CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY; CARASIL
600143	CEROID LIPOFUSCINOSIS, NEURONAL, 8; CLN8
600145	SACRAL DEFECT WITH ANTERIOR MENINGOCELE
600151	BARDET-BIEDL SYNDROME 3; BBS3
600155	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 2; HSCR2
600156	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 5; HSCR5
600160	CYCLIN-DEPENDENT KINASE INHIBITOR 2A; CDKN2A
600165	NANOPHTHALMOS 1; NNO1
600175	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; HMN8
600192	SYNOVIAL SARCOMA TRANSLOCATION, CHROMOSOME 18; SS18
600193	WAARDENBURG SYNDROME, TYPE 2B; WS2B
600195	VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL; VMCM
600202	DYSLEXIA, SUSCEPTIBILITY TO, 2; DYX2
600204	EPIPHYSEAL DYSPLASIA, MULTIPLE, 2; EDM2
600209	EXOSTOSES, MULTIPLE, TYPE III; EXT3
600223	SPINOCEREBELLAR ATAXIA 4; SCA4
600224	SPINOCEREBELLAR ATAXIA 5; SCA5
600231	PALMOPLANTAR KERATODERMA, BOTHNIAN TYPE; PPKB
600251	FACIAL CLEFTING, OBLIQUE, 1; OBLFC1
600257	CHROMOSOME 8q12.1-q21.2 DELETION SYNDROME
600263	HELICOBACTER PYLORI INFECTION, SUSCEPTIBILITY TO
600273	POLYCYSTIC KIDNEY DISEASE, INFANTILE SEVERE, WITH TUBEROUS SCLEROSIS; PKDTS
600274	FRONTOTEMPORAL DEMENTIA; FTD
600309	ATRIOVENTRICULAR SEPTAL DEFECT 3; AVSD3
600316	DEAFNESS, AUTOSOMAL RECESSIVE 3; DFNB3
600320	DIABETES MELLITUS, INSULIN-DEPENDENT, 5; IDDM5
600332	RIPPLING MUSCLE DISEASE 1; RMD1
600334	TIBIAL MUSCULAR DYSTROPHY, TARDIVE; TMD
600348	BAND HETEROTOPIA; BH
600361	HEREDITARY MOTOR AND SENSORY NEUROPATHY V
600363	SPASTIC PARAPLEGIA 6, AUTOSOMAL DOMINANT; SPG6
600373	CODAS SYNDROME
600376	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 2; HHT2
600383	MESOMELIA-SYNOSTOSES SYNDROME
600430	CHROMOSOME 2q37 DELETION SYNDROME
600462	MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 1; MLASA1
600467	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 4
600496	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3; MODY3
600501	ABCD SYNDROME; ABCDS
600510	GLAUCOMA-RELATED PIGMENT DISPERSION SYNDROME; GPDS1
600512	EPILEPSY, FAMILIAL TEMPORAL LOBE, 1; ETL1
600513	EPILEPSY, NOCTURNAL FRONTAL LOBE, 1; ENFL1
600522	PHOSPHOLIPASE A2, GROUP IVA; PLA2G4A
600593	CRANIOSYNOSTOSIS, ADELAIDE TYPE; CRSA
600624	CONE-ROD DYSTROPHY 1; CORD1
600625	OROFACIAL CLEFT 11; OFC11
600627	HYPERTRYPTOPHANEMIA; HYPTRP
600630	UV-SENSITIVE SYNDROME 1; UVSS1
600631	ENURESIS, NOCTURNAL, 1; ENUR1
600638	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3A, WITH OR WITHOUT EXTRAOCULAR INVOLVEMENT; CFEOM3A
600649	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE
600652	DEAFNESS, AUTOSOMAL DOMINANT 4A; DFNA4A
600666	POLYCYSTIC KIDNEY DISEASE 3 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD3
600668	CHONDROCALCINOSIS 1; CCAL1
600669	EPILEPSY, IDIOPATHIC GENERALIZED; EIG
600700	LIM DOMAIN-CONTAINING PREFERRED TRANSLOCATION PARTNER IN LIPOMA; LPP
600721	D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1
600740	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3
600757	OROFACIAL CLEFT 3; OFC3
600775	CRANIOSYNOSTOSIS 4; CRS4
600790	CHORIORETINAL ATROPHY, PROGRESSIVE BIFOCAL
600791	DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT; DFNB4
600792	DEAFNESS, AUTOSOMAL RECESSIVE 5; DFNB5
600794	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A
600795	FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED; FTD3
600802	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-NEGATIVE
600803	GALLBLADDER DISEASE 1; GBD1
600807	ASTHMA, SUSCEPTIBILITY TO
600808	ENURESIS, NOCTURNAL, 2; ENUR2
600850	SCHIZOPHRENIA 4; SCZD4
600852	RETINITIS PIGMENTOSA 17; RP17
600858	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 6; CMH6
600880	BUDD-CHIARI SYNDROME; BDCHS
600881	CATARACT 10, MULTIPLE TYPES; CTRCT10
600882	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B
600884	CARDIOMYOPATHY, DILATED, 1B; CMD1B
600886	HYPERFERRITINEMIA WITH OR WITHOUT CATARACT; HRFTC
600901	FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE
600919	CARDIAC ARRHYTHMIA, ANKYRIN-B-RELATED
600920	VAN DEN ENDE-GUPTA SYNDROME; VDEGS
600955	PROPROTEIN CONVERTASE 1/3 DEFICIENCY
600962	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK
600965	DEAFNESS, AUTOSOMAL DOMINANT 6; DFNA6
600969	EPIPHYSEAL DYSPLASIA, MULTIPLE, 3; EDM3
600971	DEAFNESS, AUTOSOMAL RECESSIVE 6; DFNB6
600972	ACHONDROGENESIS, TYPE IB; ACG1B
600974	DEAFNESS, AUTOSOMAL RECESSIVE 7; DFNB7
600975	GLAUCOMA 3, PRIMARY INFANTILE, B; GLC3B
600977	CONE-ROD DYSTROPHY 5; CORD5
600985	TENASCIN XB; TNXB
600987	CLEFT PALATE, CARDIAC DEFECTS, AND MENTAL RETARDATION; CPCMR
600994	DEAFNESS, AUTOSOMAL DOMINANT 5; DFNA5
600995	NEPHROTIC SYNDROME, TYPE 2; NPHS2
600996	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2; ARVD2
601001	EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 1; EBSB1
601003	BRODY MYOPATHY
601005	TIMOTHY SYNDROME; TS
601042	DYSTONIA 9; DYT9
601067	USHER SYNDROME, TYPE ID; USH1D
601068	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 1; FAME1
601071	DEAFNESS, AUTOSOMAL RECESSIVE 9; DFNB9
601072	DEAFNESS, AUTOSOMAL RECESSIVE 8; DFNB8
601088	AYME-GRIPP SYNDROME; AYGRP
601098	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C
601104	SUPRANUCLEAR PALSY, PROGRESSIVE, 1; PSNP1
601110	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; CDG1D
601130	CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9
601144	BRUGADA SYNDROME 1; BRGDA1
601152	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A
601154	CARDIOMYOPATHY, DILATED, 1E; CMD1E
601162	SPASTIC PARAPLEGIA 9A, AUTOSOMAL DOMINANT; SPG9A
601186	MICROPHTHALMIA, SYNDROMIC 9; MCOPS9
601198	HYPOCALCEMIA, AUTOSOMAL DOMINANT 1; HYPOC1
601199	CALCIUM-SENSING RECEPTOR; CASR
601200	PLEUROPULMONARY BLASTOMA; PPB
601202	CATARACT 24; CTRCT24
601214	NAXOS DISEASE; NXD
601216	DENTAL ANOMALIES AND SHORT STATURE; DASS
601224	POTOCKI-SHAFFER SYNDROME
601228	POLYPOSIS SYNDROME, HEREDITARY MIXED, 1; HMPS1
601238	CEREBELLAR ATAXIA, CAYMAN TYPE; ATCAY
601267	CHEMOKINE, CC MOTIF, RECEPTOR 2; CCR2
601277	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4A; ARCI4A
601283	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 1; NIDDM1
601287	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2F; LGMD2F
601300	ACTIVIN A RECEPTOR, TYPE IB; ACVR1B
601316	DEAFNESS, AUTOSOMAL DOMINANT 10; DFNA10
601317	DEAFNESS, AUTOSOMAL DOMINANT 11; DFNA11
601321	NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS
601331	RENAL DYSPLASIA, CYSTIC, SUSCEPTIBILITY TO; CYSRD
601338	CEREBELLAR ATAXIA, AREFLEXIA, PES CAVUS, OPTIC ATROPHY, AND SENSORINEURAL HEARING LOSS; CAPOS
601349	MICROPHTHALMIA, SYNDROMIC 8; MCOPS8
601358	NICOLAIDES-BARAITSER SYNDROME; NCBRS
601363	WILMS TUMOR 4; WT4
601367	STROKE, ISCHEMIC
601369	DEAFNESS, AUTOSOMAL DOMINANT 9; DFNA9
601373	CHEMOKINE, CC MOTIF, RECEPTOR 5; CCR5
601382	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B1; CMT4B1
601386	DEAFNESS, AUTOSOMAL RECESSIVE 12; DFNB12
601388	DIABETES MELLITUS, INSULIN-DEPENDENT, 12; IDDM12
601390	VAN MALDERGEM SYNDROME 1; VMLDS1
601399	PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY; FPDMM
601406	B-CELL CLL/LYMPHOMA 7A; BCL7A
601410	DIABETES MELLITUS, TRANSIENT NEONATAL, 1
601412	DEAFNESS, AUTOSOMAL DOMINANT 7; DFNA7
601414	RETINITIS PIGMENTOSA 18; RP18
601419	MYOPATHY, MYOFIBRILLAR, 1; MFM1
601455	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D
601457	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE
601462	MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A
601471	FACIAL PARESIS, HEREDITARY CONGENITAL, 1; HCFP1
601472	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D
601486	DELETED IN AZOOSPERMIA-LIKE; DAZL
601487	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA; PPARG
601492	MUCOPOLYSACCHARIDOSIS, TYPE IX; MPS9
601493	CARDIOMYOPATHY, DILATED, 1C, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION; CMD1C
601494	CARDIOMYOPATHY, DILATED, 1D; CMD1D
601495	AGAMMAGLOBULINEMIA 1, AUTOSOMAL RECESSIVE; AGM1
601499	AXENFELD-RIEGER SYNDROME, TYPE 2; RIEG2
601518	PROSTATE CANCER, HEREDITARY, 1; HPC1
601536	ATHABASKAN BRAINSTEM DYSGENESIS SYNDROME; ABDS
601539	PEROXISOME BIOGENESIS DISORDER 1B; PBD1B
601543	DEAFNESS, AUTOSOMAL DOMINANT 12; DFNA12
601544	DEAFNESS, AUTOSOMAL DOMINANT 3A; DFNA3A
601547	CATARACT 3, MULTIPLE TYPES; CTRCT3
601550	BLOOD GROUP--SWANN SYSTEM; SW
601551	BLOOD GROUP--FROESE
601552	FACIAL DYSMORPHISM, LENS DISLOCATION, ANTERIOR SEGMENT ABNORMALITIES, AND SPONTANEOUS FILTERING BLEBS; FDLAB
601553	HYPOTRICHOSIS, CONGENITAL, WITH JUVENILE MACULAR DYSTROPHY; HJMD
601559	STUVE-WIEDEMANN SYNDROME
601583	WILMS TUMOR 5; WT5
601596	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4C; CMT4C
601606	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1
601626	LEUKEMIA, ACUTE MYELOID; AML
601631	ANTERIOR SEGMENT DYSGENESIS 3; ASGD3
601634	NEURAL TUBE DEFECTS, FOLATE-SENSITIVE; NTDFS
601650	PARAGANGLIOMAS 2; PGL2
601665	OBESITY
601666	DIABETES MELLITUS, INSULIN-DEPENDENT, 15; IDDM15
601675	TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1
601678	BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1
601680	ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B
601682	GLAUCOMA 1, PRIMARY OPEN ANGLE, C; GLC1C
601696	NOVELTY SEEKING PERSONALITY TRAIT
601705	T-CELL IMMUNODEFICIENCY, CONGENITAL ALOPECIA, AND NAIL DYSTROPHY
601707	CURRY-JONES SYNDROME; CRJS
601709	QUEBEC PLATELET DISORDER; QPD
601718	RETINITIS PIGMENTOSA 19; RP19
601728	PHOSPHATASE AND TENSIN HOMOLOG; PTEN
601744	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 1; SLEB1
601764	SEIZURES, BENIGN FAMILIAL INFANTILE, 1; BFIS1
601776	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1
601777	CONE-ROD DYSTROPHY 6; CORD6
601780	CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6
601800	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3
601803	PALLISTER-KILLIAN SYNDROME; PKS
601808	CHROMOSOME 18q DELETION SYNDROME
601812	PREMATURE AGING SYNDROME, PENTTINEN TYPE; PENTT
601813	EXUDATIVE VITREORETINOPATHY 4; EVR4
601815	PHOSPHOGLYCERATE DEHYDROGENASE DEFICIENCY; PHGDHD
601816	BILIRUBIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; BILIQTL1
601820	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2
601846	VACUOLAR NEUROMYOPATHY
601847	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 2; PFIC2
601859	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS
601868	DEAFNESS, AUTOSOMAL DOMINANT 13; DFNA13
601869	DEAFNESS, AUTOSOMAL RECESSIVE 15; DFNB15
601884	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 1; BMND1
601885	CATARACT 14, MULTIPLE TYPES; CTRCT14
601887	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 5
601894	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 2; GFND2
601941	DIABETES MELLITUS, INSULIN-DEPENDENT, 6; IDDM6
601942	DIABETES MELLITUS, INSULIN-DEPENDENT, 10; IDDM10
601952	KERATOSIS LINEARIS WITH ICHTHYOSIS CONGENITA AND SCLEROSING KERATODERMA; KLICK
601954	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2G; LGMD2G
601977	THROMBOCYTHEMIA 2; THCYT2
601990	TUMOR PROTEIN p73; TP73
601992	FRIEDREICH ATAXIA 2; FRDA2
602014	HYPOMAGNESEMIA 1, INTESTINAL; HOMG1
602025	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 9; BMIQ9
602032	ECTODERMAL DYSPLASIA 4, HAIR/NAIL TYPE; ECTD4
602066	CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS; ICCA
602078	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 2; CFEOM2
602079	TRIMETHYLAMINURIA; TMAU
602080	PAGET DISEASE OF BONE 2, EARLY-ONSET; PDB2
602081	SPEECH-LANGUAGE DISORDER 1; SPCH1
602082	CORNEAL DYSTROPHY, THIEL-BEHNKE TYPE; CDTB
602083	USHER SYNDROME, TYPE IF; USH1F
602085	POLYDACTYLY, POSTAXIAL, TYPE A2; PAPA2
602086	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 3; ARVD3
602087	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 4; ARVD4
602088	NEPHRONOPHTHISIS 2; NPHP2
602089	HEMANGIOMA, CAPILLARY INFANTILE
602092	DEAFNESS, AUTOSOMAL RECESSIVE 18A; DFNB18A
602093	CONE DYSTROPHY 3; COD3
602096	ALZHEIMER DISEASE 5
602097	USHER SYNDROME, TYPE IE; USH1E
602099	AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE; ALS5
602111	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MISSOURI TYPE
602124	DYSTONIA 7, TORSION; DYT7
602134	TREMOR, HEREDITARY ESSENTIAL, 2; ETM2
602216	SERINE/THREONINE PROTEIN KINASE 11; STK11
602271	SPONDYLOMETAPHYSEAL DYSPLASIA, AXIAL; SMDAX
602311	AGOUTI-RELATED PROTEIN, MOUSE, HOMOLOG OF; AGRP
602342	PIERPONT SYNDROME; PRPTS
602347	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 3; PFIC3
602361	GRACILE BONE DYSPLASIA; GCLEB
602390	HEMOCHROMATOSIS, TYPE 2A; HFE2A
602398	DESMOSTEROLOSIS
602400	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 11; ARCI11
602401	ECTODERMAL DYSPLASIA 8, HAIR/TOOTH/NAIL TYPE; ECTD8
602421	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR
602433	AMYOTROPHIC LATERAL SCLEROSIS 4, JUVENILE; ALS4
602447	PARAOXONASE 2; PON2
602450	SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION
602452	BUDDING UNINHIBITED BY BENZIMIDAZOLES 1, S. CEREVISIAE, HOMOLOG OF; BUB1
602459	DEAFNESS, AUTOSOMAL DOMINANT 15; DFNA15
602471	SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, AND SKELETAL ABNORMALITIES; SAMS
602473	ENCEPHALOPATHY, ETHYLMALONIC; EE
602477	FEBRILE SEIZURES, FAMILIAL, 2; FEB2
602481	MIGRAINE, FAMILIAL HEMIPLEGIC, 2; FHM2
602482	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3
602483	AURICULOCONDYLAR SYNDROME 1; ARCND1
602485	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3
602491	HYPERLIPIDEMIA, COMBINED, 1
602499	MACROPHTHALMIA, COLOBOMATOUS, WITH MICROCORNEA; MACOM
602501	MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP
602522	BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A
602531	GRANGE SYNDROME; GRNG
602535	MARSHALL-SMITH SYNDROME; MRSHSS
602540	ICHTHYOSIS, HYSTRIX-LIKE, WITH DEAFNESS
602541	MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC
602557	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SHOHAT TYPE; SEMDSH
602579	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B
602588	BRANCHIOOTIC SYNDROME 1; BOS1
602629	DYSTONIA 6, TORSION; DYT6
602668	MYOTONIC DYSTROPHY 2; DM2
602686	MITOTIC ARREST-DEFICIENT 1, YEAST, HOMOLOG-LIKE 1; MAD1L1
602722	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE; RTADR
602723	PSORIASIS 2; PSORS2
602771	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1
602772	RETINITIS PIGMENTOSA 25; RP25
602782	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME
602849	MUENKE SYNDROME; MNKES
602875	ACROMESOMELIC DYSPLASIA, MAROTEAUX TYPE; AMDM
603010	DEAFNESS, AUTOSOMAL RECESSIVE 17; DFNB17
603013	SCHIZOPHRENIA 6; SCZD6
603034	MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5
603041	MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1
603075	MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1
603098	DEAFNESS, AUTOSOMAL RECESSIVE 13; DFNB13
603116	CDAGS SYNDROME
603147	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C
603165	DERMATITIS, ATOPIC
603194	MECKEL SYNDROME, TYPE 2; MKS2
603204	EPILEPSY, NOCTURNAL FRONTAL LOBE, 2; ENFL2
603218	HUNTINGTON DISEASE-LIKE 1; HDL1
603221	MYOPIA 3, AUTOSOMAL DOMINANT; MYP3
603233	PSEUDOHYPOPARATHYROIDISM, TYPE IB; PHP1B
603278	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 1; FSGS1
603284	CEREBRAL CAVERNOUS MALFORMATIONS 2; CCM2
603285	CEREBRAL CAVERNOUS MALFORMATIONS 3; CCM3
603324	GAP JUNCTION PROTEIN, BETA-3; GJB3
603358	GRACILE SYNDROME
603372	THYROID-STIMULATING HORMONE RECEPTOR; TSHR
603373	HYPERTHYROIDISM, FAMILIAL GESTATIONAL
603383	GLAUCOMA 1, OPEN ANGLE, F; GLC1F
603387	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1; MPPH1
603457	BOSMA ARHINIA MICROPHTHALMIA SYNDROME; BAMS
603467	FANCONI ANEMIA, COMPLEMENTATION GROUP F; FANCF
603471	CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2
603511	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1E; LGMD1E
603513	CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 1; CPSQ1
603516	SPINOCEREBELLAR ATAXIA 10; SCA10
603517	B-CELL CLL/LYMPHOMA 10; BCL10
603543	LIMB-MAMMARY SYNDROME; LMS
603546	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, TYPE 2; SEMDJL2
603552	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4; FHL4
603553	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2
603554	OMENN SYNDROME
603563	SPASTIC PARAPLEGIA 8, AUTOSOMAL DOMINANT; SPG8
603585	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIf; CDG2F
603592	XANTHINURIA, TYPE II; XAN2
603615	RAD54, S. CEREVISIAE, HOMOLOG-LIKE; RAD54L
603622	DEAFNESS, AUTOSOMAL DOMINANT 17; DFNA17
603629	DEAFNESS, AUTOSOMAL RECESSIVE 21; DFNB21
603649	CONE-ROD DYSTROPHY 7; CORD7
603671	ACROMELIC FRONTONASAL DYSOSTOSIS; AFND
603678	DEAFNESS, AUTOSOMAL RECESSIVE 14; DFNB14
603688	PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY
603689	HEREDITARY MYOPATHY WITH EARLY RESPIRATORY FAILURE; HMERF
603720	DEAFNESS, AUTOSOMAL RECESSIVE 16; DFNB16
603736	OHDO SYNDROME, SBBYS VARIANT; SBBYSS
603769	T-CELL LYMPHOMA/LEUKEMIA 1B; TCL1B
603776	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, 3; HCHOLA3
603786	STARGARDT DISEASE 4; STGD4
603813	HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH
603829	VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 1; VF1
603830	LONG QT SYNDROME 3; LQT3
603855	CYSTIC FIBROSIS, MODIFIER OF, 1; CFM1
603860	MEDULLARY CYSTIC KIDNEY DISEASE 2; MCKD2
603896	LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM
603902	BETA-THALASSEMIA, DOMINANT INCLUSION BODY TYPE
603903	SICKLE CELL ANEMIA
603909	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA; ALPS2A
603932	INTERVERTEBRAL DISC DISEASE; IDD
603933	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1
603956	CERVICAL CANCER
603964	DEAFNESS, AUTOSOMAL DOMINANT 16; DFNA16
603965	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2; FSGS2
604004	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1
604011	UNC119, C. ELEGANS, HOMOLOG OF; UNC119
604060	DEAFNESS, AUTOSOMAL RECESSIVE 20; DFNB20
604061	SEPTIN 9; SEPT9
604091	HYPOALPHALIPOPROTEINEMIA, PRIMARY
604093	KERATOSIS PILARIS ATROPHICANS; KPA
604114	PHOSPHOLIPASE C, BETA-2; PLCB2
604116	CONE-ROD DYSTROPHY 3; CORD3
604117	VOHWINKEL SYNDROME, VARIANT FORM
604121	CEREBELLAR ATAXIA, DEAFNESS, AND NARCOLEPSY, AUTOSOMAL DOMINANT; ADCADN
604124	RETINOBLASTOMA-BINDING PROTEIN 8; RBBP8
604129	EPIDERMOLYSIS BULLOSA PRURIGINOSA
604131	ALPHA-THALASSEMIA
604145	CARDIOMYOPATHY, DILATED, 1G; CMD1G
604168	CONGENITAL CATARACTS, FACIAL DYSMORPHISM, AND NEUROPATHY; CCFDN
604169	LEFT VENTRICULAR NONCOMPACTION 1; LVNC1
604173	POIKILODERMA WITH NEUTROPENIA; PN
604185	FACIAL PARESIS, HEREDITARY CONGENITAL, 2; HCFP2
604187	SPASTIC PARAPLEGIA 10, AUTOSOMAL DOMINANT; SPG10
604213	CHUDLEY-MCCULLOUGH SYNDROME; CMCS
604218	ENCEPHALOPATHY, FAMILIAL, WITH NEUROSERPIN INCLUSION BODIES; FENIB
604219	CATARACT 9, MULTIPLE TYPES; CTRCT9
604229	ANTERIOR SEGMENT DYSGENESIS 5; ASGD5
604232	LEBER CONGENITAL AMAUROSIS 3; LCA3
604233	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 1; GEFSP1
604250	HEMOCHROMATOSIS, TYPE 3; HFE3
604271	GROWTH HORMONE INSENSITIVITY, PARTIAL; GHIP
604273	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 1; MC5DN1
604278	RENAL TUBULAR ACIDOSIS, PROXIMAL, WITH OCULAR ABNORMALITIES AND MENTAL RETARDATION
604286	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2E; LGMD2E
604290	ACERULOPLASMINEMIA
604292	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3; EEC3
604302	RHEUMATOID ARTHRITIS, SYSTEMIC JUVENILE
604307	CATARACT 2, MULTIPLE TYPES; CTRCT2
604308	MASS SYNDROME
604317	MICROCEPHALY 2, PRIMARY, AUTOSOMAL RECESSIVE, WITH OR WITHOUT CORTICAL MALFORMATIONS; MCPH2
604320	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1
604321	MICROCEPHALY 4, PRIMARY, AUTOSOMAL RECESSIVE; MCPH4
604326	SPINOCEREBELLAR ATAXIA 12; SCA12
604348	ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 1; FASPS1
604352	FEBRILE SEIZURES, FAMILIAL, 4; FEB4
604356	DUANE RETRACTION SYNDROME 2; DURS2
604360	SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11
604364	EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 1; FFEVF1
604367	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 3; FPLD3
604369	SALLA DISEASE; SD
604370	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1
604373	CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2
604377	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 1; CEMCOX1
604379	HYPOTRICHOSIS 7; HYPT7
604387	NEPHRONOPHTHISIS 3; NPHP3
604391	ATAXIA-TELANGIECTASIA-LIKE DISORDER 1; ATLD1
604393	LEBER CONGENITAL AMAUROSIS 4; LCA4
604400	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 5; ARVD5
604401	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 6; ARVD6
604403	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 2; GEFSP2
604416	PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND ACNE
604432	SPINOCEREBELLAR ATAXIA 11; SCA11
604443	ACYL-CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 6; ACSL6
604454	WELANDER DISTAL MYOPATHY; WDM
604484	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, OKINAWA TYPE; HMSNO
604498	AMEGAKARYOCYTIC THROMBOCYTOPENIA, CONGENITAL; CAMT
604519	INFLAMMATORY BOWEL DISEASE 3; IBD3
604536	ECTODERMAL DYSPLASIA/SKIN FRAGILITY SYNDROME
604537	LEBER CONGENITAL AMAUROSIS 5; LCA5
604559	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IB; PFHB1B
604563	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2
604571	BARE LYMPHOCYTE SYNDROME, TYPE I
604625	TOOTH AGENESIS, SELECTIVE, 3; STHAG3
604715	ORTHOSTATIC INTOLERANCE
604717	DEAFNESS, AUTOSOMAL DOMINANT 20; DFNA20
604757	CRANIOSYNOSTOSIS 2; CRS2
604765	CARDIOMYOPATHY, DILATED, 1I; CMD1I
604772	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1
604777	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 5; ARCI5
604801	MUSCULAR DYSTROPHY, CONGENITAL, 1B; MDC1B
604802	HUNTINGTON DISEASE-LIKE 3; HDL3
604804	MICROCEPHALY 3, PRIMARY, AUTOSOMAL RECESSIVE; MCPH3
604805	SPASTIC PARAPLEGIA 12, AUTOSOMAL DOMINANT; SPG12
604809	PANBRONCHIOLITIS, DIFFUSE
604827	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 7; EIG7
604841	STICKLER SYNDROME, TYPE II; STL2
604864	OSTEOARTHRITIS WITH MILD CHONDRODYSPLASIA; OSCDP
604901	NORTH AMERICAN INDIAN CHILDHOOD CIRRHOSIS; NAIC
604906	SCHIZOPHRENIA 9; SCZD9
604928	WOLFRAM SYNDROME 2; WFS2
604931	CORTISONE REDUCTASE DEFICIENCY 1; CORTRD1
605013	MICROHYDRANENCEPHALY; MHAC
605019	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 2; FHBL2
605021	MYOCLONIC EPILEPSY, FAMILIAL INFANTILE; FIME
605027	LYMPHOMA, NON-HODGKIN, FAMILIAL
605039	BOHRING-OPITZ SYNDROME; BOPS
605041	BROOKE-SPIEGLER SYNDROME; BRSS
605074	RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1
605115	HYPERTENSION, EARLY-ONSET, AUTOSOMAL DOMINANT, WITH SEVERE EXACERBATION IN PREGNANCY
605130	WIEDEMANN-STEINER SYNDROME; WDSTS
605192	DEAFNESS, AUTOSOMAL DOMINANT 23; DFNA23
605204	TORSIN 1A; TOR1A
605218	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 2; SLEB2
605229	SPASTIC PARAPLEGIA 14, AUTOSOMAL RECESSIVE; SPG14
605231	BARDET-BIEDL SYNDROME 6; BBS6
605253	NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMAL RECESSIVE; CHN
605258	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 2; HIGM2
605259	SPINOCEREBELLAR ATAXIA 13; SCA13
605280	SPASTIC PARAPLEGIA 13, AUTOSOMAL DOMINANT; SPG13
605282	TEMTAMY PREAXIAL BRACHYDACTYLY SYNDROME; TPBS
605285	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR
605289	SPLIT-HAND/FOOT MALFORMATION 4; SHFM4
605309	MACROCEPHALY/AUTISM SYNDROME
605355	NEMALINE MYOPATHY 5; NEM5
605361	SPINOCEREBELLAR ATAXIA 14; SCA14
605362	CARDIOMYOPATHY, DILATED, 1J; CMD1J
605373	PARAGANGLIOMAS 3; PGL3
605375	EPILEPSY, NOCTURNAL FRONTAL LOBE, 3; ENFL3
605376	HETEROTAXY, VISCERAL, 2, AUTOSOMAL; HTX2
605380	FIBROBLAST GROWTH FACTOR 23; FGF23
605387	CATARACT 31, MULTIPLE TYPES; CTRCT31
605388	CEREBRAL PALSY, ATAXIC, AUTOSOMAL RECESSIVE
605389	HYPOTRICHOSIS 1; HYPT1
605392	FIBROBLAST GROWTH FACTOR RECEPTOR 1 ONCOGENE PARTNER; FGFR1OP
605407	SEGAWA SYNDROME, AUTOSOMAL RECESSIVE
605419	SCHIZOPHRENIA 10; SCZD10
605428	DEAFNESS, AUTOSOMAL RECESSIVE 26; DFNB26
605429	DEAFNESS, AUTOSOMAL RECESSIVE 26, MODIFIER OF; DFNB26M
605432	RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA 1; RUSAT1
605462	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 1; BCC1
605472	USHER SYNDROME, TYPE IIC; USH2C
605479	CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 2; BRIC2
605543	PARKINSON DISEASE 4, AUTOSOMAL DOMINANT; PARK4
605549	CONE-ROD DYSTROPHY 8; CORD8
605552	ABDOMINAL OBESITY-METABOLIC SYNDROME 1; AOMS1
605572	ABDOMINAL OBESITY-METABOLIC SYNDROME QUANTITATIVE TRAIT LOCUS 2
605583	DEAFNESS, AUTOSOMAL DOMINANT 25; DFNA25
605588	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1; CMT2B1
605589	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2
605594	DEAFNESS, AUTOSOMAL DOMINANT 39, WITH DENTINOGENESIS IMPERFECTA 1
605606	PSORIASIS 7, SUSCEPTIBILITY TO; PSORS7
605637	MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA
605670	LATE-ONSET RETINAL DEGENERATION; LORD
605676	CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR AND KERATODERMA; DCWHK
605711	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 1; MMDS1
605714	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED
605724	FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1
605726	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 2; DSMA2
605750	EXUDATIVE VITREORETINOPATHY 3; EVR3
605751	SEIZURES, BENIGN FAMILIAL INFANTILE, 2; BFIS2
605779	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 7; NDNC7
605803	DERMATITIS, ATOPIC, 2; ATOD2
605809	MYASTHENIC SYNDROME, CONGENITAL, 4A, SLOW-CHANNEL; CMS4A
605814	CITRULLINEMIA, TYPE II, NEONATAL-ONSET
605818	DEAFNESS, AUTOSOMAL RECESSIVE 27; DFNB27
605820	NONAKA MYOPATHY; NM
605822	SPONDYLOOCULAR SYNDROME; SOS
605850	DIMETHYLGLYCINE DEHYDROGENASE DEFICIENCY; DMGDHD
605872	C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER M; CLEC4M
605899	GLYCINE ENCEPHALOPATHY; GCE
605909	PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6
605911	3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D
605921	STROMAL INTERACTION MOLECULE 1; STIM1
605967	ACROPECTORAL SYNDROME; ACRPS
605990	NEPHROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO
606002	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 1; SCAR1
606003	TRANSALDOLASE DEFICIENCY
606012	DEAFNESS, AUTOSOMAL DOMINANT 18; DFNA18
606053	AUTISM, SUSCEPTIBILITY TO, 5; AUTS5
606054	PROPIONIC ACIDEMIA
606056	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIb; CDG2B
606068	RETINITIS PIGMENTOSA 28; RP28
606069	HEMOCHROMATOSIS, TYPE 4; HFE4
606070	AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21
606071	HEREDITARY MOTOR AND SENSORY NEUROPATHY, TYPE IIC; HMSN2C
606072	RIPPLING MUSCLE DISEASE 2; RMD2
606077	RNA-BINDING MOTIF PROTEIN 15; RBM15
606078	MEGAKARYOBLASTIC LEUKEMIA 1 GENE; MKL1
606159	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3
606164	DIAMOND-BLACKFAN ANEMIA 15 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA15
606170	GENITOPATELLAR SYNDROME; GTPTS
606176	DIABETES MELLITUS, PERMANENT NEONATAL; PNDM
606217	ATRIOVENTRICULAR SEPTAL DEFECT, SUSCEPTIBILITY TO, 2; AVSD2
606232	PHELAN-MCDERMID SYNDROME; PHMDS
606240	THYROID CANCER, NONMEDULLARY, 3; NMTC3
606242	MENTAL RETARDATION, MICROCEPHALY, GROWTH RETARDATION, JOINT CONTRACTURES, AND FACIAL DYSMORPHISM
606243	ALVEOLAR SOFT PART SARCOMA; ASPS
606263	PAGET DISEASE OF BONE 4; PDB4
606282	DEAFNESS, AUTOSOMAL DOMINANT 24; DFNA24
606324	PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK7
606346	DEAFNESS, AUTOSOMAL DOMINANT 22; DFNA22
606353	PRIMARY LATERAL SCLEROSIS, JUVENILE; PLSJ
606367	IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMD41
606392	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 4; MODY4
606394	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6; MODY6
606407	HYPOTONIA-CYSTINURIA SYNDROME
606438	HUNTINGTON DISEASE-LIKE 2; HDL2
606444	CREB/ATF BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CREBZF
606451	DEAFNESS, AUTOSOMAL DOMINANT 30; DFNA30
606482	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB
606483	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE A; CMTDIA
606528	HOMOZYGOUS 11p15-p14 DELETION SYNDROME
606545	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 3; ARCI3
606554	EPISODIC ATAXIA, TYPE 3; EA3
606574	ALBINISM, OCULOCUTANEOUS, TYPE IV; OCA4
606579	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1; VAMAS1
606581	POLYSUBSTANCE ABUSE, SUSCEPTIBILITY TO; PSAB
606593	LIG4 SYNDROME
606595	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2F; CMT2F
606612	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUT MENTAL RETARDATION), TYPE B, 5; MDDGB5
606640	AMYOTROPHIC LATERAL SCLEROSIS 3; ALS3
606657	GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO
606658	SPINOCEREBELLAR ATAXIA 15; SCA15
606664	GLYCINE N-METHYLTRANSFERASE DEFICIENCY
606685	CARDIOMYOPATHY, DILATED, 1L; CMD1L
606688	SPONGIFORM ENCEPHALOPATHY WITH NEUROPSYCHIATRIC FEATURES
606690	LYMPHANGIOLEIOMYOMATOSIS; LAM
606693	KUFOR-RAKEB SYNDROME; KRS
606703	DYSKINESIA, FAMILIAL, WITH FACIAL MYOKYMIA; FDFM
606705	DEAFNESS, AUTOSOMAL DOMINANT 36; DFNA36
606711	SPECIFIC LANGUAGE IMPAIRMENT 1; SLI1
606712	SPECIFIC LANGUAGE IMPAIRMENT 2; SLI2
606713	VAN DER WOUDE SYNDROME 2; VWS2
606719	MELANOMA-PANCREATIC CANCER SYNDROME
606721	PARTIAL LIPODYSTROPHY, CONGENITAL CATARACTS, AND NEURODEGENERATION SYNDROME; LCCNS
606744	SECKEL SYNDROME 2; SCKL2
606762	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6
606763	CILIARY DYSKINESIA, PRIMARY, 2; CILD2
606764	GASTROINTESTINAL STROMAL TUMOR; GIST
606766	SPERMATOGENIC FAILURE 3; SPGF3
606768	MYOPATHY, DISTAL, WITH ANTERIOR TIBIAL ONSET; DMAT
606777	GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1
606785	CRIGLER-NAJJAR SYNDROME, TYPE II
606788	ANOREXIA NERVOSA, SUSCEPTIBILITY TO; ANON
606798	BLEPHAROSPASM, BENIGN ESSENTIAL, SUSCEPTIBILITY TO
606799	STROKE, SUSCEPTIBILITY TO, 1
606812	FUMARASE DEFICIENCY; FMRD
606824	GLUCOSE/GALACTOSE MALABSORPTION; GGM
606835	DIGITAL ARTHROPATHY-BRACHYDACTYLY, FAMILIAL; FDAB
606843	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 3; HIGM3
606854	POLYMICROGYRIA, BILATERAL FRONTOPARIETAL; BFPP
606856	PANCREATIC CANCER, SUSCEPTIBILITY TO, 1
606864	PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA
606889	ALZHEIMER DISEASE 4
606893	VASCULAR MALFORMATION, PRIMARY INTRAOSSEOUS
606943	USHER SYNDROME, TYPE IG; USH1G
606952	ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B
606960	INSULINOMA TUMOR SUPPRESSOR GENE LOCUS
606963	PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; COPD
606966	NEPHRONOPHTHISIS 4; NPHP4
606989	MYELOPEROXIDASE; MPO
606995	SENIOR-LOKEN SYNDROME 3; SLSN3
606996	SENIOR-LOKEN SYNDROME 4; SLSN4
607004	BRACHYDACTYLY, TYPE A1, B; BDA1B
607014	HURLER SYNDROME
607015	HURLER-SCHEIE SYNDROME
607016	SCHEIE SYNDROME
607017	DEAFNESS, AUTOSOMAL DOMINANT 21; DFNA21
607039	DEAFNESS, AUTOSOMAL RECESSIVE 22; DFNB22
607060	PARKINSON DISEASE 8, AUTOSOMAL DOMINANT; PARK8
607078	EPIPHYSEAL DYSPLASIA, MULTIPLE, 5; EDM5
607080	46,XY GONADAL DYSGENESIS, PARTIAL, WITH MINIFASCICULAR NEUROPATHY
607084	DEAFNESS, AUTOSOMAL RECESSIVE 31; DFNB31
607088	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3
607091	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D
607093	5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; MTHFR
607095	ANAUXETIC DYSPLASIA 1; ANXD1
607101	DEAFNESS, AUTOSOMAL RECESSIVE 30; DFNB30
607107	NASOPHARYNGEAL CARCINOMA
607115	CINCA SYNDROME; CINCA
607131	AL-GAZALI-BAKALINOVA SYNDROME; AGBK
607136	SPINOCEREBELLAR ATAXIA 17; SCA17
607143	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ig; CDG1G
607151	MOYAMOYA DISEASE 2; MYMY2
607152	SPASTIC PARAPLEGIA 19, AUTOSOMAL DOMINANT; SPG19
607154	ALLERGIC RHINITIS
607155	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5
607174	MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO
607196	MICROCEPHALY, AMISH TYPE; MCPHA
607200	THYROID DYSHORMONOGENESIS 6; TDH6
607208	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6
607225	SPASTIC PARALYSIS, INFANTILE-ONSET ASCENDING; IAHSP
607236	HYPOPREBETALIPOPROTEINEMIA, ACANTHOCYTOSIS, RETINITIS PIGMENTOSA, AND PALLIDAL DEGENERATION
607239	DEAFNESS, AUTOSOMAL RECESSIVE 33; DFNB33
607250	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY; SCAN1
607259	SPASTIC PARAPLEGIA 7, AUTOSOMAL RECESSIVE; SPG7
607271	CASPASE 8 DEFICIENCY
607276	RESTING HEART RATE, VARIATION IN
607277	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 1
607278	OSTEOFIBROUS DYSPLASIA, SUSCEPTIBILITY TO; OSFD
607313	GAZE PALSY, FAMILIAL HORIZONTAL, WITH PROGRESSIVE SCOLIOSIS, 1; HGPPS1
607317	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 4; SCAR4
607323	DUANE-RADIAL RAY SYNDROME; DRRS
607326	SMITH-MCCORT DYSPLASIA 1; SMC1
607330	LATHOSTEROLOSIS
607339	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 1
607341	FOCAL CORTICAL DYSPLASIA, TYPE II; FCORD2
607346	SPINOCEREBELLAR ATAXIA 19; SCA19
607361	MECKEL SYNDROME, TYPE 3; MKS3
607364	BARTTER SYNDROME, TYPE 3; BARTS3
607371	DYSTONIA, JUVENILE-ONSET; DJO
607373	AUTISM, SUSCEPTIBILITY TO, 8; AUTS8
607398	GLUCOCORTICOID DEFICIENCY 2; GCCD2
607411	PATENT DUCTUS ARTERIOSUS 1; PDA1
607417	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 2; MRT2
607426	COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1
607432	LISSENCEPHALY 1; LIS1
607447	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 4; BMIQ4
607450	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8; ARVD8
607453	DEAFNESS, AUTOSOMAL DOMINANT 44; DFNA44
607454	SPINOCEREBELLAR ATAXIA 21; SCA21
607457	GIL BLOOD GROUP
607458	SPINOCEREBELLAR ATAXIA 18; SCA18
607459	SENSORY ATAXIC NEUROPATHY, DYSARTHRIA, AND OPHTHALMOPARESIS; SANDO
607464	THYROID CARCINOMA, HURTHLE CELL
607473	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 2; VKCFD2
607475	BOTHNIA RETINAL DYSTROPHY
607476	NEWFOUNDLAND ROD-CONE DYSTROPHY; NFRCD
607482	CARDIOMYOPATHY, DILATED, 1M; CMD1M
607483	THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2
607485	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED
607486	KNOPS BLOOD GROUP SYSTEM; KN
607487	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 25; CMH25
607488	DYSTONIA 15, MYOCLONIC; DYT15
607498	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 3
607499	BULIMIA NERVOSA, SUSCEPTIBILITY TO; BULN
607501	MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO, 4
607507	PSORIATIC ARTHRITIS, SUSCEPTIBILITY TO
607508	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 5
607516	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 6
607523	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 8; NDNC8
607536	CREB-REGULATED TRANSCRIPTION COACTIVATOR 1; CRTC1
607537	MASTERMIND-LIKE 2; MAML2
607539	CAMPTOSYNPOLYDACTYLY, COMPLEX; CCSPD
607541	CORNEAL DYSTROPHY, AVELLINO TYPE; CDA
607554	ATRIAL FIBRILLATION, FAMILIAL, 3; ATFB3
607572	LEPROSY, SUSCEPTIBILITY TO, 2; LPRS2
607584	SPASTIC PARAPLEGIA 24, AUTOSOMAL RECESSIVE; SPG24
607585	ATAXIA-TELANGIECTASIA MUTATED GENE; ATM
607594	IMMUNODEFICIENCY, COMMON VARIABLE, 1; CVID1
607595	BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD
607596	PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A
607598	LETHAL CONGENITAL CONTRACTURE SYNDROME 2; LCCS2
607602	ICHTHYOSIS, CYCLIC, WITH EPIDERMOLYTIC HYPERKERATOSIS
607616	NIEMANN-PICK DISEASE, TYPE B
607624	GRISCELLI SYNDROME, TYPE 2; GS2
607625	NIEMANN-PICK DISEASE, TYPE C2; NPC2
607626	ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS; ILVASC
607628	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11
607631	EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 1; EJA1
607634	OSTEOPETROSIS, AUTOSOMAL DOMINANT 1; OPTA1
607636	VAN BUCHEM DISEASE, TYPE 2
607641	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B
607644	CANDIDIASIS, FAMILIAL, 3; CANDF3
607654	KERATOSIS PALMOPLANTARIS STRIATA III; PPKS3
607655	SKIN FRAGILITY-WOOLLY HAIR SYNDROME; SFWHS
607657	CYSTATHIONINE GAMMA-LYASE; CTH
607671	DYSTONIA 13, TORSION, AUTOSOMAL DOMINANT; DYT13
607676	IRAK4 DEFICIENCY
607677	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2I; CMT2I
607678	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D
607681	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2; ECA2
607682	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 9; EIG9
607683	DEAFNESS, AUTOSOMAL DOMINANT 52; DFNA52
607684	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2E; CMT2E
607685	HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES
607688	PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK11
607694	LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD7
607706	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE
607721	NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR 1; NSLH1
607731	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2H; CMT2H
607734	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1F; CMT1F
607736	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2J; CMT2J
607745	SEIZURES, BENIGN FAMILIAL INFANTILE, 3; BFIS3
607748	HYPERCHOLANEMIA, FAMILIAL; FHCA
607759	INTEGRIN, ALPHA-2B; ITGA2B
607765	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1
607778	ACROCAPITOFEMORAL DYSPLASIA; ACFD
607785	JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML
607791	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D; CMTDID
607801	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1C; LGMD1C
607812	CRANIOLENTICULOSUTURAL DYSPLASIA; CLSD
607821	DEAFNESS, AUTOSOMAL RECESSIVE 37; DFNB37
607822	ALZHEIMER DISEASE 3; AD
607823	HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA SYNDROME; HLTS
607829	MITRAL VALVE PROLAPSE 2; MVP2
607831	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2K; CMT2K
607832	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 3, SUSCEPTIBILITY TO; FSGS3
607834	ANXIETY
607836	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 1; AIS1
607841	DEAFNESS, AUTOSOMAL DOMINANT 48; DFNA48
607842	AURAL ATRESIA, CONGENITAL; CAA
607847	NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF ADULTS
607850	OSTEOARTHRITIS SUSCEPTIBILITY 3; OS3
607855	MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A
607864	CAUDAL DUPLICATION ANOMALY
607872	CHROMOSOME 1p36 DELETION SYNDROME
607876	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 2; FAME2
607903	HYPOTRICHOSIS 6; HYPT6
607906	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ii; CDG1I
607907	DERMATOFIBROSARCOMA PROTUBERANS; DFSP
607921	RETINITIS PIGMENTOSA 30; RP30
607932	MICROPHTHALMIA, SYNDROMIC 6; MCOPS6
607936	PEELING SKIN SYNDROME 4; PSS4
607941	ATRIAL SEPTAL DEFECT 2; ASD2
607944	SPONDYLOENCHONDRODYSPLASIA WITH IMMUNE DYSREGULATION; SPENCDI
607948	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO
608013	GAUCHER DISEASE, PERINATAL LETHAL
608022	DIAPHANOSPONDYLODYSOSTOSIS
608027	PONTOCEREBELLAR HYPOPLASIA, TYPE 3; PCH3
608029	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 6; SCAR6
608030	AMYOTROPHIC LATERAL SCLEROSIS 6 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS6
608033	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 3; IIAE3
608049	AUTISM, SUSCEPTIBILITY TO, 3; AUTS3
608051	MACULAR DYSTROPHY, RETINAL, 2; MCDR2
608088	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE I, WITH COUGH AND GASTROESOPHAGEAL REFLUX
608089	ENDOMETRIAL CANCER
608091	JOUBERT SYNDROME 2; JBTS2
608093	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ij; CDG1J
608096	EPILEPSY, FAMILIAL TEMPORAL LOBE, 2; ETL2
608097	PERIVENTRICULAR HETEROTOPIA WITH MICROCEPHALY, AUTOSOMAL RECESSIVE; ARPHM
608099	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D
608104	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ih; CDG1H
608105	EPILEPSY, ROLANDIC, WITH PAROXYSMAL EXERCISE-INDUCED DYSTONIA AND WRITER'S CRAMP; EPRPDC
608106	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 5; HIGM5
608115	OVARIAN HYPERSTIMULATION SYNDROME; OHSS
608118	ZINC DEFICIENCY, TRANSIENT NEONATAL; TNZD
608133	RETINITIS PIGMENTOSA 7; RP7
608149	KAGAMI-OGATA SYNDROME
608156	NABLUS MASK-LIKE FACIAL SYNDROME; NMLFS
608161	MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3
608175	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3; AITD3
608180	SYNPOLYDACTYLY 2; SPD2
608189	TROPICAL CALCIFIC PANCREATITIS
608194	CONE-ROD DYSTROPHY 13; CORD13
608203	NEUTROPHIL IMMUNODEFICIENCY SYNDROME
608219	DEAFNESS, AUTOSOMAL RECESSIVE 38; DFNB38
608220	SPASTIC PARAPLEGIA 25, AUTOSOMAL RECESSIVE; SPG25
608224	DEAFNESS, AUTOSOMAL DOMINANT 41; DFNA41
608232	LEUKEMIA, CHRONIC MYELOID; CML
608233	HERMANSKY-PUDLAK SYNDROME 2; HPS2
608236	SLOWED NERVE CONDUCTION VELOCITY, AUTOSOMAL DOMINANT; SNCV
608244	OTOSCLEROSIS 3; OTSC3
608264	DEAFNESS, AUTOSOMAL RECESSIVE 40; DFNB40
608265	DEAFNESS, AUTOSOMAL RECESSIVE 39; DFNB39
608266	PARATHYROID CARCINOMA
608307	CARBAMOYL PHOSPHATE SYNTHETASE I; CPS1
608320	CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT, 1; ADCAD1
608323	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE C; CMTDIC
608328	WEILL-MARCHESANI SYNDROME 2; WMS2
608340	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE A; CMTRIA
608345	NYSTAGMUS 3, CONGENITAL, AUTOSOMAL DOMINANT; NYS3
608354	CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION; CMAVM
608355	PARKES WEBER SYNDROME; PKWS
608358	MYOPATHY, MYOSIN STORAGE, AUTOSOMAL DOMINANT; MSMA
608361	SPONDYLOEPIPHYSEAL DYSPLASIA, KIMBERLEY TYPE; SEDK
608367	MYOPIA 17, AUTOSOMAL DOMINANT; MYP17
608372	DEAFNESS, AUTOSOMAL DOMINANT 49; DFNA49
608380	RETINITIS PIGMENTOSA 26; RP26
608389	BRANCHIOOTIC SYNDROME 3; BOS3
608390	MYOTONIA, POTASSIUM-AGGRAVATED
608393	MICROCEPHALY 6, PRIMARY, AUTOSOMAL RECESSIVE; MCPH6
608394	DEAFNESS, AUTOSOMAL DOMINANT 43; DFNA43
608404	PLATELET GLYCOPROTEIN IV DEFICIENCY
608415	PROLONGED ELECTRORETINAL RESPONSE SUPPRESSION; PERRS
608423	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1F; LGMD1F
608443	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 3; MRT3
608446	MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO
608456	FAMILIAL ADENOMATOUS POLYPOSIS 2; FAP2
608470	CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB
608471	CORNEAL DYSTROPHY, LATTICE TYPE IIIA; CDL3A
608474	MYOPIA 5, AUTOSOMAL DOMINANT; MYP5
608516	MAJOR DEPRESSIVE DISORDER; MDD
608537	VHL GENE; VHL
608540	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K
608542	ANEURYSM, INTRACRANIAL BERRY, 2; ANIB2
608545	LARSEN-LIKE SYNDROME
608553	LEBER CONGENITAL AMAUROSIS 9; LCA9
608556	LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO
608565	DEAFNESS, AUTOSOMAL RECESSIVE 35; DFNB35
608567	SICK SINUS SYNDROME 1; SSS1
608569	CARDIOMYOPATHY, DILATED, 1O; CMD1O
608572	BURN-MCKEOWN SYNDROME; BMKS
608579	SEVERE CUTANEOUS ADVERSE REACTION, SUSCEPTIBILITY TO
608583	ATRIAL FIBRILLATION, FAMILIAL, 1; ATFB1
608594	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1
608611	RIBOSE 5-PHOSPHATE ISOMERASE DEFICIENCY
608612	MANDIBULOACRAL DYSPLASIA WITH TYPE B LIPODYSTROPHY; MADB
608615	OLIGODONTIA-COLORECTAL CANCER SYNDROME; ODCRCS
608622	HYPERTENSION, DIASTOLIC, RESISTANCE TO
608627	AMYOTROPHIC LATERAL SCLEROSIS 8; ALS8
608629	JOUBERT SYNDROME 3; JBTS3
608631	ASPERGER SYNDROME, SUSCEPTIBILITY TO, 2; ASPG2
608634	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; HMN2B
608636	CHROMOSOME 15q11-q13 DUPLICATION SYNDROME
608638	ASPERGER SYNDROME, SUSCEPTIBILITY TO, 1; ASPG1
608641	DEAFNESS, AUTOSOMAL DOMINANT 28; DFNA28
608643	AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY
608644	CILIARY DYSKINESIA, PRIMARY, 3; CILD3
608645	DEAFNESS, AUTOSOMAL DOMINANT 31; DFNA31
608647	CILIARY DYSKINESIA, PRIMARY, 5; CILD5
608649	ICHTHYOSIS PREMATURITY SYNDROME; IPS
608652	DEAFNESS, AUTOSOMAL DOMINANT 47; DFNA47
608653	DEAFNESS, AUTOSOMAL RECESSIVE 32, WITH OR WITHOUT IMMOTILE SPERM; DFNB32
608654	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE V; HSAN5
608673	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2L; CMT2L
608681	SPONDYLOCOSTAL DYSOSTOSIS 2, AUTOSOMAL RECESSIVE; SCDO2
608687	SPINOCEREBELLAR ATAXIA 20; SCA20
608688	AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY
608703	SPINOCEREBELLAR ATAXIA 25; SCA25
608709	LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD
608710	WEGENER GRANULOMATOSIS
608716	MICROCEPHALY 5, PRIMARY, AUTOSOMAL RECESSIVE; MCPH5
608728	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MATRILIN-3 RELATED
608747	INSULIN-LIKE GROWTH FACTOR I DEFICIENCY
608751	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 8; CMH8
608758	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 10; CMH10
608762	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 3; EIG3
608768	SPINOCEREBELLAR ATAXIA 8; SCA8
608776	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Il; CDG1L
608779	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIe; CDG2E
608782	PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY; PDHPD
608799	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E
608800	SUDDEN INFANT DEATH WITH DYSGENESIS OF THE TESTES SYNDROME; SIDDT
608804	LEUKODYSTROPHY, HYPOMYELINATING, 2; HLD2
608805	AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY, 1; ANFH1
608807	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2J; LGMD2J
608808	TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 1; DTGA1
608810	MYOPATHY, MYOFIBRILLAR, 2; MFM2
608812	COLORECTAL CANCER, SUSCEPTIBILITY TO, 1; CRCS1
608836	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL
608837	CARNEY COMPLEX VARIANT
608840	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6; MDDGB6
608850	MACULAR DYSTROPHY, RETINAL, 3; MCDR3
608864	OROFACIAL CLEFT 6, SUSCEPTIBILITY TO; OFC6
608874	OROFACIAL CLEFT 5; OFC5
608885	STOMATIN-DEFICIENT CRYOHYDROCYTOSIS WITH NEUROLOGIC DEFECTS; SDCHCN
608890	WAARDENBURG SYNDROME, TYPE 2D; WS2D
608895	NEUROPATHY, HEREDITARY, WITH OR WITHOUT AGE-RELATED MACULAR DEGENERATION; HNARMD
608898	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 3; FHL3
608901	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5
608902	DRUG METABOLISM, POOR, CYP2D6-RELATED
608907	ALZHEIMER DISEASE 9, SUSCEPTIBILITY TO; AD9
608908	MYOPIA 6; MYP6
608930	MYASTHENIC SYNDROME, CONGENITAL, 1B, FAST-CHANNEL; CMS1B
608931	MYASTHENIC SYNDROME, CONGENITAL, 4C, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS4C
608940	SPONDYLOMETAPHYSEAL DYSPLASIA WITH CONE-ROD DYSTROPHY; SMDCRD
608957	CD8 DEFICIENCY, FAMILIAL
608970	MACULAR DYSTROPHY, PATTERNED, 2; MDPT2
608971	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE
608978	MEACHAM SYNDROME
608980	BIFID NOSE WITH OR WITHOUT ANORECTAL AND RENAL ANOMALIES; BNAR
608984	ATAXIA, SENSORY, 1, AUTOSOMAL DOMINANT; SNAX1
608995	DYSLEXIA, SUSCEPTIBILITY TO, 8; DYX8
608996	PREMATURE OVARIAN FAILURE 3; POF3
609006	DEAFNESS, AUTOSOMAL RECESSIVE 36, WITH OR WITHOUT VESTIBULAR INVOLVEMENT; DFNB36
609015	MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD
609016	LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY
609027	BLOOD GROUP, INDIAN SYSTEM; IN
609029	EMANUEL SYNDROME
609033	POSTERIOR COLUMN ATAXIA WITH RETINITIS PIGMENTOSA; AXPC1
609039	NARCOLEPSY 3; NRCLP3
609040	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9; ARVD9
609041	SPASTIC PARAPLEGIA 27, AUTOSOMAL RECESSIVE; SPG27
609048	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 3; CMM3
609049	PIERSON SYNDROME
609053	FANCONI ANEMIA, COMPLEMENTATION GROUP I; FANCI
609054	FANCONI ANEMIA, COMPLEMENTATION GROUP J; FANCJ
609056	SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS
609057	NEPHROPATHY WITH PRETIBIAL EPIDERMOLYSIS BULLOSA AND DEAFNESS
609060	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1
609069	PANCREATIC AND CEREBELLAR AGENESIS; PACA
609070	HEMOGLOBIN, HIGH ALTITUDE ADAPTATION; HALAH
609115	LIMB-GIRDLE MUSCULAR DYSTROPHY, TYPE 1G; LGMD1G
609122	ANEURYSM, INTRACRANIAL BERRY, 3; ANIB3
609129	AUDITORY NEUROPATHY, AUTOSOMAL DOMINANT, 1; AUNA1
609135	APLASTIC ANEMIA
609136	PERIPHERAL DEMYELINATING NEUROPATHY, CENTRAL DYSMYELINATION, WAARDENBURG SYNDROME, AND HIRSCHSPRUNG DISEASE; PCWH
609140	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 2; PPCD2
609141	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 3; PPCD3
609148	MALARIA, MILD, SUSCEPTIBILITY TO
609152	HYPERTHYROIDISM, NONAUTOIMMUNE
609153	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2
609161	STRIATAL DEGENERATION, AUTOSOMAL DOMINANT 1; ADSD1
609162	CZECH DYSPLASIA
609165	ERYTHRODERMA, ICHTHYOSIFORM, CONGENITAL RETICULAR; CRIE
609180	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE If; CDG1F
609192	LOEYS-DIETZ SYNDROME 1; LDS1
609195	SPASTIC PARAPLEGIA 26, AUTOSOMAL RECESSIVE; SPG26
609197	GLUCOCORTICOID DEFICIENCY 3; GCCD3
609200	MYOPATHY, MYOFIBRILLAR, 3; MFM3
609218	FOVEAL HYPOPLASIA 2; FVH2
609220	BRUCK SYNDROME 2; BRKS2
609227	GRISCELLI SYNDROME, TYPE 3; GS3
609241	SCHINDLER DISEASE, TYPE I
609242	KANZAKI DISEASE
609253	FEBRILE SEIZURES, FAMILIAL, 6; FEB6
609254	SENIOR-LOKEN SYNDROME 5; SLSN5
609255	FEBRILE SEIZURES, FAMILIAL, 5; FEB5
609256	MYOPIA 7; MYP7
609257	MYOPIA 8; MYP8
609258	MYOPIA 9; MYP9
609259	MYOPIA 10; MYP10
609260	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2A2A; CMT2A2A
609265	LI-FRAUMENI SYNDROME 2; LFS2
609270	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 7; SCAR7
609273	NEMALINE MYOPATHY 6; NEM6
609283	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2
609284	NEMALINE MYOPATHY 1; NEM1
609285	NEMALINE MYOPATHY 4; NEM4
609286	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3
609289	SYNCOPE, FAMILIAL VASOVAGAL; VVS
609304	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 3; EIEE3
609306	SPINOCEREBELLAR ATAXIA 26; SCA26
609307	SPINOCEREBELLAR ATAXIA 27; SCA27
609308	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1
609310	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2
609311	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H; CMT4H
609312	DOPAMINE BETA-HYDROXYLASE, PLASMA; DBH
609313	MENTAL RETARDATION, ENTEROPATHY, DEAFNESS, PERIPHERAL NEUROPATHY, ICHTHYOSIS, AND KERATODERMA; MEDNIK
609322	RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1
609338	CAROTID INTIMAL MEDIAL THICKNESS 1
609340	SPASTIC PARAPLEGIA 28, AUTOSOMAL RECESSIVE; SPG28
609352	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MIGRATORY CIRCINATE ERYTHEMA
609376	CATARACT 35; CTRCT35
609384	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3C; CFEOM3C
609404	PREECLAMPSIA/ECLAMPSIA 4; PEE4
609423	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
609425	CHROMOSOME 3q29 DELETION SYNDROME
609428	TUKEL SYNDROME
609432	SYNDACTYLY, MESOAXIAL SYNOSTOTIC, WITH PHALANGEAL REDUCTION; MSSD
609439	DEAFNESS, AUTOSOMAL RECESSIVE 48; DFNB48
609441	ACROMESOMELIC DYSPLASIA, DEMIRHAN TYPE; AMDD
609446	PAROXYSMAL NONKINESIGENIC DYSKINESIA, 3, WITH OR WITHOUT GENERALIZED EPILEPSY; PNKD3
609452	MYOPATHY, MYOFIBRILLAR, 4; MFM4
609454	SUPRANUCLEAR PALSY, PROGRESSIVE, 2; PSNP2
609456	MUSCULAR DYSTROPHY, CONGENITAL, MEROSIN-POSITIVE
609460	GOLDBERG-SHPRINTZEN SYNDROME; GOSHS
609508	STICKLER SYNDROME, TYPE I, NONSYNDROMIC OCULAR
609524	MYOPATHY, MYOFIBRILLAR, 5; MFM5
609528	CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMA SYNDROME
609529	IMMUNOGLOBULIN A DEFICIENCY 2; IGAD2
609532	HEPATITIS C VIRUS, SUSCEPTIBILITY TO
609533	DEAFNESS, AUTOSOMAL RECESSIVE 23; DFNB23
609535	DRUG METABOLISM, POOR, CYP2C19-RELATED
609536	COMPLEMENT COMPONENT 5 DEFICIENCY; C5D
609541	SPASTIC PARAPLEGIA, OPTIC ATROPHY, AND NEUROPATHY; SPOAN
609549	NANOPHTHALMOS 2; NNO2
609560	MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE); MTDPS2
609566	PARIETAL FORAMINA 3; PFM3
609579	SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION
609583	JOUBERT SYNDROME 4; JBTS4
609597	PARIETAL FORAMINA 2; PFM2
609620	SHORT QT SYNDROME 1; SQT1
609621	SHORT QT SYNDROME 2; SQT2
609622	SHORT QT SYNDROME 3; SQT3
609625	CHROMOSOME 10q26 DELETION SYNDROME
609628	MAJEED SYNDROME; MJDS
609634	MIGRAINE, FAMILIAL HEMIPLEGIC, 3; FHM3
609636	ALZHEIMER DISEASE 10
609637	HOLOPROSENCEPHALY 5; HPE5
609638	EPIDERMOLYSIS BULLOSA, LETHAL ACANTHOLYTIC; EBLA
609640	FRIAS SYNDROME
609646	DEAFNESS, AUTOSOMAL RECESSIVE 42; DFNB42
609647	DEAFNESS, AUTOSOMAL RECESSIVE 46; DFNB46
609649	TRICHILEMMAL CYST 1; TRICY1
609698	THYROID HORMONE METABOLISM, ABNORMAL
609706	DEAFNESS, AUTOSOMAL RECESSIVE 53; DFNB53
609708	LIPOPROTEIN LIPASE; LPL
609727	SPASTIC PARAPLEGIA 29, AUTOSOMAL DOMINANT; SPG29
609734	OBESITY, EARLY-ONSET, WITH ADRENAL INSUFFICIENCY AND RED HAIR; OBAIRH
609741	CATARACT 22, MULTIPLE TYPES; CTRCT22
609753	CELIAC DISEASE, SUSCEPTIBILITY TO, 4; CELIAC4
609755	CELIAC DISEASE, SUSCEPTIBILITY TO, 3; CELIAC3
609757	WILLIAMS-BEUREN REGION DUPLICATION SYNDROME
609796	PEELING SKIN SYNDROME 2; PSS2
609800	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 4; GEFSP4
609812	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION; MODY8
609813	SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE; SCDO3
609814	COMPLEMENT FACTOR H DEFICIENCY; CFHD
609820	ERYTHROCYTOSIS, FAMILIAL, 3; ECYT3
609821	BLEEDING DISORDER, PLATELET-TYPE, 8; BDPLT8
609823	DEAFNESS, AUTOSOMAL RECESSIVE 28; DFNB28
609886	GLOMERULOCYSTIC KIDNEY DISEASE WITH HYPERURICEMIA AND ISOSTHENURIA
609887	GLAUCOMA 1, OPEN ANGLE, G; GLC1G
609889	ALPHA/BETA T-CELL LYMPHOPENIA WITH GAMMA/DELTA T-CELL EXPANSION, SEVERE CYTOMEGALOVIRUS INFECTION, AND AUTOIMMUNITY
609909	CARDIOMYOPATHY, DILATED, 1P; CMD1P
609923	RETINITIS PIGMENTOSA 31; RP31
609924	AMINOACYLASE 1 DEFICIENCY; ACY1D
609939	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 6; SLEB6
609941	DEAFNESS, AUTOSOMAL RECESSIVE 51; DFNB51
609942	NOONAN SYNDROME 3; NS3
609946	DEAFNESS, AUTOSOMAL RECESSIVE 47; DFNB47
609952	DEAFNESS, AUTOSOMAL RECESSIVE 55; DFNB55
609965	DEAFNESS, AUTOSOMAL DOMINANT 53; DFNA53
609968	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5; HHF5
609975	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 4; HHF4
609981	IMMUNODEFICIENCY 54; IMD54
610003	CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT
610006	2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY
610015	GLUTAMINE DEFICIENCY, CONGENITAL
610017	MULTIPLE SYNOSTOSES SYNDROME 2; SYNS2
610019	CATARACT 18; CTRCT18
610021	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7
610024	RETINAL CONE DYSTROPHY 3A; RCD3A
610031	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 7; CDCBM7
610042	PITT-HOPKINS-LIKE SYNDROME 1; PTHSL1
610048	CORNEAL DYSTROPHY, CONGENITAL STROMAL; CSCD
610069	POLYPOSIS SYNDROME, HEREDITARY MIXED, 2; HMPS2
610090	PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD
610092	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 3; MCOPCB3
610093	MICROPHTHALMIA, ISOLATED 2; MCOP2
610099	MYOPATHY, DISTAL, 3; MPD3
610100	GIANT AXONAL NEUROPATHY 2, AUTOSOMAL DOMINANT; GAN2
610102	COMPLEMENT COMPONENT 7 DEFICIENCY; C7D
610125	MICROPHTHALMIA, SYNDROMIC 5; MCOPS5
610127	CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10
610131	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4
610140	HEART-HAND SYNDROME, SLOVENIAN TYPE
610143	DEAFNESS, AUTOSOMAL RECESSIVE 62; DFNB62
610149	MACULAR DEGENERATION, AGE-RELATED, 7; ARMD7
610153	DEAFNESS, AUTOSOMAL RECESSIVE 49; DFNB49
610154	DEAFNESS, AUTOSOMAL RECESSIVE 44; DFNB44
610156	MENTAL RETARDATION, TRUNCAL OBESITY, RETINAL DYSTROPHY, AND MICROPENIS SYNDROME; MORMS
610158	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 2; FECD2
610163	IMMUNODEFICIENCY 25; IMD25
610168	LOEYS-DIETZ SYNDROME 2; LDS2
610181	AICARDI-GOUTIERES SYNDROME 2; AGS2
610185	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 2; CAMRQ2
610187	DIAPHRAGMATIC HERNIA 3; DIH3
610188	JOUBERT SYNDROME 5; JBTS5
610189	SENIOR-LOKEN SYNDROME 6; SLSN6
610193	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; ARVD10
610198	3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5
610199	DIABETES MELLITUS, NEONATAL, WITH CONGENITAL HYPOTHYROIDISM; NDH
610202	CATARACT 21, MULTIPLE TYPES; CTRCT21
610204	PONTOCEREBELLAR HYPOPLASIA, TYPE 5; PCH5
610205	ALAGILLE SYNDROME 2; ALGS2
610212	DEAFNESS, AUTOSOMAL RECESSIVE 66; DFNB66
610217	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B; NBIA2B
610220	DEAFNESS, AUTOSOMAL RECESSIVE 59; DFNB59
610227	SEBORRHEA-LIKE DERMATITIS WITH PSORIASIFORM ELEMENTS
610244	SPASTIC PARAPLEGIA 33, AUTOSOMAL DOMINANT; SPG33
610245	SPINOCEREBELLAR ATAXIA 23; SCA23
610246	SPINOCEREBELLAR ATAXIA 28; SCA28
610247	ESOPHAGITIS, EOSINOPHILIC, 1; EOE1
610248	DEAFNESS, AUTOSOMAL RECESSIVE 65; DFNB65
610250	SPASTIC PARAPLEGIA 31, AUTOSOMAL DOMINANT; SPG31
610251	ALCOHOL SENSITIVITY, ACUTE
610253	KLEEFSTRA SYNDROME 1; KLEFS1
610256	ANTERIOR SEGMENT DYSGENESIS 2; ASGD2
610265	DEAFNESS, AUTOSOMAL RECESSIVE 67; DFNB67
610282	RETINITIS PIGMENTOSA 35; RP35
610283	CONE-ROD DYSTROPHY 10; CORD10
610293	GLYCOSYLPHOSPHATIDYLINOSITOL DEFICIENCY; GPID
610297	PARKINSON DISEASE 13, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK13
610313	CRISPONI/COLD-INDUCED SWEATING SYNDROME 2; CISS2
610329	AICARDI-GOUTIERES SYNDROME 3; AGS3
610333	AICARDI-GOUTIERES SYNDROME 4; AGS4
610353	EPILEPSY, NOCTURNAL FRONTAL LOBE, 4; ENFL4
610356	RETINAL CONE DYSTROPHY 3B; RCD3B
610357	SPASTIC PARAPLEGIA 30, AUTOSOMAL RECESSIVE; SPG30
610359	RETINITIS PIGMENTOSA 33; RP33
610370	DIARRHEA 4, MALABSORPTIVE, CONGENITAL; DIAR4
610374	DIABETES MELLITUS, TRANSIENT NEONATAL, 2
610377	MEVALONIC ACIDURIA; MEVA
610379	WEST NILE VIRUS, SUSCEPTIBILITY TO
610381	CONE-ROD DYSTROPHY 11; CORD11
610419	DEAFNESS, AUTOSOMAL RECESSIVE 68; DFNB68
610420	PREAURICULAR TAG, ISOLATED, AUTOSOMAL DOMINANT, 1
610422	ALOPECIA-MENTAL RETARDATION SYNDROME 2; APMR2
610424	HEPATITIS B VIRUS, SUSCEPTIBILITY TO
610425	CATARACT 23, MULTIPLE TYPES; CTRCT23
610427	CONE-ROD SYNAPTIC DISORDER, CONGENITAL NONPROGRESSIVE; CRSD
610442	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, GENEVIEVE TYPE; SEMDG
610443	KOOLEN-DE VRIES SYNDROME; KDVS
610444	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 3; CSNBAD3
610445	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 1; CSNBAD1
610448	CHILBLAIN LUPUS 1; CHBL1
610455	TUMORAL CALCINOSIS, NORMOPHOSPHATEMIC, FAMILIAL; NFTC
610460	THIOPURINES, POOR METABOLISM OF, 1; THPM1
610474	CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME; CATSHLS
610475	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2; PPNAD2
610476	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; ARVD11
610478	RETINAL CONE DYSTROPHY 4; RCD4
610489	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1
610498	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 2; COXPD2
610504	PRETERM PREMATURE RUPTURE OF THE MEMBRANES; PPROM
610505	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3; COXPD3
610508	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 7; MODY7
610532	LEUKODYSTROPHY, HYPOMYELINATING, 5; HLD5
610535	GLAUCOMA 1, OPEN ANGLE, M; GLC1M
610536	MANDIBULOFACIAL DYSOSTOSIS, GUION-ALMEIDA TYPE; MFDGA
610539	GAUCHER DISEASE, ATYPICAL, DUE TO SAPOSIN C DEFICIENCY
610542	MYASTHENIC SYNDROME, CONGENITAL, 12; CMS12
610543	CHROMOSOME 16p13.3 DELETION SYNDROME, PROXIMAL
610549	DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS
610551	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 1; IIAE1
610582	DIABETES MELLITUS, TRANSIENT NEONATAL, 3
610599	RETINITIS PIGMENTOSA 36; RP36
610600	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY
610612	LEBER CONGENITAL AMAUROSIS 12; LCA12
610618	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3
610623	CATARACT 11, MULTIPLE TYPES; CTRCT11
610628	HYPOGONADOTROPIC HYPOGONADISM 4 WITH OR WITHOUT ANOSMIA; HH4
610629	DIAMOND-BLACKFAN ANEMIA 3; DBA3
610644	PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND 46,XX SEX REVERSAL
610651	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB
610655	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 4; HHT4
610665	Fc FRAGMENT OF IgG, LOW AFFINITY IIIb, RECEPTOR FOR; FCGR3B
610678	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4; COXPD4
610682	OSTEOGENESIS IMPERFECTA, TYPE VII; OI7
610687	NEMALINE MYOPATHY 7; NEM7
610688	JOUBERT SYNDROME 6; JBTS6
610698	MACULAR DEGENERATION, AGE-RELATED, 4; ARMD4
610706	DEAFNESS, CONGENITAL, WITH INNER EAR AGENESIS, MICROTIA, AND MICRODONTIA
610708	OPTIC ATROPHY 5; OPA5
610713	BRACHYDACTYLY-SYNDACTYLY SYNDROME; BDSD
610717	NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY; NLSDM
610725	NEPHROTIC SYNDROME, TYPE 3; NPHS3
610733	NOONAN SYNDROME 4; NS4
610738	NEUTROPENIA, SEVERE CONGENITAL, 3, AUTOSOMAL RECESSIVE; SCN3
610743	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 8; SCAR8
610753	ALOPECIA AREATA 2; AA2
610755	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV; MEN4
610756	CEREBROOCULOFACIOSKELETAL SYNDROME 2; COFS2
610758	CEREBROOCULOFACIOSKELETAL SYNDROME 4; COFS4
610759	CORNELIA DE LANGE SYNDROME 3; CDLS3
610762	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 6; HDLCQ6
610768	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M
610773	MITOCHONDRIAL PHOSPHATE CARRIER DEFICIENCY
610798	IMMUNODEFICIENCY DUE TO DEFECT IN MAPBP-INTERACTING PROTEIN
610799	INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 1; IPD1
610805	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 1; CAKUT1
610828	HOLOPROSENCEPHALY 7; HPE7
610829	HOLOPROSENCEPHALY 9; HPE9
610832	FANCONI ANEMIA, COMPLEMENTATION GROUP N; FANCN
610840	MITRAL VALVE PROLAPSE 3; MVP3
610842	PSEUDOXANTHOMA ELASTICUM-LIKE DISORDER WITH MULTIPLE COAGULATION FACTOR DEFICIENCY
610852	CILIARY DYSKINESIA, PRIMARY, 6; CILD6
610878	VESICOURETERAL REFLUX 2; VUR2
610883	POTOCKI-LUPSKI SYNDROME; PTLS
610896	BRANCHIOOTORENAL SYNDROME 2; BOR2
610913	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 2; SMDP2
610915	OSTEOGENESIS IMPERFECTA, TYPE VIII; OI8
610921	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 3; SMDP3
610927	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 9; SLEB9
610938	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 7; CHDS7
610947	CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT 2; ADCAD2
610951	CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7
610954	PITT-HOPKINS SYNDROME; PTHS
610965	XFE PROGEROID SYNDROME; XFEPS
610967	OSTEOGENESIS IMPERFECTA, TYPE V; OI5
610968	OSTEOGENESIS IMPERFECTA, TYPE XI; OI11
610978	CHOREOATHETOSIS AND CONGENITAL HYPOTHYROIDISM WITH OR WITHOUT PULMONARY DYSFUNCTION; CAHTP
610984	COMPLEMENT FACTOR I DEFICIENCY; CFID
610988	LEPROSY, SUSCEPTIBILITY TO, 4; LPRS4
610992	PHOSPHOSERINE AMINOTRANSFERASE DEFICIENCY; PSATD
611022	DEAFNESS, AUTOSOMAL RECESSIVE 24; DFNB24
611031	EPISODIC KINESIGENIC DYSKINESIA 2; EKD2
611038	MICROPHTHALMIA, ISOLATED 3; MCOP3
611040	MICROPHTHALMIA, ISOLATED 5; MCOP5
611064	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 5
611067	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 4; DSMA4
611081	INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 10; IBD10
611087	POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY; PMSE
611090	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 12; MRT12
611091	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 5; MRT5
611092	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 6; MRT6
611093	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7
611095	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 9; MRT9
611096	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 10; MRT10
611097	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 11; MRT11
611102	DEAFNESS-INFERTILITY SYNDROME; DIS
611105	LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL
611107	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 4; MRT4
611126	MITOCHONDRIAL COMPLEX I DEFICIENCY DUE TO ACAD9 DEFICIENCY
611131	RETINITIS PIGMENTOSA 37; RP37
611134	MECKEL SYNDROME, TYPE 4; MKS4
611136	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 13; EIG13
611147	PAROXYSMAL NONKINESIGENIC DYSKINESIA 2; PNKD2
611162	MALARIA, SUSCEPTIBILITY TO
611174	HAMAMY SYNDROME; HMMS
611182	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIh; CDG2H
611209	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G
611225	SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE; SPG18
611228	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4J; CMT4J
611252	SPASTIC PARAPLEGIA 32, AUTOSOMAL RECESSIVE; SPG32
611263	SHORT-RIB THORACIC DYSPLASIA 2 WITH OR WITHOUT POLYDACTYLY; SRTD2
611277	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 3; GEFSP3
611283	ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY
611291	SEVERE COMBINED IMMUNODEFICIENCY WITH MICROCEPHALY, GROWTH RETARDATION, AND SENSITIVITY TO IONIZING RADIATION
611302	SPASTIC ATAXIA 2, AUTOSOMAL RECESSIVE; SPAX2
611307	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2L; LGMD2L
611363	ATRIAL SEPTAL DEFECT 4; ASD4
611364	MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 4; EJM4
611369	LETHAL CONGENITAL CONTRACTURE SYNDROME 3; LCCS3
611376	MUNGAN SYNDROME; MGS
611377	BRACHYDACTYLY, TYPE B2; BDB2
611378	MACULAR DEGENERATION, AGE-RELATED, 9; ARMD9
611383	USHER SYNDROME, TYPE IID; USH2D
611390	SPASTIC ATAXIA 3, AUTOSOMAL RECESSIVE; SPAX3
611391	CATARACT 33, MULTIPLE TYPES; CTRCT33
611407	CARDIOMYOPATHY, DILATED, 1W; CMD1W
611431	LEGIUS SYNDROME
611451	DEAFNESS, AUTOSOMAL RECESSIVE 63; DFNB63
611465	GALLBLADDER DISEASE 4; GBD4
611489	CORTICOSTEROID-BINDING GLOBULIN DEFICIENCY
611490	OSTEOPETROSIS,  AUTOSOMAL RECESSIVE 4; OPTB4
611493	ATRIAL FIBRILLATION, FAMILIAL, 4; ATFB4
611494	ATRIAL FIBRILLATION, FAMILIAL, 5; ATFB5
611497	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 6; OPTB6
611498	NEPHRONOPHTHISIS 7; NPHP7
611521	IMMUNODEFICIENCY 35; IMD35
611523	PONTOCEREBELLAR HYPOPLASIA, TYPE 6; PCH6
611528	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 12; ARVD12
611543	CAVITARY OPTIC DISC ANOMALIES; CODA
611544	CATARACT 17, MULTIPLE TYPES; CTRCT17
611548	PREMATURE OVARIAN FAILURE 5; POF5
611553	NOONAN SYNDROME 5; NS5
611554	LEOPARD SYNDROME 2; LPRD2
611556	GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B
611560	JOUBERT SYNDROME 7; JBTS7
611561	MECKEL SYNDROME, TYPE 5; MKS5
611571	OTOSCLEROSIS 4; OTSC4
611572	OTOSCLEROSIS 7; OTSC7
611584	WAARDENBURG SYNDROME, TYPE 2E; WS2E
611588	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 4; MDDGC4
611590	RENAL TUBULAR ACIDOSIS, DISTAL, WITH HEMOLYTIC ANEMIA
611597	CATARACT 12, MULTIPLE TYPES; CTRCT12
611603	LISSENCEPHALY 3; LIS3
611615	CARDIOMYOPATHY, DILATED, 1X; CMD1X
611630	EPILEPSY, FAMILIAL TEMPORAL LOBE, 3; ETL3
611631	EPILEPSY, FAMILIAL TEMPORAL LOBE, 4; ETL4
611634	FEBRILE SEIZURES, FAMILIAL, 9; FEB9
611637	PRIMARY LATERAL SCLEROSIS, ADULT, 1; PLSA1
611638	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 5; MCOPCB5
611664	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 7; SHEP7
611666	PHOSPHOLIPID PHOSPHATASE 6; PLPP6
611705	SALIH MYOPATHY; SALMY
611706	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 12; MGR12
611718	HYPOMAGNESEMIA 4, RENAL; HOMG4
611719	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 5; COXPD5
611721	COMBINED SAPOSIN DEFICIENCY
611722	KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY
611724	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8
611726	EPILEPSY, PROGRESSIVE MYOCLONIC, 3, WITH OR WITHOUT INTRACELLULAR INCLUSIONS; EPM3
611731	APC GENE; APC
611742	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9
611755	LEBER CONGENITAL AMAUROSIS 10; LCA10
611762	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 2; FCAS2
611771	LIPOPROTEIN GLOMERULOPATHY; LPG
611773	ANGIOPATHY, HEREDITARY, WITH NEPHROPATHY, ANEURYSMS, AND MUSCLE CRAMPS; HANAC
611775	KAWASAKI DISEASE
611777	BRUGADA SYNDROME 2; BRGDA2
611783	ERYTHROCYTOSIS, FAMILIAL, 4; ECYT4
611788	AORTIC ANEURYSM, FAMILIAL THORACIC 6; AAT6
611804	ELLIPTOCYTOSIS 1; EL1
611809	BESTROPHINOPATHY, AUTOSOMAL RECESSIVE; ARB
611812	46,XX SEX REVERSAL WITH DYSGENESIS OF KIDNEYS, ADRENALS, AND LUNGS; SERKAL
611816	TEMPLE-BARAITSER SYNDROME; TMBTS
611818	LONG QT SYNDROME 9; LQT9
611819	LONG QT SYNDROME 10; LQT10
611820	LONG QT SYNDROME 11; LQT11
611862	WHITE BLOOD CELL COUNT QUANTITATIVE TRAIT LOCUS 1; WBCQ1
611863	MICROTIA WITH NASOLACRIMAL DUCT IMPERFORATION AND EYE COLOBOMA
611867	CHROMOSOME 22q11.2 DELETION SYNDROME, DISTAL
611868	PROSTATE CANCER, HEREDITARY, 12; HPC12
611875	BRUGADA SYNDROME 3; BRGDA3
611876	BRUGADA SYNDROME 4; BRGDA4
611878	CARDIOMYOPATHY, DILATED, 1Y; CMD1Y
611879	CARDIOMYOPATHY, DILATED, 1Z; CMD1Z
611880	CARDIOMYOPATHY, DILATED, 2A; CMD2A
611881	GLYCOGEN STORAGE DISEASE XII; GSD12
611884	CILIARY DYSKINESIA, PRIMARY, 7; CILD7
611890	LETHAL ARTHROGRYPOSIS WITH ANTERIOR HORN CELL DISEASE; LAAHD
611895	AMYOTROPHIC LATERAL SCLEROSIS 9; ALS9
611907	EPISODIC ATAXIA, TYPE 7; EA7
611913	CHROMOSOME 16p11.2 DELETION SYNDROME, 593-KB
611928	PROSTATE CANCER, HEREDITARY, 13; HPC13
611936	CHROMOSOME 3q29 DUPLICATION SYNDROME
611938	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2
611942	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 6; ECA6
611943	RIDDLE SYNDROME
611944	LYMPHEDEMA, HEREDITARY, IB; LMPH1B
611945	SPASTIC PARAPLEGIA 37, AUTOSOMAL DOMINANT; SPG37
611953	MACULAR DEGENERATION, AGE-RELATED, 11; ARMD11
612001	CHROMOSOME 15q13.3 DELETION SYNDROME
612004	THROMBOCYTOPENIA 4; THC4
612015	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE In; CDG1N
612016	COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4
612018	CATARACT 47; CTRCT47
612020	SPASTIC PARAPLEGIA 39, AUTOSOMAL RECESSIVE; SPG39
612052	SMOKING AS A QUANTITATIVE TRAIT LOCUS 3; SQTL3
612067	DYSTONIA 16; DYT16
612069	AMYOTROPHIC LATERAL SCLEROSIS 10 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS10
612073	MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5
612075	MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY); MTDPS8A
612076	HYPOURICEMIA, RENAL, 2; RHUC2
612079	ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME; ANES
612089	HYPOPHOSPHATEMIC RICKETS AND HYPERPARATHYROIDISM
612095	RETINITIS PIGMENTOSA 41; RP41
612096	OTOSCLEROSIS 8; OTSC8
612098	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 11; CMH11
612100	AUTISM, SUSCEPTIBILITY TO, 15; AUTS15
612109	OCULOAURICULAR SYNDROME; OCACS
612119	TREHALASE DEFICIENCY
612124	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 12; CMH12
612126	GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2
612132	ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH T-CELL IMMUNODEFICIENCY, AUTOSOMAL DOMINANT
612138	EPIDERMOLYSIS BULLOSA SIMPLEX WITH PYLORIC ATRESIA; EBSPA
612158	CARDIOMYOPATHY, DILATED, 1AA, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION; CMD1AA
612160	HISTIOCYTOMA, ANGIOMATOID FIBROUS
612164	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 4; EIEE4
612165	RETINITIS PIGMENTOSA 29; RP29
612199	CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS 1; CRMCC1
612201	ATRIAL FIBRILLATION, FAMILIAL, 6; ATFB6
612219	EWING SARCOMA; ES
612225	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 9; MODY9
612227	DIABETES MELLITUS, KETOSIS-PRONE; KPD
612229	COLORECTAL CANCER, SUSCEPTIBILITY TO, 3; CRCS3
612233	LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4
612237	CHONDROSARCOMA, EXTRASKELETAL MYXOID
612240	ATRIAL FIBRILLATION, FAMILIAL, 7; ATFB7
612242	CHROMOSOME 10q22.3-q23.2 DELETION SYNDROME
612244	INFLAMMATORY BOWEL DISEASE 13; IBD13
612245	INFLAMMATORY BOWEL DISEASE 14; IBD14
612247	CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS; CAN
612251	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 10; SLEB10
612253	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 11; SLEB11
612260	MYD88 DEFICIENCY; MYD88D
612261	INFLAMMATORY BOWEL DISEASE 17; IBD17
612269	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 5; ECA5
612271	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 11; SHEP11
612278	INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 19; IBD19
612281	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 6; ARCI6
612284	MECKEL SYNDROME, TYPE 6; MKS6
612285	JOUBERT SYNDROME 9; JBTS9
612286	NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 1; NPHLOP1
612287	NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 2; NPHLOP2
612289	FONTAINE PROGEROID SYNDROME; FPS
612290	MICROTIA, HEARING IMPAIRMENT, AND CLEFT PALATE
612291	JOUBERT SYNDROME 8; JBTS8
612292	BIRK-BAREL SYNDROME
612300	HEMOLYTIC ANEMIA, CD59-MEDIATED, WITH OR WITHOUT IMMUNE-MEDIATED POLYNEUROPATHY; HACD59
612301	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 7; OPTB7
612304	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; THPH4
612310	PREMATURE OVARIAN FAILURE 6; POF6
612313	GLASS SYNDROME; GLASS
612319	SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35
612335	SPASTIC PARAPLEGIA 38, AUTOSOMAL DOMINANT; SPG38
612336	THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL DOMINANT; THPH5
612337	MENTAL RETARDATION, AUTOSOMAL DOMINANT 22; MRD22
612347	JERVELL AND LANGE-NIELSEN SYNDROME 2; JLNS2
612348	THROMBOPHILIA, FAMILIAL, DUE TO DECREASED RELEASE OF TISSUE PLASMINOGEN ACTIVATOR; THPH9
612350	EHLERS-DANLOS SYNDROME, SPONDYLODYSPLASTIC TYPE, 3; EDSSPD3
612353	POROKERATOSIS 6, MULTIPLE TYPES; POROK6
612354	INFLAMMATORY BOWEL DISEASE 21; IBD21
612356	HEPARIN COFACTOR II DEFICIENCY
612362	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 12; BMIQ12
612370	HYPOGONADOTROPIC HYPOGONADISM 5 WITH OR WITHOUT ANOSMIA; HH5
612371	MAJOR AFFECTIVE DISORDER 7; MAFD7
612376	ACUTE PROMYELOCYTIC LEUKEMIA; APL
612379	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iq; CDG1Q
612387	SARCOIDOSIS, SUSCEPTIBILITY TO, 2; SS2
612389	PONTOCEREBELLAR HYPOPLASIA, TYPE 2B; PCH2B
612390	PONTOCEREBELLAR HYPOPLASIA, TYPE 2C; PCH2C
612394	BONE FRAGILITY WITH CONTRACTURES, ARTERIAL RUPTURE, AND DEAFNESS
612400	OSTEOARTHRITIS SUSCEPTIBILITY 5; OS5
612406	DYSTONIA 17, TORSION, AUTOSOMAL RECESSIVE; DYT17
612416	FACTOR XI DEFICIENCY
612422	CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 3; RCM3
612423	PREKALLIKREIN DEFICIENCY
612431	DEAFNESS, AUTOSOMAL DOMINANT 27; DFNA27
612433	DEAFNESS, AUTOSOMAL RECESSIVE 45; DFNB45
612437	EPILEPSY, PROGRESSIVE MYOCLONIC, 1B; EPM1B
612438	LEUKODYSTROPHY, HYPOMYELINATING, 6; HLD6
612444	CILIARY DYSKINESIA, PRIMARY, 9; CILD9
612446	COMPLEMENT COMPONENT 6 DEFICIENCY; C6D
612447	SKELETAL DEFECTS, GENITAL HYPOPLASIA, AND MENTAL RETARDATION
612460	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 14; BMIQ14
612462	PSEUDOHYPOPARATHYROIDISM, TYPE IC; PHP1C
612463	PSEUDOPSEUDOHYPOPARATHYROIDISM; PPHP
612474	CHROMOSOME 1q21.1 DELETION SYNDROME, 1.35-MB
612475	CHROMOSOME 1q21.1 DUPLICATION SYNDROME
612513	CHROMOSOME 2p16.1-p15 DELETION SYNDROME
612518	CILIARY DYSKINESIA, PRIMARY, 10; CILD10
612520	DIABETES MELLITUS, INSULIN-DEPENDENT, 20; IDDM20
612522	DIABETES MELLITUS, INSULIN-DEPENDENT, 22; IDDM22
612526	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3
612527	DIAMOND-BLACKFAN ANEMIA 4; DBA4
612528	DIAMOND-BLACKFAN ANEMIA 5; DBA5
612529	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA2; AI2A2
612530	CHROMOSOME 1q41-q42 DELETION SYNDROME
612539	SPASTIC PARAPLEGIA 42, AUTOSOMAL DOMINANT; SPG42
612540	MYOPATHY, CONGENITAL, COMPTON-NORTH; MYPCN
612541	NEUTROPENIA, SEVERE CONGENITAL, 4, AUTOSOMAL RECESSIVE; SCN4
612551	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 4, SUSCEPTIBILITY TO; FSGS4
612555	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2
612556	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; ADIPQTL1
612560	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 12; BMND12
612561	DIAMOND-BLACKFAN ANEMIA 6; DBA6
612562	DIAMOND-BLACKFAN ANEMIA 7; DBA7
612563	DIAMOND-BLACKFAN ANEMIA 8; DBA8
612567	INFLAMMATORY BOWEL DISEASE 25, AUTOSOMAL RECESSIVE; IBD25
612572	RETINITIS PIGMENTOSA 46; RP46
612576	CHROMOSOME 17p13.3, TELOMERIC, DUPLICATION SYNDROME
612577	AMYOTROPHIC LATERAL SCLEROSIS 11; ALS11
612580	MENTAL RETARDATION, AUTOSOMAL DOMINANT 3; MRD3
612581	MENTAL RETARDATION, AUTOSOMAL DOMINANT 4; MRD4
612582	CHROMOSOME 6pter-p24 DELETION SYNDROME
612591	COLORECTAL CANCER, SUSCEPTIBILITY TO, 10; CRCS10
612621	MENTAL RETARDATION, AUTOSOMAL DOMINANT 5; MRD5
612623	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2; MVCD2
612624	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; MVCD3
612626	CHROMOSOME 15q26-qter DELETION SYNDROME
612628	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 4; MVCD4
612630	HAIR MORPHOLOGY 1; HRM1
612631	ADENYLATE KINASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO
612633	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5; MVCD5
612634	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6; MVCD6
612635	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7
612642	DEAFNESS, AUTOSOMAL DOMINANT 59; DFNA59
612643	DEAFNESS, AUTOSOMAL DOMINANT 3B; DFNA3B
612644	DEAFNESS, AUTOSOMAL DOMINANT 2B; DFNA2B
612645	DEAFNESS, AUTOSOMAL RECESSIVE 1B; DFNB1B
612649	CILIARY DYSKINESIA, PRIMARY, 11; CILD11
612650	CILIARY DYSKINESIA, PRIMARY, 12; CILD12
612651	ENDOCRINE-CEREBROOSTEODYSPLASIA; ECO
612653	SPHEROCYTOSIS, TYPE 4; SPH4
612656	EPISODIC ATAXIA, TYPE 6; EA6
612657	CONE-ROD DYSTROPHY 12; CORD12
612671	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 4; UAQTL4
612674	POLYNEUROPATHY, HEARING LOSS, ATAXIA, RETINITIS PIGMENTOSA, AND CATARACT; PHARC
612690	SPHEROCYTOSIS, TYPE 5; SPH5
612691	POLYMICROGYRIA, BILATERAL TEMPOROOCCIPITAL; BTOP
612692	AGAMMAGLOBULINEMIA 6, AUTOSOMAL RECESSIVE; AGM6
612702	HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA; HH6
612703	MICROCEPHALY 7, PRIMARY, AUTOSOMAL RECESSIVE; MCPH7
612712	LEBER CONGENITAL AMAUROSIS 13; LCA13
612713	KAHRIZI SYNDROME; KHRZ
612714	EXOCRINE PANCREATIC INSUFFICIENCY, DYSERYTHROPOIETIC ANEMIA, AND CALVARIAL HYPEROSTOSIS
612716	DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY
612717	MYOPIA 15, AUTOSOMAL DOMINANT; MYP15
612718	CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3
612736	CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2
612740	PORPHYRIA, ACUTE HEPATIC
612775	CONE-ROD DYSTROPHY 9; CORD9
612780	SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, AND ELECTROLYTE IMBALANCE; SESAMES
612781	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IB; IGHD1B
612782	IMMUNODEFICIENCY 9; IMD9
612783	IMMUNODEFICIENCY 10; IMD10
612789	DEAFNESS, AUTOSOMAL RECESSIVE 71; DFNB71
612794	ATRIAL SEPTAL DEFECT 5; ASD5
612797	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 12; HDLCQ12
612798	QUESTION MARK EARS, ISOLATED; QME
612813	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, AGGRECAN TYPE; SEMDAG
612838	BRUGADA SYNDROME 5; BRGDA5
612840	LEUKOCYTE ADHESION DEFICIENCY, TYPE III; LAD3
612841	HYPOTRICHOSIS 5; HYPT5
612847	BRACHYOLMIA TYPE 4 WITH MILD EPIPHYSEAL AND METAPHYSEAL CHANGES; BCYM4
612852	OSTEOMYELITIS, STERILE MULTIFOCAL, WITH PERIOSTITIS AND PUSTULOSIS; OMPP
612868	CORNEAL DYSTROPHY, POSTERIOR AMORPHOUS; PACD
612874	ERYTHROCYTE AMP DEAMINASE DEFICIENCY
612877	CARDIOMYOPATHY, DILATED, 1BB; CMD1BB
612885	PREMATURE OVARIAN FAILURE 10; POF10
612899	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 8; EIG8
612900	CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 2; CPSQ2
612908	KERATOSIS PALMOPLANTARIS STRIATA II; PPKS2
612918	CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI
612921	THREE M SYNDROME 2; 3M2
612922	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 2; AHUS2
612923	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3; AHUS3
612924	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 4; AHUS4
612925	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 5; AHUS5
612926	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 6; AHUS6
612932	GLYCOGEN STORAGE DISEASE XIII; GSD13
612933	GLYCOGEN STORAGE DISEASE XI; GSD11
612936	SPASTIC PARAPLEGIA 50, AUTOSOMAL RECESSIVE; SPG50
612937	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O
612938	GROWTH RETARDATION, DEVELOPMENTAL DELAY, AND FACIAL DYSMORPHISM; GDFD
612940	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB; ARCL2B
612943	RETINITIS PIGMENTOSA 42; RP42
612949	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39; EIEE39
612951	LEUKOENCEPHALOPATHY, CYSTIC, WITHOUT MEGALENCEPHALY
612952	AICARDI-GOUTIERES SYNDROME 5; AGS5
612953	PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14
612954	MYOPATHY, MYOFIBRILLAR, 6; MFM6
612955	LONG QT SYNDROME 12; LQT12
612956	VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 2; VF2
612961	MULTIPLE SYNOSTOSES SYNDROME 3; SYNS3
612964	PREMATURE OVARIAN FAILURE 7; POF7
612965	46,XY SEX REVERSAL 3; SRXY3
612975	SHORT SLEEPER
612989	OPTIC ATROPHY 7 WITH OR WITHOUT AUDITORY NEUROPATHY; OPA7
612997	SPERMATOGENIC FAILURE 7; SPGF7
612998	EMERY-DREIFUSS MUSCULAR DYSTROPHY 4, AUTOSOMAL DOMINANT; EDMD4
612999	EMERY-DREIFUSS MUSCULAR DYSTROPHY 5, AUTOSOMAL DOMINANT; EDMD5
613000	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 1; FNEPPK1
613001	ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS; ECCL
613002	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 2; IIAE2
613003	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7
613011	LYMPHOPROLIFERATIVE SYNDROME 1; LPFS1
613013	NEUROBLASTOMA, SUSCEPTIBILITY TO, 2; NBLST2
613014	NEUROBLASTOMA, SUSCEPTIBILITY TO, 3; NBLST3
613021	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 2; BESC2
613024	FOLLICULAR LYMPHOMA, SUSCEPTIBILITY TO, 1; FL1
613026	CHROMOSOME 19q13.11 DELETION SYNDROME, DISTAL
613027	GLYCOGEN STORAGE DISEASE IXc; GSD9C
613028	GLIOMA SUSCEPTIBILITY 2; GLM2
613029	GLIOMA SUSCEPTIBILITY 3; GLM3
613038	PITUITARY HORMONE DEFICIENCY, COMBINED, 1; CPHD1
613060	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10
613065	LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL
613068	NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY
613070	LIVER FAILURE, INFANTILE, TRANSIENT; LFIT
613071	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 3; BESC3
613073	METAPHYSEAL ANADYSPLASIA 2; MANDP2
613074	DEAFNESS, AUTOSOMAL DOMINANT 50; DFNA50
613075	MACS SYNDROME
613076	MYOPATHY, MITOCHONDRIAL PROGRESSIVE, WITH CONGENITAL CATARACT, HEARING LOSS, AND DEVELOPMENTAL DELAY
613077	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5
613078	NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD
613079	DEAFNESS, AUTOSOMAL RECESSIVE 77; DFNB77
613080	46,XY SEX REVERSAL 5; SRXY5
613086	GLAUCOMA 3, PRIMARY CONGENITAL, D; GLC3D
613087	ATRIAL SEPTAL DEFECT 6; ASD6
613090	BARTTER SYNDROME, TYPE 4B, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4B
613091	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3
613092	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 2; HNFJ2
613093	CONE DYSTROPHY 4; COD4
613094	MICROPHTHALMIA, ISOLATED 4; MCOP4
613095	POLYCYSTIC KIDNEY DISEASE 2 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD2
613096	SPASTIC PARAPLEGIA 36, AUTOSOMAL DOMINANT; SPG36
613098	INCREASED ANALGESIA FROM KAPPA-OPIOID RECEPTOR AGONIST, FEMALE-SPECIFIC
613099	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 5; CMM5
613100	GLAUCOMA 1, OPEN ANGLE, O; GLC1O
613101	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 5; FHL5
613102	HYPOTRICHOSIS AND RECURRENT SKIN VESICLES
613105	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR 2; CACD2
613107	NEUTROPENIA, SEVERE CONGENITAL, 2, AUTOSOMAL DOMINANT; SCN2
613108	CANDIDIASIS, FAMILIAL, 4; CANDF4
613112	MACROTHROMBOCYTOPENIA, AUTOSOMAL DOMINANT, TUBB1-RELATED
613115	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIB; HSAN2B
613116	THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY; THPH11
613118	ANTITHROMBIN III DEFICIENCY; AT3D
613119	BRUGADA SYNDROME 6; BRGDA6
613120	BRUGADA SYNDROME 7; BRGDA7
613122	CARDIOMYOPATHY, DILATED, 1CC; CMD1CC
613123	BRUGADA SYNDROME 8; BRGDA8
613135	PARKINSONISM-DYSTONIA, INFANTILE, 1; PKDYS1
613148	INFLAMMATORY BOWEL DISEASE 28, AUTOSOMAL RECESSIVE; IBD28
613150	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2
613151	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 3; MDDGB3
613152	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT MENTAL RETARDATION), TYPE B, 4; MDDGB4
613153	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5
613154	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6
613155	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 1; MDDGB1
613156	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 2; MDDGB2
613157	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3
613158	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 2; MDDGC2
613159	NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1; NPHPL1
613161	BETA-UREIDOPROPIONASE DEFICIENCY; UPB1D
613162	SPASTIC PARAPLEGIA 45, AUTOSOMAL RECESSIVE; SPG45
613163	GABA-TRANSAMINASE DEFICIENCY
613172	CARDIOMYOPATHY, DILATED, 1DD; CMD1DD
613174	CHROMOSOME 5p13 DUPLICATION SYNDROME
613177	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IC; ARCL1C
613179	PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY
613180	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 8; CDCBM8
613192	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 13; MRT13
613193	CILIARY DYSKINESIA, PRIMARY, 13; CILD13
613194	RETINITIS PIGMENTOSA 50; RP50
613195	WEILL-MARCHESANI SYNDROME 4; WMS4
613204	MUSCULAR DYSTROPHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY
613205	MUSCULAR DYSTROPHY, CONGENITAL, LMNA-RELATED
613206	SPASTIC PARAPLEGIA 44, AUTOSOMAL RECESSIVE; SPG44
613211	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA3; AI2A3
613216	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1C; CSNB1C
613217	DIARRHEA 5, WITH TUFTING ENTEROPATHY, CONGENITAL; DIAR5
613223	LEPROSY, SUSCEPTIBILITY TO, 5; LPRS5
613224	NOONAN SYNDROME 6; NS6
613225	FACTOR XIII, A SUBUNIT, DEFICIENCY OF
613227	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 3; CAMRQ3
613229	TRICHOTILLOMANIA; TTM
613235	FACTOR XIII, B SUBUNIT, DEFICIENCY OF
613237	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 5; FSGS5
613239	THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 2; TTPP2
613243	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 13; CMH13
613244	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 8; HNPCC8
613251	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 14; CMH14
613252	CARDIOMYOPATHY, DILATED, 1EE; CMD1EE
613254	TUBEROUS SCLEROSIS 2; TSC2
613255	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 15; CMH15
613265	WAARDENBURG SYNDROME, TYPE 4B; WS4B
613266	WAARDENBURG SYNDROME, TYPE 4C; WS4C
613267	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 3; FECD3
613268	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 4; FECD4
613270	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 6; FECD6
613280	HYPERMANGANESEMIA WITH DYSTONIA 1; HMNDYT1
613282	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1; NAFLD1
613285	DEAFNESS, AUTOSOMAL RECESSIVE 25; DFNB25
613286	CARDIOMYOPATHY, DILATED, 1FF; CMD1FF
613287	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2N; CMT2N
613291	BILE ACID MALABSORPTION, PRIMARY; PBAM
613307	DEAFNESS, AUTOSOMAL RECESSIVE 79; DFNB79
613308	DIAMOND-BLACKFAN ANEMIA 9; DBA9
613309	DIAMOND-BLACKFAN ANEMIA 10; DBA10
613310	EXUDATIVE VITREORETINOPATHY 5; EVR5
613312	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 2; ARHR2
613313	HEMOCHROMATOSIS, TYPE 2B; HFE2B
613319	MIYOSHI MUSCULAR DYSTROPHY 3; MMD3
613320	SPONDYLOMETAPHYSEAL DYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE; SMDMDM
613325	RHABDOID TUMOR PREDISPOSITION SYNDROME 2; RTPS2
613327	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 4; CGL4
613328	ROIFMAN-CHITAYAT SYNDROME
613329	PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY
613330	SPONDYLO-MEGAEPIPHYSEAL-METAPHYSEAL DYSPLASIA; SMMD
613339	EPILEPSY, HOT WATER, 1; HWE1
613341	LEBER CONGENITAL AMAUROSIS 14; LCA14
613345	HYPOKALEMIC PERIODIC PARALYSIS, TYPE 2; HOKPP2
613347	PANCREATIC CANCER, SUSCEPTIBILITY TO, 2
613348	PANCREATIC CANCER, SUSCEPTIBILITY TO, 3
613353	MONONEUROPATHY OF THE MEDIAN NERVE, MILD; MNMN
613355	CHROMOSOME 17q23.1-q23.2 DELETION SYNDROME
613364	SPASTIC PARAPLEGIA 41, AUTOSOMAL DOMINANT; SPG41
613370	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 10; MODY10
613371	SPINOCEREBELLAR ATAXIA 30; SCA30
613375	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 11; MODY11
613376	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; HMN2C
613382	BRACHYDACTYLY, TYPE E2; BDE2
613385	AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM; ADMFD
613387	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2; NAFLD2
613388	FANCONI RENOTUBULAR SYNDROME 2; FRTS2
613390	FANCONI ANEMIA, COMPLEMENTATION GROUP O; FANCO
613391	DEAFNESS, AUTOSOMAL RECESSIVE 84A; DFNB84A
613392	DEAFNESS, AUTOSOMAL RECESSIVE 85; DFNB85
613398	WARSAW BREAKAGE SYNDROME; WABS
613399	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3; BROVCA3
613402	MICROCEPHALY, SEIZURES, AND DEVELOPMENTAL DELAY; MCSZ
613404	ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 2; ARCS2
613406	WITTEVEEN-KOLK SYNDROME; WITKOS
613411	OGUCHI DISEASE 2
613412	ESOPHAGITIS, EOSINOPHILIC, 2; EOE2
613418	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 15; BMND15
613424	CARDIOMYOPATHY, DILATED, 1R; CMD1R
613426	CARDIOMYOPATHY, DILATED, 1S; CMD1S
613428	RETINITIS PIGMENTOSA 54; RP54
613435	AMYOTROPHIC LATERAL SCLEROSIS 12; ALS12
613436	AUTISM, SUSCEPTIBILITY TO, 17; AUTS17
613443	MENTAL RETARDATION, AUTOSOMAL DOMINANT 20; MRD20
613451	FRONTONASAL DYSPLASIA 2; FND2
613453	DEAFNESS, AUTOSOMAL RECESSIVE 91; DFNB91
613454	RETT SYNDROME, CONGENITAL VARIANT
613456	FRONTONASAL DYSPLASIA 3; FND3
613457	CHROMOSOME 14q11-q22 DELETION SYNDROME
613458	CHROMOSOME 16p13.3 DUPLICATION SYNDROME
613463	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 5; FGQTL5
613464	RETINITIS PIGMENTOSA 51; RP51
613470	HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY
613471	REYNOLDS SYNDROME
613477	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 5; EIEE5
613480	LYMPHEDEMA, HEREDITARY, IC; LMPH1C
613485	LONG QT SYNDROME 13; LQT13
613488	MYXOID LIPOSARCOMA
613489	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIj; CDG2J
613490	ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD
613493	IMMUNODEFICIENCY, COMMON VARIABLE, 3; CVID3
613494	IMMUNODEFICIENCY, COMMON VARIABLE, 4; CVID4
613495	IMMUNODEFICIENCY, COMMON VARIABLE, 5; CVID5
613496	IMMUNODEFICIENCY, COMMON VARIABLE, 6; CVID6
613500	AGAMMAGLOBULINEMIA 2, AUTOSOMAL RECESSIVE; AGM2
613501	AGAMMAGLOBULINEMIA 3, AUTOSOMAL RECESSIVE; AGM3
613502	AGAMMAGLOBULINEMIA 4, AUTOSOMAL RECESSIVE; AGM4
613506	AGAMMAGLOBULINEMIA 5, AUTOSOMAL DOMINANT; AGM5
613507	GLYCOGEN STORAGE DISEASE XV; GSD15
613508	SODIUM SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1; SSQTL1
613509	CHROMOSOME 4q21 DELETION SYNDROME
613517	MICROPHTHALMIA, ISOLATED 6; MCOP6
613530	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1H; LGMD1H
613544	CHROMOSOME 6q11-q14 DELETION SYNDROME
613546	AROMATASE DEFICIENCY
613550	NEPHRONOPHTHISIS 11; NPHP11
613554	VON WILLEBRAND DISEASE, TYPE 2; VWD2
613558	DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51
613559	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 7; COXPD7
613561	MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 2; MLASA2
613563	NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA; NSLL
613566	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 6; HBFQTL6
613571	DISORDERED STEROIDOGENESIS DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY
613573	ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 1; EDSS1
613575	RETINITIS PIGMENTOSA 55; RP55
613576	ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 2; EDSS2
613581	RETINITIS PIGMENTOSA 56; RP56
613582	RETINITIS PIGMENTOSA 57; RP57
613587	OCCULT MACULAR DYSTROPHY; OCMD
613589	LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 6; LDLCQ6
613603	CHROMOSOME 4q32.1-q32.2 TRIPLICATION SYNDROME
613604	CHROMOSOME 16p12.2-p11.2 DELETION SYNDROME, 7.1- TO 8.7-MB
613606	FORSYTHE-WAKELING SYNDROME; FWS
613608	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 3; FAME3
613610	CRANIOECTODERMAL DYSPLASIA 2; CED2
613611	CHOANAL ATRESIA AND LYMPHEDEMA; CATLPH
613612	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi; CDG2I
613615	SENIOR-LOKEN SYNDROME 7; SLSN7
613616	HYPEROXALURIA, PRIMARY, TYPE III; HP3
613617	RETINITIS PIGMENTOSA 58; RP58
613618	CHROMOSOME 17q23.1-q23.2 DUPLICATION SYNDROME
613625	FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 2; F5F8D2
613630	COCOON SYNDROME
613638	CHROMOSOME 19p13.13 DELETION SYNDROME
613640	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C
613641	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB
613642	CARDIOMYOPATHY, DILATED, 1GG; CMD1GG
613643	PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK5
613646	METHYLMALONIC ACIDURIA, TRANSIENT, DUE TO TRANSCOBALAMIN RECEPTOR DEFECT
613647	SPASTIC PARAPLEGIA 48, AUTOSOMAL RECESSIVE; SPG48
613652	C1q DEFICIENCY; C1QD
613656	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 13; MGR13
613657	D-2-HYDROXYGLUTARIC ACIDURIA 2; D2HGA2
613658	RAJAB SYNDROME
613659	GASTRIC CANCER
613660	CONE-ROD DYSTROPHY 15; CORD15
613661	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip; CDG1P
613662	MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B
613668	MICROCEPHALY, POSTNATAL PROGRESSIVE, WITH SEIZURES AND BRAIN ATROPHY
613670	MENTAL RETARDATION WITH LANGUAGE IMPAIRMENT AND WITH OR WITHOUT AUTISTIC FEATURES
613671	MENTAL RETARDATION, ANTERIOR MAXILLARY PROTRUSION, AND STRABISMUS; MRAMS
613672	SPASTIC ATAXIA 4, AUTOSOMAL RECESSIVE; SPAX4
613673	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IV; CDAN4
613674	VESICOURETERAL REFLUX 3; VUR3
613675	CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-MB
613676	SECKEL SYNDROME 4; SCKL4
613677	HYPERALDOSTERONISM, FAMILIAL, TYPE III; HALD3
613679	PROTHROMBIN DEFICIENCY, CONGENITAL
613680	BEAULIEU-BOYCOTT-INNES SYNDROME; BBIS
613681	CHROMOSOME 2q31.1 DUPLICATION SYNDROME
613684	RUBINSTEIN-TAYBI SYNDROME 2; RSTS2
613685	DEAFNESS, AUTOSOMAL RECESSIVE 83; DFNB83
613686	SPONDYLOCOSTAL DYSOSTOSIS 4, AUTOSOMAL RECESSIVE; SCDO4
613688	LONG QT SYNDROME 2; LQT2
613689	MAMMARY-DIGITAL-NAIL SYNDROME; MDNS
613690	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 7; CMH7
613693	LONG QT SYNDROME 6; LQT6
613694	CARDIOMYOPATHY, DILATED, 1U; CMD1U
613695	LONG QT SYNDROME 5; LQT5
613697	CARDIOMYOPATHY, DILATED, 1V; CMD1V
613702	KLIPPEL-FEIL SYNDROME 3, AUTOSOMAL DOMINANT; KFS3
613703	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 6; MCOPCB6
613704	MICROPHTHALMIA, ISOLATED 7; MCOP7
613705	OROFACIAL CLEFT 10; OFC10
613706	NOONAN SYNDROME 7; NS7
613707	LEOPARD SYNDROME 3; LPRD3
613708	NEUROPATHY, HEREDITARY SENSORY, TYPE ID; HSN1D
613710	THIAMINE METABOLISM DYSFUNCTION SYNDROME 4 (BILATERAL STRIATAL DEGENERATION AND PROGRESSIVE POLYNEUROPATHY TYPE); THMD4
613711	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 3; HSCR3
613712	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 4; HSCR4
613717	TREACHER COLLINS SYNDROME 2; TCS2
613718	DEAFNESS, AUTOSOMAL RECESSIVE 74; DFNB74
613720	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 7; EIEE7
613721	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 11; EIEE11
613722	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 12; EIEE12
613723	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Q; LGMD2Q
613724	LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN
613728	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 10; SCAR10
613730	HEMORRHAGIC DESTRUCTION OF THE BRAIN, SUBEPENDYMAL CALCIFICATION, AND CATARACTS; HDBSCC
613731	RETINITIS PIGMENTOSA 4; RP4
613733	MEN1 GENE; MEN1
613735	BRAIN MALFORMATIONS WITH OR WITHOUT URINARY TRACT DEFECTS; BRMUTD
613736	ACNE INVERSA, FAMILIAL, 2, WITH OR WITHOUT DOWLING-DEGOS DISEASE; ACNINV2
613737	ACNE INVERSA, FAMILIAL, 3; ACNINV3
613743	ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL, PARTIAL OR COMPLETE
613744	SPASTIC PARAPLEGIA 51, AUTOSOMAL RECESSIVE; SPG51
613750	RETINITIS PIGMENTOSA 27; RP27
613751	HETEROTAXY, VISCERAL, 4, AUTOSOMAL; HTX4
613752	HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY
613756	RETINITIS PIGMENTOSA 49; RP49
613757	MACULAR DEGENERATION, AGE-RELATED, 6; ARMD6
613758	RETINITIS PIGMENTOSA 47; RP47
613759	INFECTIONS, RECURRENT, WITH ENCEPHALOPATHY, HEPATIC DYSFUNCTION, AND CARDIOVASCULAR MALFORMATIONS
613761	MACULAR DEGENERATION, AGE-RELATED, 5; ARMD5
613762	46,XY SEX REVERSAL 6; SRXY6
613763	CATARACT 16, MULTIPLE TYPES; CTRCT16
613765	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 9; CMH9
613767	RETINITIS PIGMENTOSA 45; RP45
613769	RETINITIS PIGMENTOSA 44; RP44
613776	CHROMOSOME 17p13.1 DELETION SYNDROME
613779	COMPLEMENT COMPONENT 3 DEFICIENCY, AUTOSOMAL RECESSIVE; C3D
613780	AORTIC ANEURYSM, FAMILIAL THORACIC 7; AAT7
613783	COMPLEMENT COMPONENT C1s DEFICIENCY; C1SD
613784	MACULAR DEGENERATION, AGE-RELATED, 12; ARMD12
613789	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2
613790	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE I; C8D1
613791	MASP2 DEFICIENCY
613792	CHROMOSOME 3pter-p25 DELETION SYNDROME
613793	BLOOD GROUP, CROMER SYSTEM; CROM
613794	RETINITIS PIGMENTOSA 20; RP20
613795	LOEYS-DIETZ SYNDROME 3; LDS3
613796	IMMUNODEFICIENCY 31B; IMD31B
613800	MEIER-GORLIN SYNDROME 2; MGORS2
613801	RETINITIS PIGMENTOSA 40; RP40
613803	MEIER-GORLIN SYNDROME 3; MGORS3
613804	MEIER-GORLIN SYNDROME 4; MGORS4
613805	MEIER-GORLIN SYNDROME 5; MGORS5
613807	CILIARY DYSKINESIA, PRIMARY, 14; CILD14
613808	CILIARY DYSKINESIA, PRIMARY, 15; CILD15
613809	RETINITIS PIGMENTOSA 39; RP39
613810	RETINITIS PIGMENTOSA 43; RP43
613811	PONTOCEREBELLAR HYPOPLASIA, TYPE 2D; PCH2D
613812	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 3; CBAS3
613818	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 9; MDDGC9
613819	SHORT-RIB THORACIC DYSPLASIA 4 WITH OR WITHOUT POLYDACTYLY; SRTD4
613820	NEPHRONOPHTHISIS 12; NPHP12
613823	SECKEL SYNDROME 5; SCKL5
613824	NEPHRONOPHTHISIS 9; NPHP9
613825	COMPLEMENT COMPONENT 9 DEFICIENCY; C9D
613826	LEBER CONGENITAL AMAUROSIS 6; LCA6
613827	RETINITIS PIGMENTOSA 48; RP48
613829	LEBER CONGENITAL AMAUROSIS 7; LCA7
613830	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1D; CSNB1D
613834	MULTISYSTEMIC SMOOTH MUSCLE DYSFUNCTION SYNDROME
613835	LEBER CONGENITAL AMAUROSIS 8; LCA8
613837	LEBER CONGENITAL AMAUROSIS 11; LCA11
613838	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 16; CMH16
613839	MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY
613843	LEBER CONGENITAL AMAUROSIS 15; LCA15
613845	HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME; HUPRAS
613848	OSTEOGENESIS IMPERFECTA, TYPE X; OI10
613849	OSTEOGENESIS IMPERFECTA, TYPE XII; OI12
613850	INOSINE TRIPHOSPHATASE DEFICIENCY
613854	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 6; CHTD6
613855	EPISODIC ATAXIA, TYPE 5; EA5
613856	ACHROMATOPSIA 4; ACHM4
613857	OROFACIAL CLEFT 13; OFC13
613860	FICOLIN 3 DEFICIENCY
613861	RETINITIS PIGMENTOSA 59; RP59
613862	RETINITIS PIGMENTOSA 38; RP38
613863	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 7; GEFSP7
613865	DEAFNESS, AUTOSOMAL RECESSIVE 61; DFNB61
613869	MYOPATHY, MYOFIBRILLAR, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED
613870	HIRSCHSPRUNG DISEASE, CARDIAC DEFECTS, AND AUTONOMIC DYSFUNCTION; HCAD
613873	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 17; CMH17
613874	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 18; CMH18
613875	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 19; CMH19
613876	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 20; CMH20
613877	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 4; FPLD4
613881	CARDIOMYOPATHY, DILATED, 1HH; CMD1HH
613882	HYPOMAGNESEMIA 6, RENAL; HOMG6
613884	CHROMOSOME 13q14 DELETION SYNDROME
613885	MECKEL SYNDROME, TYPE 8; MKS8
613886	OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY; OBHD
613887	CATARACT 36; CTRCT36
613908	SPINOCEREBELLAR ATAXIA 35; SCA35
613909	SPINOCEREBELLAR ATAXIA 32; SCA32
613912	COMPLEMENT FACTOR D DEFICIENCY; CFDD
613916	DEAFNESS, AUTOSOMAL RECESSIVE 89; DFNB89
613925	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2A; MLC2A
613926	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2B, REMITTING, WITH OR WITHOUT MENTAL RETARDATION; MLC2B
613930	ALOPECIA-MENTAL RETARDATION SYNDROME 3; APMR3
613933	ACETYL-CoA CARBOXYLASE DEFICIENCY; ACACAD
613938	PARASOMNIA, SLEEPWALKING TYPE; PSMNSW
613943	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 8; ARCI8
613944	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 2; IGAN2
613949	OKT4 EPITOPE DEFICIENCY
613950	SCHIZOPHRENIA 15; SCZD15
613951	FANCONI ANEMIA, COMPLEMENTATION GROUP P; FANCP
613953	IMMUNODEFICIENCY 51; IMD51
613954	AMYOTROPHIC LATERAL SCLEROSIS 14 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS14
613955	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 2; PLCA2
613956	CANDIDIASIS, FAMILIAL, 6; CANDF6
613957	SPERMATOGENIC FAILURE 8; SPGF8
613958	SPERMATOGENIC FAILURE 9; SPGF9
613960	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE, TYPE III; CDG3
613969	MYOPIA 19, AUTOSOMAL DOMINANT; MYP19
613970	MENTAL RETARDATION, AUTOSOMAL DOMINANT 6, WITH OR WITHOUT SEIZURES; MRD6
613972	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 6; CMM6
613977	CYANOSIS, TRANSIENT NEONATAL; TNCY
613978	HEMOGLOBIN H DISEASE; HBH
613980	ATRIAL FIBRILLATION, FAMILIAL, 9; ATFB9
613981	HYPOTRICHOSIS 3; HYPT3
613982	OSTEOGENESIS IMPERFECTA, TYPE VI; OI6
613983	RETINITIS PIGMENTOSA 60; RP60
613985	BETA-THALASSEMIA
613986	PITUITARY HORMONE DEFICIENCY, COMBINED, 6; CPHD6
613987	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 2; DKCB2
613988	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 3; DKCB3
613989	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 2; DKCA2
613990	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3; DKCA3
614008	NESTOR-GUILLERMO PROGERIA SYNDROME; NGPS
614009	BLEEDING DISORDER, PLATELET-TYPE, 13, SUSCEPTIBILITY TO; BDPLT13
614017	CILIARY DYSKINESIA, PRIMARY, 16; CILD16
614018	EPILEPSY, PROGRESSIVE MYOCLONIC, 6; EPM6
614019	LISSENCEPHALY 4; LIS4
614020	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 14; MRT14
614021	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3
614022	ATRIAL FIBRILLATION, FAMILIAL, 10; ATFB10
614023	PHOSPHOSERINE PHOSPHATASE DEFICIENCY; PSPHD
614024	PROTEIN Z DEFICIENCY
614025	HEPATIC LIPASE DEFICIENCY
614028	APOLIPOPROTEIN C-III DEFICIENCY
614033	HYDROXYACYL GLUTATHIONE HYDROLASE DEFICIENCY
614034	HEME OXYGENASE 1 DEFICIENCY; HMOX1D
614035	DEAFNESS, AUTOSOMAL RECESSIVE 29; DFNB29
614036	ALPHA-2-MACROGLOBULIN DEFICIENCY; A2MD
614037	LEUKOTRIENE C4 SYNTHASE DEFICIENCY
614038	LYMPHEDEMA, PRIMARY, WITH MYELODYSPLASIA
614039	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 1; CDCBM1
614042	MOYAMOYA DISEASE 5; MYMY5
614044	TRYPSINOGEN DEFICIENCY
614049	ATRIAL FIBRILLATION, FAMILIAL, 11; ATFB11
614050	ATRIAL FIBRILLATION, FAMILIAL, 12; ATFB12
614052	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 2; MC5DN2
614053	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 3; MC5DN3
614055	ACETYL-CoA ACETYLTRANSFERASE-2 DEFICIENCY; ACAT2D
614063	N-ACETYLASPARTATE DEFICIENCY; NACED
614065	MYOPATHY, DISTAL, 4; MPD4
614066	SPASTIC PARAPLEGIA 47, AUTOSOMAL RECESSIVE; SPG47
614067	SPASTIC PARAPLEGIA 52, AUTOSOMAL RECESSIVE; SPG52
614069	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 2; ICF2
614070	PSORIASIS 13, SUSCEPTIBILITY TO; PSORS13
614072	HERMANSKY-PUDLAK SYNDROME 3; HPS3
614073	HERMANSKY-PUDLAK SYNDROME 4; HPS4
614074	HERMANSKY-PUDLAK SYNDROME 5; HPS5
614075	HERMANSKY-PUDLAK SYNDROME 6; HPS6
614076	HERMANSKY-PUDLAK SYNDROME 7; HPS7
614077	HERMANSKY-PUDLAK SYNDROME 8; HPS8
614078	CHONDRODYSPLASIA WITH JOINT DISLOCATIONS, GPAPP TYPE
614079	ASPERGILLOSIS, SUSCEPTIBILITY TO
614080	MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1
614081	ANHAPTOGLOBINEMIA; AHP
614082	FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG
614083	FANCONI ANEMIA, COMPLEMENTATION GROUP L; FANCL
614089	ATRIAL SEPTAL DEFECT 3; ASD3
614090	SICK SINUS SYNDROME 3, SUSCEPTIBILITY TO; SSS3
614091	SHORT-RIB THORACIC DYSPLASIA 7 WITH OR WITHOUT POLYDACTYLY; SRTD7
614096	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 8; COXPD8
614097	ACATALASEMIA
614098	KEPPEN-LUBINSKY SYNDROME; KPLBS
614099	CRANIOECTODERMAL DYSPLASIA 3; CED3
614101	PLASMA FIBRONECTIN DEFICIENCY
614102	IMMUNOGLOBULIN KAPPA LIGHT CHAIN DEFICIENCY; IGKCD
614104	MENTAL RETARDATION, AUTOSOMAL DOMINANT 7; MRD7
614105	METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; MMSDHD
614111	PYRUVATE DEHYDROGENASE E1-BETA DEFICIENCY; PDHBD
614113	MENTAL RETARDATION, AUTOSOMAL DOMINANT 2; MRD2
614114	MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 2; MVA2
614115	CORTICAL MALFORMATIONS, OCCIPITAL; OCCM
614116	NEUROPATHY, HEREDITARY SENSORY, TYPE IE; HSN1E
614120	HYDROLETHALUS SYNDROME 2; HLS2
614122	CHITOTRIOSIDASE DEFICIENCY; CHITD
614128	LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD
614129	PERRAULT SYNDROME 3; PRLTS3
614131	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 6; FSGS6
614134	STICKLER SYNDROME, TYPE IV; STL4
614135	EPIPHYSEAL DYSPLASIA, MULTIPLE, 6; EDM6
614149	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; NDNC9
614152	DEAFNESS, AUTOSOMAL DOMINANT 64; DFNA64
614153	SPINOCEREBELLAR ATAXIA 36; SCA36
614156	HYPERBILIVERDINEMIA; HBLVD
614157	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 10; NDNC10
614158	BLEEDING DISORDER, PLATELET-TYPE, 14; BDPLT14
614160	MUSCLE HYPERTROPHY; MSLHP
614162	IMMUNODEFICIENCY 31C; IMD31C
614163	DELAYED SLEEP PHASE DISORDER, SUSCEPTIBILITY TO; DSPD
614164	GLUTATHIONE PEROXIDASE DEFICIENCY; GPXD
614165	PARAGANGLIOMAS 5; PGL5
614167	MYOPIA 21, AUTOSOMAL DOMINANT; MYP21
614171	HERMANSKY-PUDLAK SYNDROME 9; HPS9
614172	IMMUNODEFICIENCY 21; IMD21
614173	JOUBERT SYNDROME 13; JBTS13
614175	MECKEL SYNDROME, TYPE 10; MKS10
614180	RETINITIS PIGMENTOSA 61; RP61
614181	RETINITIS PIGMENTOSA 62; RP62
614185	GELEOPHYSIC DYSPLASIA 2; GPHYSD2
614186	LEBER CONGENITAL AMAUROSIS 16; LCA16
614187	HYPERTELORISM, PREAURICULAR SINUS, PUNCTAL PITS, AND DEAFNESS; HPPD
614188	CRANIOSYNOSTOSIS AND DENTAL ANOMALIES; CRSDA
614190	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 3; PPNAD3
614192	MACROCEPHALY, MACROSOMIA, AND FACIAL DYSMORPHISM SYNDROME; MMFD
614193	TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 2; TFQTL2
614195	CRANIOFACIAL ANOMALIES AND ANTERIOR SEGMENT DYSGENESIS SYNDROME; CAASDS
614196	NEPHROTIC SYNDROME, TYPE 6; NPHS6
614198	MYASTHENIC SYNDROME, CONGENITAL, 16; CMS16
614199	NEPHROTIC SYNDROME, TYPE 5, WITH OR WITHOUT OCULAR ABNORMALITIES; NPHS5
614200	BLEEDING DISORDER, PLATELET-TYPE, 9; BDPLT9
614201	BLEEDING DISORDER, PLATELET-TYPE, 11; BDPLT11
614202	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15
614203	PARKINSON DISEASE 17; PARK17
614204	PSORIASIS 14, PUSTULAR; PSORS14
614205	THREE M SYNDROME 3; 3M3
614207	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 3; HPMRS3
614209	MECKEL SYNDROME, TYPE 9; MKS9
614211	DEAFNESS, AUTOSOMAL DOMINANT 33; DFNA33
614212	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 4; IIAE4
614213	NEUROPATHY, HEREDITARY SENSORY, TYPE IIC; HSN2C
614219	ADAMS-OLIVER SYNDROME 2; AOS2
614222	WARBURG MICRO SYNDROME 3; WARBM3
614224	RETINAL ARTERIAL MACROANEURYSM WITH SUPRAVALVULAR PULMONIC STENOSIS; RAMSVPS
614225	WARBURG MICRO SYNDROME 2; WARBM2
614226	HOLOPROSENCEPHALY 11; HPE11
614227	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 3; HNFJ3
614228	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2O; CMT2O
614229	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 11; SCAR11
614230	CHROMOSOME 8q21.11 DELETION SYNDROME
614231	MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME; MEDS
614233	HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 1; FPH1
614238	HYPOTRICHOSIS 10; HYPT10
614249	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 18; MRT18
614250	NARCOLEPSY 7; NRCLP7
614251	PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK18
614254	NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT HYPERKINETIC MOVEMENTS AND SEIZURES, AUTOSOMAL DOMINANT; NDHMSD
614255	MENTAL RETARDATION, AUTOSOMAL DOMINANT 9; MRD9
614256	MENTAL RETARDATION, AUTOSOMAL DOMINANT 10; MRD10
614257	MENTAL RETARDATION, AUTOSOMAL DOMINANT 11; MRD11
614261	MICROCEPHALY-CAPILLARY MALFORMATION SYNDROME; MICCAP
614262	ARTHROGRYPOSIS, PERTHES DISEASE, AND UPWARD GAZE PALSY; APUG
614265	COMBINED MALONIC AND METHYLMALONIC ACIDURIA; CMAMMA
614266	BARRETT ESOPHAGUS
614278	PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY; PAFAD
614279	46,XY SEX REVERSAL 8; SRXY8
614280	EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 9; EJM9
614284	STICKLER SYNDROME, TYPE V; STL5
614286	MYELODYSPLASTIC SYNDROME; MDS
614291	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 4; BROVCA4
614292	MYOPIA, HIGH, WITH CATARACT AND VITREORETINAL DEGENERATION; MCVD
614293	HYDATIDIFORM MOLE, RECURRENT, 2; HYDM2
614294	CHROMOSOME 15q25 DELETION SYNDROME
614296	WOLFRAM-LIKE SYNDROME, AUTOSOMAL DOMINANT; WFSL
614298	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 4; NBIA4
614299	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 2 WITH HYPERGLYCINEMIA; MMDS2
614300	HYPERMETHIONINEMIA DUE TO ADENOSINE KINASE DEFICIENCY
614302	EMERY-DREIFUSS MUSCULAR DYSTROPHY 7, AUTOSOMAL DOMINANT; EDMD7
614303	EDICT SYNDROME; EDICT
614305	SCLEROSTEOSIS 2; SOST2
614306	COGNITIVE IMPAIRMENT WITH OR WITHOUT CEREBELLAR ATAXIA; CIAT
614307	ALPHA-METHYLACYL-CoA RACEMASE DEFICIENCY; AMACRD
614320	PANCREATIC CANCER, SUSCEPTIBILITY TO, 4; PNCA4
614321	MYOPATHY, DISTAL, TATEYAMA TYPE; MPDT
614322	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 12; SCAR12
614324	OVARIAN DYSGENESIS 3; ODG3
614325	PITT-HOPKINS-LIKE SYNDROME 2; PTHSL2
614326	FEINGOLD SYNDROME 2; FGLDS2
614327	TUMOR PREDISPOSITION SYNDROME; TPDS
614328	INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 1; NISBD1
614329	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 31; MRT31
614331	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6; HNPCC6
614332	CHROMOSOME 2p16.3 DELETION SYNDROME
614333	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 29; MRT29
614335	ARTHROGRYPOSIS, DISTAL, TYPE 1B; DA1B
614337	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4
614338	PANCREATIC LIPASE DEFICIENCY; PNLIPD
614340	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 27; MRT27
614341	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 33; MRT33
614342	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 30; MRT30
614343	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 19; MRT19
614344	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 23; MRT23
614345	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 24; MRT24
614346	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 25; MRT25
614347	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 28; MRT28
614350	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5; HNPCC5
614369	PERIPHERAL NEUROPATHY, MYOPATHY, HOARSENESS, AND HEARING LOSS; PNMHH
614370	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 5; SMDP5
614371	DENGUE VIRUS, SUSCEPTIBILITY TO
614372	MANNOSE-BINDING LECTIN DEFICIENCY; MBLD
614373	AMYOTROPHIC LATERAL SCLEROSIS 16, JUVENILE; ALS16
614374	BLOOD GROUP, CHIDO/RODGERS SYSTEM
614376	SHORT-RIB THORACIC DYSPLASIA 5 WITH OR WITHOUT POLYDACTYLY; SRTD5
614377	NEPHRONOPHTHISIS 13; NPHP13
614378	CRANIOECTODERMAL DYSPLASIA 4; CED4
614379	COMPLEMENT COMPONENT 4B DEFICIENCY; C4BD
614380	COMPLEMENT COMPONENT 4A DEFICIENCY; C4AD
614381	LEUKODYSTROPHY, HYPOMYELINATING, 8, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD8
614382	BACTEREMIA, SUSCEPTIBILITY TO, 1; BACTS1
614383	BACTEREMIA, SUSCEPTIBILITY TO, 2; BACTS2
614385	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 7; HNPCC7
614388	ENCEPHALOPATHY DUE TO DEFECTIVE MITOCHONDRIAL AND PEROXISOMAL FISSION 1; EMPF1
614389	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1
614390	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 2; RPRGL2
614391	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 3; RPRGL3
614395	GRAFT-VERSUS-HOST DISEASE, SUSCEPTIBILITY TO; GVHDS
614399	MYOPATHY, AREFLEXIA, RESPIRATORY DISTRESS, AND DYSPHAGIA, EARLY-ONSET; EMARDD
614400	GLUCOCORTICOID THERAPY, RESPONSE TO; GCTR
614401	ACCELERATED TUMOR FORMATION, SUSCEPTIBILITY TO; ACTFS
614402	MICROPHTHALMIA, SYNDROMIC 11; MCOPS11
614408	MYOPATHY, CENTRONUCLEAR, 3; CNM3
614409	SPASTIC PARAPLEGIA 46, AUTOSOMAL RECESSIVE; SPG46
614411	GLYCEROL QUANTITATIVE TRAIT LOCUS; GLYCQTL
614414	DEAFNESS, AUTOSOMAL RECESSIVE 96; DFNB96
614415	CHILBLAIN LUPUS 2; CHBL2
614416	RADIOHUMERAL FUSIONS WITH OTHER SKELETAL AND CRANIOFACIAL ANOMALIES; RHFCA
614417	EPILEPSY, FAMILIAL TEMPORAL LOBE, 5; ETL5
614418	FEBRILE SEIZURES, FAMILIAL, 11; FEB11
614420	SYSTEMIC LUPUS ERYTHEMATOSUS 16; SLEB16
614422	CATARACT 37; CTRCT37
614424	JOUBERT SYNDROME 14; JBTS14
614429	VENTRICULAR SEPTAL DEFECT 1; VSD1
614430	ATRIOVENTRICULAR SEPTAL DEFECT 4; AVSD4
614431	VENTRICULAR SEPTAL DEFECT 2; VSD2
614432	VENTRICULAR SEPTAL DEFECT 3; VSD3
614433	ATRIAL SEPTAL DEFECT 8; ASD8
614434	CUTIS LAXA, AUTOSOMAL DOMINANT 2; ADCL2
614435	HYPOPLASTIC LEFT HEART SYNDROME 2; HLHS2
614436	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2P; CMT2P
614437	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IB; ARCL1B
614438	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIB; ARCL3B
614441	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 2; PHOAR2
614450	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 6; CHNG6
614455	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E; CMTDIE
614456	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8; CMM8
614457	ICHTHYOSIS, SPASTIC QUADRIPLEGIA, AND MENTAL RETARDATION; ISQMR
614458	THIAMINE METABOLISM DYSFUNCTION SYNDROME 5 (EPISODIC ENCEPHALOPATHY TYPE); THMD5
614462	HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS
614464	JOUBERT SYNDROME 15; JBTS15
614465	JOUBERT SYNDROME 16; JBTS16
614466	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 6; CHDS6
614468	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3
614470	RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER; RALD
614473	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 2; GACI2
614474	ATRIOVENTRICULAR SEPTAL DEFECT 5; AVSD5
614475	ATRIAL SEPTAL DEFECT 9; ASD9
614480	HYPERTRIGLYCERIDEMIA, TRANSIENT INFANTILE; HTGTI
614482	CONGENITAL CATARACTS, HEARING LOSS, AND NEURODEGENERATION; CCHLND
614483	PORENCEPHALY 2; POREN2
614485	TRIGONOCEPHALY 2; TRIGNO2
614486	THROMBOPHILIA DUE TO THROMBOMODULIN DEFECT; THPH12
614487	SPASTIC ATAXIA 5, AUTOSOMAL RECESSIVE; SPAX5
614490	BLOOD GROUP, JUNIOR SYSTEM; JR
614491	PSEUDOHYPOALDOSTERONISM, TYPE IIB; PHA2B
614492	PSEUDOHYPOALDOSTERONISM, TYPE IIC; PHA2C
614493	WISKOTT-ALDRICH SYNDROME 2; WAS2
614494	RETINITIS PIGMENTOSA 63; RP63
614495	PSEUDOHYPOALDOSTERONISM, TYPE IID; PHA2D
614496	PSEUDOHYPOALDOSTERONISM, TYPE IIE; PHA2E
614497	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 7; MCOPCB7
614498	RIGIDITY AND MULTIFOCAL SEIZURE SYNDROME, LETHAL NEONATAL; RMFSL
614499	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 34, WITH VARIANT LISSENCEPHALY; MRT34
614500	CONE-ROD DYSTROPHY 16; CORD16
614501	PSYCHOMOTOR RETARDATION, EPILEPSY, AND CRANIOFACIAL DYSMORPHISM; PMRED
614504	USHER SYNDROME, TYPE IIIB; USH3B
614507	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ir; CDG1R
614508	MIRROR MOVEMENTS 2; MRMV2
614514	THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL RECESSIVE; THPH6
614519	HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO; ICH
614521	THROMBOCYTHEMIA 3; THCYT3
614524	FIBROCHONDROGENESIS 2; FBCG2
614526	CHROMOSOME 17q12 DUPLICATION SYNDROME
614527	CHROMOSOME 17q12 DELETION SYNDROME
614541	CHROMOSOME 16q22 DELETION SYNDROME
614557	EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE, 2; EDSKSCL2
614558	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 13; EIEE13
614559	INFANTILE CEREBELLAR-RETINAL DEGENERATION; ICRD
614561	LEUKOENCEPHALOPATHY, BRAIN CALCIFICATIONS, AND CYSTS; LCC
614563	MENTAL RETARDATION, AUTOSOMAL DOMINANT 13; MRD13
614564	CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL; FCTCS
614565	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1E; CSNB1E
614576	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIl; CDG2L
614582	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 9; COXPD9
614583	BARAITSER-WINTER SYNDROME 2; BRWS2
614588	DYSTONIA 21; DYT21
614592	BENT BONE DYSPLASIA SYNDROME; BBDS
614594	PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTIC PLAQUES
614595	PREECLAMPSIA/ECLAMPSIA 5; PEE5
614602	TRICHOHEPATOENTERIC SYNDROME 2; THES2
614607	COFFIN-SIRIS SYNDROME 2; CSS2
614608	COFFIN-SIRIS SYNDROME 3; CSS3
614609	COFFIN-SIRIS SYNDROME 4; CSS4
614613	ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS2
614614	DEAFNESS, AUTOSOMAL DOMINANT 4B; DFNA4B
614615	JOUBERT SYNDROME 17; JBTS17
614616	DIARRHEA 6; DIAR6
614617	DEAFNESS, AUTOSOMAL RECESSIVE 86; DFNB86
614618	HYPEREKPLEXIA 3; HKPX3
614619	HYPEREKPLEXIA 2; HKPX2
614621	UV-SENSITIVE SYNDROME 2; UVSS2
614622	KERATOCONUS 5; KTCN5
614623	KERATOCONUS 6; KTCN6
614628	KERATOCONUS 8; KTCN8
614629	KERATOCONUS 7; KTCN7
614640	UV-SENSITIVE SYNDROME 3; UVSS3
614643	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7
614650	COENZYME Q10 DEFICIENCY, PRIMARY, 6; COQ10D6
614651	COENZYME Q10 DEFICIENCY, PRIMARY, 2; COQ10D2
614652	COENZYME Q10 DEFICIENCY, PRIMARY, 3; COQ10D3
614653	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VI; HSAN6
614654	COENZYME Q10 DEFICIENCY, PRIMARY, 5; COQ10D5
614662	CORTISONE REDUCTASE DEFICIENCY 2; CORTRD2
614665	MECONIUM ILEUS
614669	AURICULOCONDYLAR SYNDROME 2; ARCND2
614672	CARDIOMYOPATHY, DILATED, 2B; CMD2B
614673	MICROCEPHALY 8, PRIMARY, AUTOSOMAL RECESSIVE; MCPH8
614674	PERIODIC FEVER, MENSTRUAL CYCLE-DEPENDENT
614675	BONE MARROW FAILURE SYNDROME 1; BMFS1
614676	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 21; CMH21
614678	PONTOCEREBELLAR HYPOPLASIA, TYPE 1B; PCH1B
614679	CILIARY DYSKINESIA, PRIMARY, 17; CILD17
614680	INFLUENZA, SEVERE, SUSCEPTIBILITY TO
614689	SOLUBLE INTERLEUKIN-6 RECEPTOR, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS
614691	CATARACT 38; CTRCT38
614696	AMYOTROPHIC LATERAL SCLEROSIS 17; ALS17
614699	IMMUNODEFICIENCY, COMMON VARIABLE, 7; CVID7
614700	IMMUNODEFICIENCY, COMMON VARIABLE, 8, WITH AUTOIMMUNITY; CVID8
614701	CORNELIA DE LANGE SYNDROME 4; CDLS4
614702	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 10; COXPD10
614706	CEROID LIPOFUSCINOSIS, NEURONAL, 11; CLN11
614707	BROWN-VIALETTO-VAN LAERE SYNDROME 2; BVVLS2
614714	POROKERATOSIS 7, MULTIPLE TYPES; POROK7
614723	ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD
614727	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIk; CDG2K
614728	SECKEL SYNDROME 6; SCKL6
614731	PROSTATE CANCER, HEREDITARY, 2; HPC2
614732	INTRAUTERINE GROWTH RETARDATION, METAPHYSEAL DYSPLASIA, ADRENAL HYPOPLASIA CONGENITA, AND GENITAL ANOMALIES
614736	GLUCOCORTICOID DEFICIENCY 4 WITH OR WITHOUT MINERALOCORTICOID DEFICIENCY; GCCD4
614739	3-METHYLGLUTACONIC ACIDURIA WITH DEAFNESS, ENCEPHALOPATHY, AND LEIGH-LIKE SYNDROME; MEGDEL
614740	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 7; BCC7
614741	MITOCHONDRIAL PYRUVATE CARRIER DEFICIENCY; MPYCD
614742	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1; PFBMFT1
614743	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 2; PFBMFT2
614744	FACIAL PARESIS, HEREDITARY CONGENITAL, 3; HCFP3
614745	BLOOD GROUP, JOHN MILTON HAGEN SYSTEM; JMH
614748	INTERSTITIAL LUNG DISEASE, NEPHROTIC SYNDROME, AND EPIDERMOLYSIS BULLOSA, CONGENITAL; ILNEB
614749	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 2; HPMRS2
614750	MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13
614751	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B
614752	INTERLEUKIN 6, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS
614753	SOTOS SYNDROME 2; SOTOS2
614756	CEREBELLAR ATAXIA, NONPROGRESSIVE, WITH MENTAL RETARDATION; CANPMR
614779	HETEROTAXY, VISCERAL, 6, AUTOSOMAL; HTX6
614782	TREMOR, HEREDITARY ESSENTIAL, 4; ETM4
614800	SHORT STATURE, OPTIC NERVE ATROPHY, AND PELGER-HUET ANOMALY; SOPH
614807	MYOPATHY, CENTRONUCLEAR, 4; CNM4
614808	AMYOTROPHIC LATERAL SCLEROSIS 18; ALS18
614809	CFHR5 DEFICIENCY
614810	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 5; MS5
614813	SHORT STATURE, ONYCHODYSPLASIA, FACIAL DYSMORPHISM, AND HYPOTRICHOSIS; SOFT
614814	ADAMS-OLIVER SYNDROME 3; AOS3
614815	JOUBERT SYNDROME 18; JBTS18
614816	LOEYS-DIETZ SYNDROME 4; LDS4
614817	INTERSTITIAL NEPHRITIS, KARYOMEGALIC; KMIN
614819	WEILL-MARCHESANI SYNDROME 3; WMS3
614820	ALTERNATING HEMIPLEGIA OF CHILDHOOD 2; AHC2
614822	SPERMATOGENIC FAILURE 10; SPGF10
614823	AORTIC VALVE DISEASE 2; AOVD2
614826	NYSTAGMUS 7, CONGENITAL, AUTOSOMAL DOMINANT; NYS7
614830	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8
614831	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 13; SCAR13
614832	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA4; AI2A4
614833	MICROCEPHALY, SHORT STATURE, AND POLYMICROGYRIA WITH OR WITHOUT SEIZURES; MSSP
614837	HYPOGONADOTROPIC HYPOGONADISM 8 WITH OR WITHOUT ANOSMIA; HH8
614838	HYPOGONADOTROPIC HYPOGONADISM 9 WITH OR WITHOUT ANOSMIA; HH9
614839	HYPOGONADOTROPIC HYPOGONADISM 10 WITH OR WITHOUT ANOSMIA; HH10
614840	HYPOGONADOTROPIC HYPOGONADISM 11 WITH OR WITHOUT ANOSMIA; HH11
614841	HYPOGONADOTROPIC HYPOGONADISM 12 WITH OR WITHOUT ANOSMIA; HH12
614842	HYPOGONADOTROPIC HYPOGONADISM 13 WITH OR WITHOUT ANOSMIA; HH13
614844	NEPHRONOPHTHISIS 14; NPHP14
614845	NEPHRONOPHTHISIS 15; NPHP15
614847	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 12; EIG12
614849	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 5; IIAE5
614850	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 6; IIAE6
614851	SECKEL SYNDROME 7; SCKL7
614852	MICROCEPHALY 9, PRIMARY, AUTOSOMAL RECESSIVE; MCPH9
614856	OSTEOGENESIS IMPERFECTA, TYPE XIII; OI13
614857	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblJ TYPE; MAHCJ
614858	HYPOGONADOTROPIC HYPOGONADISM 14 WITH OR WITHOUT ANOSMIA; HH14
614859	PEROXISOME BIOGENESIS DISORDER 3A (ZELLWEGER); PBD3A
614860	DYSTONIA 23; DYT23
614861	DEAFNESS, AUTOSOMAL RECESSIVE 98; DFNB98
614862	PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4A
614863	PEROXISOME BIOGENESIS DISORDER 4B; PBD4B
614866	PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER); PBD5A
614867	PEROXISOME BIOGENESIS DISORDER 5B; PBD5B
614868	T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AND AUTOIMMUNITY WITH OR WITHOUT CARDIAC MALFORMATIONS; TIIAC
614869	USHER SYNDROME, TYPE IJ; USH1J
614870	PEROXISOME BIOGENESIS DISORDER 6A (ZELLWEGER); PBD6A
614871	PEROXISOME BIOGENESIS DISORDER 6B; PBD6B
614872	PEROXISOME BIOGENESIS DISORDER 7A (ZELLWEGER); PBD7A
614873	PEROXISOME BIOGENESIS DISORDER 7B; PBD7B
614874	CILIARY DYSKINESIA, PRIMARY, 18; CILD18
614876	PEROXISOME BIOGENESIS DISORDER 8A (ZELLWEGER); PBD8A
614877	PEROXISOME BIOGENESIS DISORDER 8B; PBD8B
614878	AUTOINFLAMMATION, ANTIBODY DEFICIENCY, AND IMMUNE DYSREGULATION, PLCG2-ASSOCIATED; APLAID
614879	PEROXISOME BIOGENESIS DISORDER 9B; PBD9B
614880	HYPOGONADOTROPIC HYPOGONADISM 15 WITH OR WITHOUT ANOSMIA; HH15
614881	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 5; DSMA5
614882	PEROXISOME BIOGENESIS DISORDER 10A (ZELLWEGER); PBD10A
614883	PEROXISOME BIOGENESIS DISORDER 11A (ZELLWEGER); PBD11A
614885	PEROXISOME BIOGENESIS DISORDER 11B; PBD11B
614886	PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER); PBD12A
614887	PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER); PBD13A
614889	IMMUNODEFICIENCY 28; IMD28
614890	IMMUNODEFICIENCY 29; IMD29
614891	IMMUNODEFICIENCY 30; IMD30
614892	IMMUNODEFICIENCY 31A; IMD31A
614893	IMMUNODEFICIENCY 32A; IMD32A
614895	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 4F; CMT4F
614896	SINOATRIAL NODE DYSFUNCTION AND DEAFNESS; SANDD
614897	HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA; HH16
614898	SPASTIC PARAPLEGIA 53, AUTOSOMAL RECESSIVE; SPG53
614899	DEAFNESS, AUTOSOMAL RECESSIVE 93; DFNB93
614900	DIAMOND-BLACKFAN ANEMIA 11; DBA11
614915	LETHAL CONGENITAL CONTRACTURE SYNDROME 4; LCCS4
614916	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4
614920	PEROXISOME BIOGENESIS DISORDER 14B; PEX14B
614921	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T
614922	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 11; COXPD11
614923	BRANCHED-CHAIN KETO ACID DEHYDROGENASE KINASE DEFICIENCY; BCKDKD
614924	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 12; COXPD12
614926	PERRAULT SYNDROME 2; PRLTS2
614927	ECTODERMAL DYSPLASIA 5, HAIR/NAIL TYPE; ECTD5
614928	ECTODERMAL DYSPLASIA 6, HAIR/NAIL TYPE; ECTD6
614929	ECTODERMAL DYSPLASIA 7, HAIR/NAIL TYPE; ECTD7
614931	ECTODERMAL DYSPLASIA 9, HAIR/NAIL TYPE; ECTD9
614932	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 13; COXPD13
614934	DEAFNESS, AUTOSOMAL RECESSIVE 70; DFNB70
614935	CILIARY DYSKINESIA, PRIMARY, 19; CILD19
614936	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IB; PPKP1B
614937	MYOCLONUS, FAMILIAL CORTICAL; FCM
614940	ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL DOMINANT; ECTD11A
614941	ECTODERMAL DYSPLASIA 11B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL RECESSIVE; ECTD11B
614944	DEAFNESS, AUTOSOMAL RECESSIVE 84B; DFNB84B
614945	DEAFNESS, AUTOSOMAL RECESSIVE 18B; DFNB18B
614946	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 14; COXPD14
614947	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 15; COXPD15
614954	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 3; CHTD3
614959	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 14; EIEE14
614961	PONTOCEREBELLAR HYPOPLASIA, TYPE 8; PCH8
614962	LEPTIN DEFICIENCY OR DYSFUNCTION; LEPD
614963	LEPTIN RECEPTOR DEFICIENCY
614969	PONTOCEREBELLAR HYPOPLASIA, TYPE 7; PCH7
614970	JOUBERT SYNDROME 20; JBTS20
614972	CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY 3; ICP3
614974	FOCAL FACIAL DERMAL DYSPLASIA 4; FFDD4
614976	CARPENTER SYNDROME 2; CRPT2
614980	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 2; CHTD2
614990	USHER SYNDROME, TYPE IK; USH1K
615005	EPILEPSY, NOCTURNAL FRONTAL LOBE, 5; ENFL5
615006	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 15; EIEE15
615007	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 4; IBGC4
615008	NEPHROTIC SYNDROME, TYPE 7; NPHS7
615009	SCHUURS-HOEIJMAKERS SYNDROME; SHMS
615010	AICARDI-GOUTIERES SYNDROME 6; AGS6
615011	PHOSPHOHYDROXYLYSINURIA; PHLU
615022	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 7; ARCI7
615023	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 9; ARCI9
615024	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 10; ARCI10
615025	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q
615026	RIBOFLAVIN DEFICIENCY; RBFVD
615028	EPIDERMOLYSIS BULLOSA, NONSPECIFIC, AUTOSOMAL RECESSIVE; EBNS
615030	SPASTIC PARAPLEGIA 56, AUTOSOMAL RECESSIVE; SPG56
615031	SPASTIC PARAPLEGIA 49, AUTOSOMAL RECESSIVE; SPG49
615032	AUTISM, SUSCEPTIBILITY TO, 18; AUTS18
615033	SPASTIC PARAPLEGIA 54, AUTOSOMAL RECESSIVE; SPG54
615034	DYSTONIA 24; DYT24
615035	SPASTIC PARAPLEGIA 55, AUTOSOMAL RECESSIVE; SPG55
615040	EPISODIC PAIN SYNDROME, FAMILIAL, 1; FEPS1
615041	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10
615042	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U
615043	SPASTIC PARAPLEGIA 43, AUTOSOMAL RECESSIVE; SPG43
615048	SPINAL MUSCULAR ATROPHY, JOKELA TYPE; SMAJ
615058	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1F; CSNB1F
615059	HYPOTRICHOSIS 11; HYPT11
615065	ARTHROGRYPOSIS, DISTAL, TYPE 5D; DA5D
615066	OSTEOGENESIS IMPERFECTA, TYPE XIV; OI14
615067	CILIARY DYSKINESIA, PRIMARY, 20; CILD20
615071	ALAZAMI SYNDROME; ALAZS
615072	BRACHYDACTYLY, TYPE A1, C; BDA1C
615073	DYSTONIA 25; DYT25
615074	MENTAL RETARDATION, AUTOSOMAL DOMINANT 18; MRD18
615075	MENTAL RETARDATION, AUTOSOMAL DOMINANT 19; MRD19
615081	SPERMATOGENIC FAILURE 11; SPGF11
615082	C3HEX, ABILITY TO SMELL
615083	COLORECTAL CANCER, SUSCEPTIBILITY TO, 12; CRCS12
615084	MITOCHONDRIAL DNA DEPLETION SYNDROME 11; MTDPS11
615085	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 8; OPTB8
615091	AUTISM, SUSCEPTIBILITY TO, 19; AUTS19
615092	LEFT VENTRICULAR NONCOMPACTION 7; LVNC7
615095	MICROCEPHALY 10, PRIMARY, AUTOSOMAL RECESSIVE; MCPH10
615107	COWDEN SYNDROME 4; CWS4
615108	COWDEN SYNDROME 5; CWS5
615109	COWDEN SYNDROME 6; CWS6
615112	UROFACIAL SYNDROME 2; UFS2
615113	MICROPHTHALMIA, ISOLATED 8; MCOP8
615119	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 2; CEMCOX2
615120	MYASTHENIC SYNDROME, CONGENITAL, 8; CMS8
615122	LYMPHOPROLIFERATIVE SYNDROME 2; LPFS2
615127	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 4; FAME4
615134	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 9; CMM9
615135	MAPLE SYRUP URINE DISEASE, MILD VARIANT; MSUDMV
615139	FACIAL DYSMORPHISM, IMMUNODEFICIENCY, LIVEDO, AND SHORT STATURE; FILS
615145	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 9; MCOPCB9
615147	RETINAL DYSTROPHY, IRIS COLOBOMA, AND COMEDOGENIC ACNE SYNDROME; RDCCAS
615155	STEEL SYNDROME; STLS
615156	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6
615157	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 2; MC3DN2
615158	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 3; MC3DN3
615159	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 4; MC3DN4
615160	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 5; MC3DN5
615162	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 35; MRT35
615163	CONE-ROD DYSTROPHY 17; CORD17
615179	ALBINISM, OCULOCUTANEOUS, TYPE VII; OCA7
615181	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11
615182	COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD
615184	CARDIOMYOPATHY, DILATED, 1II; CMD1II
615185	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE F; CMTDIF
615188	CATARACT 39, MULTIPLE TYPES; CTRCT39
615190	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 5; DKCB5
615191	LISSENCEPHALY 5; LIS5
615193	BLEEDING DISORDER, PLATELET-TYPE, 15; BDPLT15
615206	IMMUNODEFICIENCY 11; IMD11A
615207	IMMUNODEFICIENCY 56; IMD56
615214	AGAMMAGLOBULINEMIA 7, AUTOSOMAL RECESSIVE; AGM7
615217	ATAXIA-OCULOMOTOR APRAXIA 3; AOA3
615219	HYDROCEPHALUS, CONGENITAL, 2, WITH OR WITHOUT BRAIN OR EYE ANOMALIES; HYC2
615220	OSTEOGENESIS IMPERFECTA, TYPE XV; OI15
615221	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 16; BMND16
615222	SMITH-MCCORT DYSPLASIA 2; SMC2
615224	ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 2; FASPS2
615225	PALMOPLANTAR CARCINOMA, MULTIPLE SELF-HEALING; MSPC
615226	POLYDACTYLY, POSTAXIAL, TYPE A6; PAPA6
615228	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 4; MC5DN4
615232	SCHIZOPHRENIA 18; SCZD18
615233	RETINITIS PIGMENTOSA 66; RP66
615234	ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 2; AHMIO2
615235	CARDIOMYOPATHY, DILATED, 1JJ; CMD1JJ
615237	CONGENITAL SHORT BOWEL SYNDROME; CSBS
615238	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5; FPLD5
615244	NEPHROTIC SYNDROME, TYPE 8; NPHS8
615248	CARDIOMYOPATHY, DILATED, 1KK; CMD1KK
615249	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12
615264	BLOOD GROUP, VEL SYSTEM; VEL
615266	HYPOGONADOTROPIC HYPOGONADISM 17 WITH OR WITHOUT ANOSMIA; HH17
615267	HYPOGONADOTROPIC HYPOGONADISM 18 WITH OR WITHOUT ANOSMIA; HH18
615268	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 4; CAMRQ4
615269	HYPOGONADOTROPIC HYPOGONADISM 19 WITH OR WITHOUT ANOSMIA; HH19
615270	HYPOGONADOTROPIC HYPOGONADISM 20 WITH OR WITHOUT ANOSMIA; HH20
615271	HYPOGONADOTROPIC HYPOGONADISM 21 WITH OR WITHOUT ANOSMIA; HH21
615272	FANCONI ANEMIA, COMPLEMENTATION GROUP Q; FANCQ
615273	CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG
615274	CATARACT 15, MULTIPLE TYPES; CTRCT15
615277	CATARACT 19, MULTIPLE TYPES; CTRCT19
615278	CARDIOFACIOCUTANEOUS SYNDROME 2; CFC2
615279	CARDIOFACIOCUTANEOUS SYNDROME 3; CFC3
615280	CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4
615281	HYPOMYELINATION WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LEG SPASTICITY; HBSL
615282	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 2; CDCBM2
615284	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B3; CMT4B3
615285	NEUTROPENIA, SEVERE CONGENITAL, 5, AUTOSOMAL RECESSIVE; SCN5
615286	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 36; MRT36
615287	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13
615290	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2, AUTOSOMAL DOMINANT; SMALED2
615293	MYOFIBROMATOSIS, INFANTILE, 2; IMF2
615294	CILIARY DYSKINESIA, PRIMARY, 21; CILD21
615297	ADAMS-OLIVER SYNDROME 4; AOS4
615298	SYMPHALANGISM, PROXIMAL, 1B; SYM1B
615300	PERRAULT SYNDROME 4; PRLTS4
615312	ALBINISM, OCULOCUTANEOUS, TYPE V; OCA5
615314	CRANIOSYNOSTOSIS 3; CRS3
615325	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2R; LGMD2R
615327	DOWLING-DEGOS DISEASE 2; DDD2
615328	SHAHEEN SYNDROME; SHNS
615330	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 3; MMDS3
615338	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 16; EIEE16
615342	PULMONARY HYPERTENSION, PRIMARY, 2; PPH2
615343	PULMONARY HYPERTENSION, PRIMARY, 3; PPH3
615344	PULMONARY HYPERTENSION, PRIMARY, 4; PPH4
615346	PRECOCIOUS PUBERTY, CENTRAL, 2; CPPB2
615348	NEMALINE MYOPATHY 8; NEM8
615349	EHLERS-DANLOS SYNDROME, SPONDYLODYSPLASTIC TYPE, 2; EDSSPD2
615350	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 14; MDDGA14
615351	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 14; MDDGB14
615352	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 14; MDDGC14
615355	NOONAN SYNDROME 8; NS8
615356	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2S; LGMD2S
615360	LEBER CONGENITAL AMAUROSIS 17; LCA17
615361	HYPOCALCEMIA, AUTOSOMAL DOMINANT 2; HYPOC2
615362	CEROID LIPOFUSCINOSIS, NEURONAL, 13; CLN13
615363	ESTROGEN RESISTANCE; ESTRR
615368	LETHAL CONGENITAL CONTRACTURE SYNDROME 5; LCCS5
615369	EPILEPTIC ENCEPHALOPATHY, CHILDHOOD-ONSET; EEOC
615371	PULMONARY HYPERTENSION, NEONATAL, SUSCEPTIBILITY TO; PHN
615373	LEFT VENTRICULAR NONCOMPACTION 8; LVNC8
615374	CONE-ROD DYSTROPHY 18; CORD18
615376	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE C; CMTRIC
615377	ATRIAL FIBRILLATION, FAMILIAL, 13; ATFB13
615378	ATRIAL FIBRILLATION, FAMILIAL, 14; ATFB14
615381	MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHY SYNDROME; MDPL
615382	NEPHRONOPHTHISIS 16; NPHP16
615386	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 14; SCAR14
615387	T-CELL RECEPTOR-ALPHA/BETA DEFICIENCY
615395	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16
615396	LEFT VENTRICULAR NONCOMPACTION 10; LVNC10
615397	MECKEL SYNDROME, TYPE 11; MKS11
615398	MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3
615399	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 2; PNH2
615400	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 5; FAME5
615401	IMMUNODEFICIENCY 8; IMD8
615402	DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 3; DUH3
615411	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 3; CDCBM3
615412	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 4; CDCBM4
615413	SPERMATOGENIC FAILURE 12; SPGF12
615414	MICROCEPHALY 11, PRIMARY, AUTOSOMAL RECESSIVE; MCPH11
615415	RENAL-HEPATIC-PANCREATIC DYSPLASIA 2; RHPD2
615418	MITOCHONDRIAL DNA DEPLETION SYNDROME 12B (CARDIOMYOPATHIC TYPE), AUTOSOMAL RECESSIVE; MTDPS12B
615419	HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTIC FACIES 1; IHPRF1
615420	MYOPIA 22, AUTOSOMAL DOMINANT; MYP22
615422	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 2; IBMPFD2
615424	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 3; IBMPFD3
615425	EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 2; EBSB2
615426	AMYOTROPHIC LATERAL SCLEROSIS 20; ALS20
615429	DEAFNESS, AUTOSOMAL RECESSIVE 88; DFNB88
615431	MYOPIA 23, AUTOSOMAL RECESSIVE; MYP23
615432	SPECIFIC LANGUAGE IMPAIRMENT 5; SLI5
615433	CHROMOSOME 3q13.31 DELETION SYNDROME
615434	RETINITIS PIGMENTOSA 82 WITH OR WITHOUT SITUS INVERSUS; RP82
615436	AORTIC ANEURYSM, FAMILIAL THORACIC 8; AAT8
615438	INFANTILE LIVER FAILURE SYNDROME 1; ILFS1
615439	MACULAR DEGENERATION, AGE-RELATED, 13; ARMD13
615440	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 17; COXPD17
615441	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5
615444	CILIARY DYSKINESIA, PRIMARY, 22; CILD22
615451	CILIARY DYSKINESIA, PRIMARY, 23; CILD23
615453	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 6; MC3DN6
615457	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 18; BMIQ18
615458	MICROCORNEA, MYOPIC CHORIORETINAL ATROPHY, AND TELECANTHUS; MMCAT
615465	HARTSFIELD SYNDROME; HRTFDS
615468	IMMUNODEFICIENCY 12; IMD12
615471	MITOCHONDRIAL DNA DEPLETION SYNDROME 13 (ENCEPHALOMYOPATHIC TYPE); MTDPS13
615473	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 17; EIEE17
615474	PRIMARY ALDOSTERONISM, SEIZURES, AND NEUROLOGIC ABNORMALITIES; PASNA
615476	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 18; EIEE18
615481	CILIARY DYSKINESIA, PRIMARY, 24; CILD24
615482	CILIARY DYSKINESIA, PRIMARY, 25; CILD25
615483	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 5; IBGC5
615485	BAINBRIDGE-ROPERS SYNDROME; BRPS
615486	INTERSTITIAL LUNG AND LIVER DISEASE; ILLD
615489	MACULAR DEGENERATION, AGE-RELATED, 14; ARMD14
615490	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2R; CMT2R
615491	SPASTIC PARAPLEGIA 79, AUTOSOMAL RECESSIVE; SPG79
615493	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 37; MRT37
615500	CILIARY DYSKINESIA, PRIMARY, 26; CILD26
615501	MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP C; MOCODC
615502	MENTAL RETARDATION, AUTOSOMAL DOMINANT 21; MRD21
615503	SHORT-RIB THORACIC DYSPLASIA 8 WITH OR WITHOUT POLYDACTYLY; SRTD8
615504	CILIARY DYSKINESIA, PRIMARY, 27; CILD27
615505	CILIARY DYSKINESIA, PRIMARY, 28; CILD28
615506	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5
615508	ERYTHRODERMA, CONGENITAL, WITH PALMOPLANTAR KERATODERMA, HYPOTRICHOSIS, AND HYPER-IgE; EPKHE
615510	ALACRIMA, ACHALASIA, AND MENTAL RETARDATION SYNDROME; AAMR
615511	MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD
615512	TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; TPID
615513	IMMUNODEFICIENCY 14; IMD14
615515	AMYOTROPHIC LATERAL SCLEROSIS 19; ALS19
615516	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 38; MRT38
615517	HEMOCHROMATOSIS, TYPE 5; HFE5
615518	IMMUNODEFICIENCY 13; IMD13
615522	COLE DISEASE; COLED
615523	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 8; FECD8
615524	MICROPHTHALMIA, SYNDROMIC 12; MCOPS12
615527	CANDIDIASIS, FAMILIAL, 8; CANDF8
615528	PARKINSON DISEASE 19A, JUVENILE-ONSET; PARK19A
615529	CRANIOSYNOSTOSIS 5, SUSCEPTIBILITY TO; CRS5
615530	PARKINSON DISEASE 20, EARLY-ONSET; PARK20
615537	RETICULATE ACROPIGMENTATION OF KITAMURA; RAK
615538	CHROMOSOME 22q13 DUPLICATION SYNDROME
615539	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 2; EDSMC2
615540	DEAFNESS, AUTOSOMAL RECESSIVE 76; DFNB76
615541	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 39; MRT39
615542	TESTICULAR ANOMALIES WITH OR WITHOUT CONGENITAL HEART DISEASE; TACHD
615544	PERIVENTRICULAR NODULAR HETEROTOPIA 6; PVNH6
615545	LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 3; ALL3
615546	VAN MALDERGEM SYNDROME 2; VMLDS2
615547	SCHAAF-YANG SYNDROME; SHFYNG
615548	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VII; HSAN7
615550	DIAMOND-BLACKFAN ANEMIA 12; DBA12
615551	EPISODIC PAIN SYNDROME, FAMILIAL, 2; FEPS2
615552	EPISODIC PAIN SYNDROME, FAMILIAL, 3; FEPS3
615553	ARTHROGRYPOSIS, MENTAL RETARDATION, AND SEIZURES; AMRS
615554	MULTIPLE FIBROADENOMAS OF THE BREAST; MFAB
615555	HYPERPROLACTINEMIA; HPRL
615557	MELIOIDOSIS, SUSCEPTIBILITY TO
615558	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1
615559	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3
615560	OTOFACIOCERVICAL SYNDROME 2; OTFCS2
615561	COMPLEMENT FACTOR B DEFICIENCY; CFBD
615565	RETINITIS PIGMENTOSA 67; RP67
615573	NEPHROTIC SYNDROME, TYPE 9; NPHS9
615574	ASPARAGINE SYNTHETASE DEFICIENCY; ASNSD
615575	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; HMN2D
615577	IMMUNODEFICIENCY, COMMON VARIABLE, 10; CVID10
615578	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 18; COXPD18
615582	LOEYS-DIETZ SYNDROME 5; LDS5
615583	VERHEIJ SYNDROME; VRJS
615589	OTOSCLEROSIS 10; OTSC10
615590	ALZHEIMER DISEASE 18; AD18
615591	MACULAR DEGENERATION, AGE-RELATED, 15; ARMD15
615592	IMMUNODEFICIENCY 15; IMD15
615593	IMMUNODEFICIENCY 16; IMD16
615595	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 19; COXPD19
615596	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iw; CDG1W
615597	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ix; CDG1X
615598	PALMOPLANTAR KERATODERMA, NAGASHIMA TYPE; PPKN
615599	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 40; MRT40
615602	MEMORY QUANTITATIVE TRAIT LOCUS; MEMRYQTL
615604	L-FERRITIN DEFICIENCY; LFTD
615605	FANCONI RENOTUBULAR SYNDROME 3; FRTS3
615607	IMMUNODEFICIENCY 17; IMD17
615612	DEVELOPMENTAL DYSPLASIA OF THE HIP 2; DDH2
615615	IMMUNODEFICIENCY 18; IMD18
615616	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 13; ARVD13
615617	IMMUNODEFICIENCY 19; IMD19
615625	SPASTIC PARAPLEGIA 72, AUTOSOMAL RECESSIVE; SPG72
615629	DEAFNESS, AUTOSOMAL DOMINANT 56; DFNA56
615630	SHORT-RIB THORACIC DYSPLASIA 10 WITH OR WITHOUT POLYDACTYLY; SRTD10
615631	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ib; CDAN1B
615632	NEUROPATHY, HEREDITARY SENSORY, TYPE IF; HSN1F
615633	SHORT-RIB THORACIC DYSPLASIA 11 WITH OR WITHOUT POLYDACTYLY; SRTD11
615636	JOUBERT SYNDROME 21; JBTS21
615637	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 41; MRT41
615643	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 6; NBIA6
615649	DEAFNESS, AUTOSOMAL DOMINANT 54; DFNA54
615651	LEUKOENCEPHALOPATHY WITH ATAXIA; LKPAT
615654	DEAFNESS, AUTOSOMAL DOMINANT 58; DFNA58
615656	CHROMOSOME 15q11.2 DELETION SYNDROME
615658	SPASTIC PARAPLEGIA 57, AUTOSOMAL RECESSIVE; SPG57
615663	WARBURG MICRO SYNDROME 4; WARBM4
615665	JOUBERT SYNDROME 22; JBTS22
615668	CHROMOSOME 5q12 DELETION SYNDROME
615670	SCHWANNOMATOSIS 2; SWNTS2
615673	MYOPATHY WITH EXTRAPYRAMIDAL SIGNS; MPXPS
615674	DOWLING-DEGOS DISEASE 3; DDD3
615681	SPASTIC PARAPLEGIA 62, AUTOSOMAL RECESSIVE; SPG62
615683	SPASTIC PARAPLEGIA 64, AUTOSOMAL RECESSIVE; SPG64
615685	SPASTIC PARAPLEGIA 61, AUTOSOMAL RECESSIVE; SPG61
615686	SPASTIC PARAPLEGIA 63, AUTOSOMAL RECESSIVE; SPG63
615688	POLYARTERITIS NODOSA, CHILDHOOD-ONSET; PAN
615696	DOWLING-DEGOS DISEASE 4; DDD4
615703	MORBID OBESITY AND SPERMATOGENIC FAILURE; MOSPGF
615704	POIKILODERMA, HEREDITARY FIBROSING, WITH TENDON CONTRACTURES, MYOPATHY, AND PULMONARY FIBROSIS; POIKTMP
615705	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 15; SCAR15
615706	AURICULOCONDYLAR SYNDROME 3; ARCND3
615707	IMMUNODEFICIENCY 20; IMD20
615709	SACRAL AGENESIS WITH VERTEBRAL ANOMALIES; SAVA
615710	MITCHELL-RILEY SYNDROME; MTCHRS
615715	BONE MARROW FAILURE SYNDROME 2; BMFS2
615716	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 4; HPMRS4
615721	RENAL HYPODYSPLASIA/APLASIA 2; RHDA2
615722	BOSCH-BOONSTRA-SCHAAF OPTIC ATROPHY SYNDROME; BBSOAS
615723	PREMATURE OVARIAN FAILURE 8; POF8
615724	PREMATURE OVARIAN FAILURE 9; POF9
615725	RETINITIS PIGMENTOSA 68; RP68
615726	PACHYONYCHIA CONGENITA 3; PC3
615728	PACHYONYCHIA CONGENITA 4; PC4
615731	NEMALINE MYOPATHY 9; NEM9
615735	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL OR DIFFUSE; PPKNEFD
615744	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 19; EIEE19
615745	ATRIAL STANDSTILL 2; ATRST2
615749	ECULIZUMAB, POOR RESPONSE TO
615750	MOYAMOYA DISEASE 6 WITH OR WITHOUT ACHALASIA; MYMY6
615751	CARBONIC ANHYDRASE VA DEFICIENCY, HYPERAMMONEMIA DUE TO; CA5AD
615752	POLYMICROGYRIA, BILATERAL PERISYLVIAN, AUTOSOMAL RECESSIVE; BPPR
615758	IMMUNODEFICIENCY 22; IMD22
615760	MICROCEPHALY, PROGRESSIVE, WITH SEIZURES AND CEREBRAL AND CEREBELLAR ATROPHY; MSCCA
615761	MENTAL RETARDATION, AUTOSOMAL DOMINANT 23; MRD23
615763	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 5; CDCBM5
615767	IMMUNODEFICIENCY, COMMON VARIABLE, 11; CVID11
615768	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 16; SCAR16
615770	ATRIAL FIBRILLATION, FAMILIAL, 15; ATFB15
615771	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 6; CDCBM6
615774	OOCYTE MATURATION DEFECT 1; OOMD1
615777	DESBUQUOIS DYSPLASIA 2; DBQD2
615779	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 4; CHTD4
615780	RETINITIS PIGMENTOSA 69; RP69
615785	WHITE SPONGE NEVUS 2; WSN2
615789	SHORT STATURE WITH MICROCEPHALY AND DISTINCTIVE FACIES
615802	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 42; MRT42
615803	PONTOCEREBELLAR HYPOPLASIA, TYPE 10; PCH10
615807	SECKEL SYNDROME 8; SCKL8
615809	PONTOCEREBELLAR HYPOPLASIA, TYPE 9; PCH9
615812	ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3
615816	IMMUNODEFICIENCY 23; IMD23
615817	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 43; MRT43
615821	CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR, KERATODERMA, AND TOOTH AGENESIS; DCWHKTA
615824	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 7; MC3DN7
615828	MENTAL RETARDATION, AUTOSOMAL DOMINANT 24; MRD24
615829	XIA-GIBBS SYNDROME
615830	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4
615833	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 21; EIEE21
615834	MENTAL RETARDATION, AUTOSOMAL DOMINANT 26; MRD26
615837	DEAFNESS, AUTOSOMAL RECESSIVE 101; DFNB101
615838	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 8; MC3DN8
615841	SPERMATOGENIC FAILURE 13; SPGF13
615842	SPERMATOGENIC FAILURE 14; SPGF14
615846	AICARDI-GOUTIERES SYNDROME 7; AGS7
615848	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10; CMM10
615849	CULLER-JONES SYNDROME; CJS
615851	PONTOCEREBELLAR HYPOPLASIA, TYPE 2E; PCH2E
615859	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 23; EIEE23
615860	CONE-ROD DYSTROPHY 19; CORD19
615861	NEPHROTIC SYNDROME, TYPE 10; NPHS10
615862	NEPHRONOPHTHISIS 18; NPHP18
615863	DIARRHEA 7; DIAR7
615866	MENTAL RETARDATION, AUTOSOMAL DOMINANT 27; MRD27
615871	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 24; EIEE24
615872	CILIARY DYSKINESIA, PRIMARY, 29; CILD29
615873	HELSMOORTEL-VAN DER AA SYNDROME; HVDAS
615877	MICROPHTHALMIA/COLOBOMA AND SKELETAL DYSPLASIA SYNDROME; MCSKS
615878	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 4; PFIC4
615879	TATTON-BROWN-RAHMAN SYNDROME; TBRS
615881	PLASMA TRIGLYCERIDE LEVEL QUANTITATIVE TRAIT LOCUS; TGQTL
615883	MYOPATHY, TUBULAR AGGREGATE, 2; TAM2
615885	HYPOTRICHOSIS 12; HYPT12
615887	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA5; AI2A5
615888	BLEEDING DISORDER, PLATELET-TYPE, 18; BDPLT18
615889	LEUKOENCEPHALOPATHY, PROGRESSIVE, WITH OVARIAN FAILURE; LKENP
615892	OROFACIAL CLEFT 14; OFC14
615895	POLYGLUCOSAN BODY MYOPATHY 1 WITH OR WITHOUT IMMUNODEFICIENCY; PGBM1
615896	HYPOTRICHOSIS 13; HYPT13
615897	IMMUNODEFICIENCY 24; IMD24
615905	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 25; EIEE25
615907	LYMPHEDEMA, HEREDITARY, ID; LMPH1D
615909	DIAMOND-BLACKFAN ANEMIA 13; DBA13
615911	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 2; FTDALS2
615916	CARDIOMYOPATHY, DILATED, 1NN; CMD1NN
615917	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 20; COXPD20
615918	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 21; COXPD21
615919	ATAXIA-TELANGIECTASIA-LIKE DISORDER 2; ATLD2
615922	RETINITIS PIGMENTOSA 70; RP70
615923	EPIPHYSEAL CHONDRODYSPLASIA, MIURA TYPE; ECDM
615924	ENCEPHALOPATHY, PROGRESSIVE, WITH OR WITHOUT LIPODYSTROPHY; PELD
615925	GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL; GHDP
615926	WEBB-DATTANI SYNDROME; WEDAS
615934	STING-ASSOCIATED VASCULOPATHY, INFANTILE-ONSET; SAVI
615935	PANCREATIC AGENESIS 2; PAGEN2
615937	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 2; MPPH2
615938	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 3; MPPH3
615942	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 44; MRT44
615945	SPINOCEREBELLAR ATAXIA 37; SCA37
615946	MYOPIA 24, AUTOSOMAL DOMINANT; MYP24
615947	HYPERLIPOPROTEINEMIA, TYPE ID
615948	OROFACIODIGITAL SYNDROME XIV; OFD14
615952	AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 1; ADMIO1
615953	KALLIKREIN, DECREASED URINARY ACTIVITY OF
615954	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 2; AIMAH2
615957	SPINOCEREBELLAR ATAXIA 38; SCA38
615959	MYOPATHY, CENTRONUCLEAR, 5; CNM5
615960	PORETTI-BOLTSHAUSER SYNDROME; PTBHS
615961	ACID-LABILE SUBUNIT DEFICIENCY; ACLSD
615962	GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR
615963	VESICOURETERAL REFLUX 8; VUR8
615966	IMMUNODEFICIENCY 26 WITH OR WITHOUT NEUROLOGIC ABNORMALITIES; IMD26
615969	ALPHA-FETOPROTEIN DEFICIENCY; AFPD
615970	ALPHA-FETOPROTEIN, HEREDITARY PERSISTENCE OF; HPAFP
615972	NANOPHTHALMOS 4; NNO4
615973	CONE-ROD DYSTROPHY 20; CORD20
615974	DEAFNESS, AUTOSOMAL RECESSIVE 102; DFNB102
615978	IMMUNODEFICIENCY 27B; IMD27B
615979	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 45; MRT45
615980	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 6; FPLD6
615981	BARDET-BIEDL SYNDROME 2; BBS2
615982	BARDET-BIEDL SYNDROME 4; BBS4
615983	BARDET-BIEDL SYNDROME 5; BBS5
615984	BARDET-BIEDL SYNDROME 7; BBS7
615985	BARDET-BIEDL SYNDROME 8; BBS8
615986	BARDET-BIEDL SYNDROME 9; BBS9
615987	BARDET-BIEDL SYNDROME 10; BBS10
615988	BARDET-BIEDL SYNDROME 11; BBS11
615989	BARDET-BIEDL SYNDROME 12; BBS12
615990	BARDET-BIEDL SYNDROME 13; BBS13
615991	BARDET-BIEDL SYNDROME 14; BBS14
615993	BARDET-BIEDL SYNDROME 16; BBS16
615994	BARDET-BIEDL SYNDROME 17; BBS17
615995	BARDET-BIEDL SYNDROME 18; BBS18
615996	BARDET-BIEDL SYNDROME 19; BBS19
615999	HYPERTHYROXINEMIA, FAMILIAL DYSALBUMINEMIC; FDAH
616000	ANALBUMINEMIA; ANALBA
616001	BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 2; BNAH2
616002	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 7; FSGS7
616004	DYSFIBRINOGENEMIA, CONGENITAL
616005	IMMUNODEFICIENCY 36; IMD36
616006	HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 2; HKLLS2
616007	CATARACTS, GROWTH HORMONE DEFICIENCY, SENSORY NEUROPATHY, SENSORINEURAL HEARING LOSS, AND SKELETAL DYSPLASIA; CAGSSS
616022	NEUTROPENIA, SEVERE CONGENITAL, 6, AUTOSOMAL RECESSIVE; SCN6
616025	GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 11; GPIBD11
616026	FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THE YOUNG; FRTS4
616028	ADAMS-OLIVER SYNDROME 5; AOS5
616029	ECTODERMAL DYSPLASIA/SHORT STATURE SYNDROME; ECTDS
616030	HYPOGONADOTROPIC HYPOGONADISM 22 WITH OR WITHOUT ANOSMIA; HH22
616032	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 8; FSGS8
616033	MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM 1; MSSGM1
616034	2,4-DIENOYL-CoA REDUCTASE DEFICIENCY; DECRD
616037	CILIARY DYSKINESIA, PRIMARY, 30; CILD30
616038	NEU-LAXOVA SYNDROME 2; NLS2
616039	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE D; CMTRID
616040	MYASTHENIC SYNDROME, CONGENITAL, 7, PRESYNAPTIC; CMS7
616042	DEAFNESS, AUTOSOMAL RECESSIVE 103; DFNB103
616044	DEAFNESS, AUTOSOMAL DOMINANT 65; DFNA65
616045	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 22; COXPD22
616050	AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS; AIFEC
616051	MICROCEPHALY 13, PRIMARY, AUTOSOMAL RECESSIVE; MCPH13
616052	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 7; MDDGC7
616053	SPINOCEREBELLAR ATAXIA 40; SCA40
616055	EPISODIC ATAXIA, TYPE 8; EA8
616056	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 26; EIEE26
616059	MIRROR MOVEMENTS 3; MRMV3
616063	POROKERATOSIS 8, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK8
616067	46,XY SEX REVERSAL 9; SRXY9
616069	INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2; NISBD2
616078	MENTAL RETARDATION, AUTOSOMAL DOMINANT 29; MRD29
616079	RETINAL DYSTROPHY WITH INNER RETINAL DYSFUNCTION AND GANGLION CELL ABNORMALITIES; RDGCA
616080	MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE; MCPH12
616081	PONTOCEREBELLAR HYPOPLASIA, TYPE 1C; PCH1C
616083	MENTAL RETARDATION, AUTOSOMAL DOMINANT 30; MRD30
616084	SIDEROBLASTIC ANEMIA WITH B-CELL IMMUNODEFICIENCY, PERIODIC FEVERS, AND DEVELOPMENTAL DELAY; SIFD
616087	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 5; NIDDM5
616089	BLOOD GROUP, GERBICH SYSTEM; GE
616093	BLOOD GROUP, ABO SYSTEM
616094	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 12; MDDGC12
616095	MONOCARBOXYLATE TRANSPORTER 1 DEFICIENCY; MCT1D
616098	IMMUNODEFICIENCY 37; IMD37
616099	PALMOPLANTAR KERATODERMA AND WOOLLY HAIR; PPKWH
616100	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE V; ALPS5
616106	PSORIASIS 15, PUSTULAR, SUSCEPTIBILITY TO; PSORS15
616108	RETINAL DYSTROPHY, JUVENILE CATARACTS, AND SHORT STATURE SYNDROME; RDJCSS
616111	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 9; MC3DN9
616113	POLYENDOCRINE-POLYNEUROPATHY SYNDROME; PEPNS
616115	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 4; FCAS4
616116	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 46; MRT46
616117	CARDIAC CONDUCTION DISEASE WITH OR WITHOUT DILATED CARDIOMYOPATHY; CCDD
616118	MACULAR DEGENERATION, EARLY-ONSET; EOMD
616126	IMMUNODEFICIENCY 38 WITH BASAL GANGLIA CALCIFICATION; IMD38
616127	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 17; SCAR17
616138	PERRAULT SYNDROME 5; PRLTS5
616139	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 27; EIEE27
616140	LEUKODYSTROPHY, HYPOMYELINATING, 9; HLD9
616145	CATEL-MANZKE SYNDROME; CATMANS
616151	MACULAR DYSTROPHY, VITELLIFORM, 4; VMD4
616152	MACULAR DYSTROPHY, VITELLIFORM, 5; VMD5
616154	PEROXISOMAL FATTY ACYL-CoA REDUCTASE 1 DISORDER; PFCRD
616155	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S
616158	MENTAL RETARDATION, AUTOSOMAL DOMINANT 31; MRD31
616165	NEMALINE MYOPATHY 10; NEM10
616166	AORTIC ANEURYSM, FAMILIAL THORACIC 9; AAT9
616170	MACULAR DYSTROPHY WITH CENTRAL CONE INVOLVEMENT; CCMD
616171	MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 2; MCCRP2
616172	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 9; GEFSP9
616176	BLEEDING DISORDER, PLATELET-TYPE, 19; BDPLT19
616185	OVARIAN DYSGENESIS 4; ODG4
616187	EPILEPSY, PROGRESSIVE MYOCLONIC 7; EPM7
616188	RETINAL DYSTROPHY AND OBESITY; RDOB
616192	ATAXIA, COMBINED CEREBELLAR AND PERIPHERAL, WITH HEARING LOSS AND DIABETES MELLITUS; ACPHD
616193	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 47; MRT47
616198	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 23; COXPD23
616199	POLYGLUCOSAN BODY MYOPATHY 2; PGBM2
616200	RUIJS-AALFS SYNDROME; RJALS
616201	CHRONIC ATRIAL AND INTESTINAL DYSRHYTHMIA; CAID
616202	CEREBELLOFACIODENTAL SYNDROME; CFDS
616204	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 18; SCAR18
616208	AMYOTROPHIC LATERAL SCLEROSIS 22 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS22
616209	MYOPATHY, ISOLATED MITOCHONDRIAL, AUTOSOMAL DOMINANT; IMMD
616211	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 28; EIEE28
616212	LISSENCEPHALY 6 WITH MICROCEPHALY; LIS6
616214	HYPERPROINSULINEMIA
616216	THROMBOCYTOPENIA 5; THC5
616217	NEPHRONOPHTHISIS 19; NPHP19
616219	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 5; CFEOM5
616220	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 9; FSGS9
616221	AMELOGENESIS IMPERFECTA, TYPE IH; AI1H
616222	TEMPLE SYNDROME
616224	MYASTHENIC SYNDROME, CONGENITAL, 22; CMS22
616227	MYASTHENIC SYNDROME, CONGENITAL, 15; CMS15
616228	MYASTHENIC SYNDROME, CONGENITAL, 14; CMS14
616229	OSTEOGENESIS IMPERFECTA, TYPE XVI; OI16
616230	EPILEPSY, PROGRESSIVE MYOCLONIC, 8; EPM8
616231	MYOPATHY, VACUOLAR, WITH CASQ1 AGGREGATES; VMCQA
616239	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 24; COXPD24
616247	LONG QT SYNDROME 14; LQT14
616248	LETHAL CONGENITAL CONTRACTURE SYNDROME 6; LCCS6
616249	LONG QT SYNDROME 15; LQT15
616255	SHORT STATURE WITH NONSPECIFIC SKELETAL ABNORMALITIES; SNSK
616258	MECKEL SYNDROME 12; MKS12
616260	TENORIO SYNDROME; TNORS
616263	NEUROLOGIC, ENDOCRINE, AND PANCREATIC DISEASE, MULTISYSTEM, INFANTILE-ONSET; IMNEPD
616265	PEELING SKIN SYNDROME 3; PSS3
616266	CONGENITAL CONTRACTURES OF THE LIMBS AND FACE, HYPOTONIA, AND DEVELOPMENTAL DELAY; CLIFAHDD
616267	ATAXIA-OCULOMOTOR APRAXIA 4; AOA4
616268	MENTAL RETARDATION, AUTOSOMAL DOMINANT 32; MRD32
616269	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 48; MRT48
616270	AMELOGENESIS IMPERFECTA, TYPE IF; AI1F
616271	3-METHYLGLUTACONIC ACIDURIA WITH CATARACTS, NEUROLOGIC INVOLVEMENT, AND NEUTROPENIA; MEGCANN
616276	COENZYME Q10 DEFICIENCY, PRIMARY, 7; COQ10D7
616277	MITOCHONDRIAL SHORT-CHAIN ENOYL-CoA HYDRATASE 1 DEFICIENCY; ECHS1D
616278	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 5; CBAS5
616279	CATARACT 43; CTRCT43
616280	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U
616281	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 49; MRT49
616282	SPASTIC PARAPLEGIA 73, AUTOSOMAL DOMINANT; SPG73
616286	LETHAL CONGENITAL CONTRACTURE SYNDROME 7; LCCS7
616287	LETHAL CONGENITAL CONTRACTURE SYNDROME 8; LCCS8
616289	OPTIC ATROPHY 9; OPA9
616291	LICHTENSTEIN-KNORR SYNDROME; LIKNS
616294	COLE-CARPENTER SYNDROME 2; CLCRP2
616295	PEELING SKIN WITH LEUKONYCHIA, ACRAL PUNCTATE KERATOSES, CHEILITIS, AND KNUCKLE PADS; PLACK
616298	SINGLETON-MERTEN SYNDROME 2; SGMRT2
616299	LIPOYLTRANSFERASE 1 DEFICIENCY; LIPT1D
616300	SHORT-RIB THORACIC DYSPLASIA 13 WITH OR WITHOUT POLYDACTYLY; SRTD13
616304	MYASTHENIC SYNDROME, CONGENITAL, 17; CMS17
616307	SENIOR-LOKEN SYNDROME 8; SLSN8
616311	MENTAL RETARDATION, AUTOSOMAL DOMINANT 33; MRD33
616313	MYASTHENIC SYNDROME, CONGENITAL, 2A, SLOW-CHANNEL; CMS2A
616314	MYASTHENIC SYNDROME, CONGENITAL, 2C, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS2C
616321	MYASTHENIC SYNDROME, CONGENITAL, 3A, SLOW-CHANNEL; CMS3A
616322	MYASTHENIC SYNDROME, CONGENITAL, 3B, FAST-CHANNEL; CMS3B
616323	MYASTHENIC SYNDROME, CONGENITAL, 3C, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS3C
616324	MYASTHENIC SYNDROME, CONGENITAL, 4B, FAST-CHANNEL; CMS4B
616325	MYASTHENIC SYNDROME, CONGENITAL, 9, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS9
616326	MYASTHENIC SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS11
616329	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13; MODY13
616330	MYASTHENIC SYNDROME, CONGENITAL, 18; CMS18
616331	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 2; DRS2
616335	MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 3; MCCRP3
616339	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 29; EIEE29
616340	DEAFNESS, AUTOSOMAL DOMINANT 67; DFNA67
616341	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 30; EIEE30
616342	LISSENCEPHALY 7 WITH CEREBELLAR HYPOPLASIA; LIS7
616345	IMMUNODEFICIENCY 39; IMD39
616346	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 31; EIEE31
616351	MENTAL RETARDATION, AUTOSOMAL DOMINANT 34; MRD34
616353	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 6; DKCB6
616354	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 20; SCAR20
616355	MENTAL RETARDATION, AUTOSOMAL DOMINANT 35; MRD35
616357	DEAFNESS, AUTOSOMAL DOMINANT 40; DFNA40
616361	PARKINSON DISEASE 21; PARK21
616362	MENTAL RETARDATION, AUTOSOMAL DOMINANT 36; MRD36
616364	WHITE-SUTTON SYNDROME; WHSUS
616366	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 32; EIEE32
616367	MANDIBULOFACIAL DYSOSTOSIS WITH ALOPECIA; MFDA
616368	CHOPS SYNDROME; CHOPS
616370	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 4; MMDS4
616371	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 4; PFBMFT4
616373	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 3; PFBMFT3
616389	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1G; CSNB1G
616390	TRICHOTHIODYSTROPHY 2, PHOTOSENSITIVE; TTD2
616393	MENTAL RETARDATION, AUTOSOMAL DOMINANT 38; MRD38
616394	RETINITIS PIGMENTOSA 71; RP71
616395	TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE; TTD3
616398	DYSTONIA 26, MYOCLONIC; DYT26
616399	BRUGADA SYNDROME 9; BRGDA9
616400	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 2; FNEPPK2
616402	MICROCEPHALY 14, PRIMARY, AUTOSOMAL RECESSIVE; MCPH14
616409	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 33; EIEE33
616410	SPINOCEREBELLAR ATAXIA 41; SCA41
616411	DYSTONIA 27; DYT27
616413	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 6; IBGC6
616414	AUTOIMMUNE INTERSTITIAL LUNG, JOINT, AND KIDNEY DISEASE; AILJK
616415	FAMILIAL ADENOMATOUS POLYPOSIS 3; FAP3
616418	HYPOMAGNESEMIA, SEIZURES, AND MENTAL RETARDATION; HOMGSMR
616420	LEUKODYSTROPHY, HYPOMYELINATING, 10; HLD10
616421	MYOCLONIC-ATONIC EPILEPSY; MAE
616425	46,XY SEX REVERSAL 10; SRXY10
616428	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 10; MCOPCB10
616430	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 25; COXPD25
616433	IMMUNODEFICIENCY 40; IMD40
616435	FANCONI ANEMIA, COMPLEMENTATION GROUP T; FANCT
616436	EPILEPSY, FAMILIAL TEMPORAL LOBE, 7; ETL7
616437	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 3; FTDALS3
616439	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 4; FTDALS4
616445	CANDIDIASIS, FAMILIAL, 9; CANDF9
616449	BASEL-VANAGAITE-SMIRIN-YOSEF SYNDROME; BVSYS
616451	SPASTIC PARAPLEGIA 74, AUTOSOMAL RECESSIVE; SPG74
616452	B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY; BENTA
616455	ZIMMERMANN-LABAND SYNDROME 2; ZLS2
616457	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 50; EIEE50
616459	AL-RAQAD SYNDROME; ARS
616460	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 50; MRT50
616461	EPILEPSY, FAMILIAL TEMPORAL LOBE, 8; ETL8
616462	ACROFACIAL DYSOSTOSIS, CINCINNATI TYPE; AFDCIN
616468	EXUDATIVE VITREORETINOPATHY 6; EVR6
616469	RETINITIS PIGMENTOSA 72; RP72
616470	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 2; UCMD2
616471	BETHLEM MYOPATHY 2; BTHLM2
616479	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2
616481	CILIARY DYSKINESIA, PRIMARY, 32; CILD32
616482	ACHONDROPLASIA, SEVERE, WITH DEVELOPMENTAL DELAY AND ACANTHOSIS NIGRICANS; SADDAN
616483	INFANTILE LIVER FAILURE SYNDROME 2; ILFS2
616486	MICROCEPHALY 15, PRIMARY, AUTOSOMAL RECESSIVE; MCPH15
616487	EPIDERMOLYSIS BULLOSA SIMPLEX WITH NAIL DYSTROPHY; EBSND
616488	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VIII; HSAN8
616489	GROWTH RESTRICTION, SEVERE, WITH DISTINCTIVE FACIES; GRDF
616490	JOUBERT SYNDROME 23; JBTS23
616491	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2V; CMT2V
616494	LEUKODYSTROPHY, HYPOMYELINATING, 11; HLD11
616500	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 3; CEMCOX3
616501	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 4; CEMCOX4
616502	CONE-ROD DYSTROPHY 21; CORD21
616503	LETHAL CONGENITAL CONTRACTURE SYNDROME 9; LCCS9
616505	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB; HMSN6B
616507	OSTEOGENESIS IMPERFECTA, TYPE XVII; OI17
616509	CATARACT 44; CTRCT44
616511	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 14; MODY14
616515	DEAFNESS, AUTOSOMAL RECESSIVE 104; DFNB104
616516	EMERY-DREIFUSS MUSCULAR DYSTROPHY 3, AUTOSOMAL RECESSIVE; EDMD3
616517	ACHROMATOPSIA 7; ACHM7
616521	MENTAL RETARDATION, AUTOSOMAL DOMINANT 39; MRD39
616531	POLYMICROGYRIA, PERISYLVIAN, WITH CEREBELLAR HYPOPLASIA AND ARTHROGRYPOSIS; PMGYCHA
616532	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 7; IIAE7
616534	THYROID CANCER, NONMEDULLARY, 4; NMTC4
616535	THYROID CANCER, NONMEDULLARY, 5; NMTC5
616538	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9
616539	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 26; COXPD26
616540	EPILEPSY, PROGRESSIVE MYOCLONIC, 9; EPM9
616541	SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION; SSMED
616544	RETINITIS PIGMENTOSA 73; RP73
616546	SHORT-RIB THORACIC DYSPLASIA 14 WITH POLYDACTYLY; SRTD14
616549	KLIPPEL-FEIL SYNDROME 4, AUTOSOMAL RECESSIVE, WITH NEMALINE MYOPATHY AND FACIAL DYSMORPHISM; KFS4
616553	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6; DKCA6
616559	NOONAN SYNDROME 9; NS9
616562	RETINITIS PIGMENTOSA 74; RP74
616564	NOONAN SYNDROME 10; NS10
616566	SPONDYLOCOSTAL DYSOSTOSIS 6, AUTOSOMAL RECESSIVE; SCDO6
616568	GLIOMA SUSCEPTIBILITY 9; GLM9
616570	CEREBROOCULOFACIOSKELETAL SYNDROME 3; COFS3
616576	IMMUNODEFICIENCY, COMMON VARIABLE, 12; CVID12
616577	EPILEPSY, HEARING LOSS, AND MENTAL RETARDATION SYNDROME; EHLMRS
616579	MENTAL RETARDATION, AUTOSOMAL DOMINANT 40; MRD40
616580	AU-KLINE SYNDROME; AUKS
616583	SPONDYLOEPIPHYSEAL DYSPLASIA, STANESCU TYPE; SEDSTN
616586	SPASTIC PARAPLEGIA 9B, AUTOSOMAL RECESSIVE; SPG9B
616589	ADAMS-OLIVER SYNDROME 6; AOS6
616592	KOSAKI OVERGROWTH SYNDROME; KOGS
616602	CRANIOSYNOSTOSIS 6; CRS6
616603	CUTIS LAXA, AUTOSOMAL DOMINANT 3; ADCL3
616604	CHROMOSOME 14q32 DUPLICATION SYNDROME, 700-KB
616606	RING CHROMOSOME 14 SYNDROME
616617	HEIMLER SYNDROME 2; HMLR2
616622	IMMUNODEFICIENCY 42; IMD42
616625	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2W; CMT2W
616629	SENIOR-LOKEN SYNDROME 9; SLSN9
616631	POROKERATOSIS 9, MULTIPLE TYPES; POROK9
616632	SEIZURES, CORTICAL BLINDNESS, AND MICROCEPHALY SYNDROME; SCBMS
616636	IMMUNODEFICIENCY 44; IMD44
616638	SMITH-KINGSMORE SYNDROME; SKS
616640	EPILEPSY, PROGRESSIVE MYOCLONIC, 10; EPM10
616645	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 34; EIEE34
616647	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 35; EIEE35
616648	OPTIC ATROPHY 8; OPA8
616649	SPHEROCYTOSIS, TYPE 2; SPH2
616651	ROIFMAN SYNDROME; RFMN
616652	YUAN-HAREL-LUPSKI SYNDROME; YUHAL
616654	JOUBERT SYNDROME 24; JBTS24
616657	SPASTIC TETRAPLEGIA, THIN CORPUS CALLOSUM, AND PROGRESSIVE MICROCEPHALY; SPATCCM
616668	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2X; CMT2X
616669	IMMUNODEFICIENCY 45; IMD45
616672	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 27; COXPD27
616680	SPASTIC PARAPLEGIA 75, AUTOSOMAL RECESSIVE; SPG75
616681	MICROCEPHALY 16, PRIMARY, AUTOSOMAL RECESSIVE; MCPH16
616682	SEIZURES, SCOLIOSIS, AND MACROCEPHALY SYNDROME; SSMS
616683	LEUKODYSTROPHY, HYPOMYELINATING, 12; HLD12
616684	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4K; CMT4K
616685	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 14; EIG14
616687	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Y; CMT2Y
616688	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Z; CMT2Z
616689	DEHYDRATED HEREDITARY STOMATOCYTOSIS 2; DHS2
616697	DEAFNESS, AUTOSOMAL DOMINANT 69; DFNA69
616705	DEAFNESS, AUTOSOMAL RECESSIVE 97; DFNB97
616707	DEAFNESS, AUTOSOMAL DOMINANT 68; DFNA68
616708	DESANTO-SHINAWI SYNDROME; DESSH
616710	PARKINSON DISEASE 22, AUTOSOMAL DOMINANT; PARK22
616716	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 5; RCDP5
616719	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21; SCAR21
616720	MYASTHENIC SYNDROME, CONGENITAL, 19; CMS19
616721	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIn; CDG2N
616722	RETINAL DYSTROPHY AND IRIS COLOBOMA WITH OR WITHOUT CONGENITAL CATARACT; RDICC
616723	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, FADEN-ALKURAYA TYPE; SEMDFA
616724	TOOTH AGENESIS, SELECTIVE, 7; STHAG7
616726	CILIARY DYSKINESIA, PRIMARY, 33; CILD33
616728	CLEFT PALATE, PSYCHOMOTOR RETARDATION, AND DISTINCTIVE FACIAL FEATURES; CPRF
616730	NEPHROTIC SYNDROME, TYPE 11; NPHS11
616732	OPTIC ATROPHY 10 WITH OR WITHOUT ATAXIA, MENTAL RETARDATION, AND SEIZURES; OPA10
616733	COENZYME Q10 DEFICIENCY, PRIMARY, 8; COQ10D8
616734	SKIN CREASES, CONGENITAL SYMMETRIC CIRCUMFERENTIAL, 2; CSCSC2
616736	TREMOR, HEREDITARY ESSENTIAL, 5; ETM5
616737	TAKENOUCHI-KOSAKI SYNDROME; TKS
616738	RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA 2; RUSAT2
616739	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 51; MRT51
616740	IMMUNODEFICIENCY 46; IMD46
616744	AUTOINFLAMMATORY SYNDROME, FAMILIAL, BEHCET-LIKE; AISBL
616749	HETEROTAXY, VISCERAL, 7, AUTOSOMAL; HTX7
616754	BOMBAY PHENOTYPE
616756	SPASTIC PARAPLEGIA AND PSYCHOMOTOR RETARDATION WITH OR WITHOUT SEIZURES; SPPRS
616760	WOOLLY HAIR, AUTOSOMAL RECESSIVE 3; ARWH3
616763	LEUKODYSTROPHY AND ACQUIRED MICROCEPHALY WITH OR WITHOUT DYSTONIA; LDAMD
616777	SECKEL SYNDROME 9; SCKL9
616779	CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY, TYPE 2; CADASIL2
616780	OOCYTE MATURATION DEFECT 2; OOMD2
616781	JOUBERT SYNDROME 25; JBTS25
616784	JOUBERT SYNDROME 26; JBTS26
616788	OROFACIAL CLEFT 15; OFC15
616789	MENTAL RETARDATION AND DISTINCTIVE FACIAL FEATURES WITH OR WITHOUT CARDIAC DEFECTS; MRFACD
616794	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 28; COXPD28
616795	SPINOCEREBELLAR ATAXIA 42; SCA42
616801	HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTIC FACIES 2; IHPRF2
616803	LAMB-SHAFFER SYNDROME; LAMSHF
616806	WILMS TUMOR 6; WT6
616809	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 6; HPMRS6
616811	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 29; COXPD29
616812	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2X; LGMD2X
616814	PREIMPLANTATION EMBRYONIC LETHALITY 1; PREMBL1
616816	HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION; IHPMR
616817	MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM 2; MSSGM2
616818	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 3; IGAN3
616819	CORPUS CALLOSUM, AGENESIS OF, WITH FACIAL ANOMALIES AND CEREBELLAR ATAXIA; CCAFCA
616827	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2W; LGMD2W
616828	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIo; CDG2O
616829	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIp; CDG2P
616831	LUSCAN-LUMISH SYNDROME; LLS
616833	PAGET DISEASE OF BONE 6; PDB6
616834	MICROCEPHALY, CONGENITAL CATARACT, AND PSORIASIFORM DERMATITIS; MCCPD
616835	MEIER-GORLIN SYNDROME 6; MGORS6
616839	EXERCISE INTOLERANCE, RIBOFLAVIN-RESPONSIVE; RREI
616840	PARKINSON DISEASE 23, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK23
616843	LYMPHEDEMA, HEREDITARY, III; LMPH3
616849	BRACHYDACTYLY, TYPE A1, D; BDA1D
616851	CATARACT 45; CTRCT45
616852	MYOPATHY, SCAPULOHUMEROPERONEAL; SHPM
616854	EVEN-PLUS SYNDROME; EVPLS
616858	COWDEN SYNDROME 7; CWS7
616859	SPASTICITY, CHILDHOOD-ONSET, WITH HYPERGLYCINEMIA; SPAHGC
616860	ANEMIA, SIDEROBLASTIC, 3, PYRIDOXINE-REFRACTORY; SIDBA3
616863	CHROMOSOME 16p13.2 DELETION SYNDROME
616866	SPINAL MUSCULAR ATROPHY WITH CONGENITAL BONE FRACTURES 1; SMABF1
616867	SPINAL MUSCULAR ATROPHY WITH CONGENITAL BONE FRACTURES 2; SMABF2
616868	DIARRHEA 8, SECRETORY SODIUM, CONGENITAL; DIAR8
616871	MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO; MPLPF
616873	IMMUNODEFICIENCY, COMMON VARIABLE, 13; CVID13
616875	CEREBELLAR ATROPHY, VISUAL IMPAIRMENT, AND PSYCHOMOTOR RETARDATION; CAVIPMR
616878	METABOLIC ENCEPHALOMYOPATHIC CRISES, RECURRENT, WITH RHABDOMYOLYSIS, CARDIAC ARRHYTHMIAS, AND NEURODEGENERATION; MECRCN
616881	LEUKODYSTROPHY, HYPOMYELINATING, 13; HLD13
616882	ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 3; FASPS3
616887	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 52; MRT52
616890	SPLIT-FOOT MALFORMATION WITH MESOAXIAL POLYDACTYLY; SFMMP
616892	NEPHROTIC SYNDROME, TYPE 12; NPHS12
616893	NEPHROTIC SYNDROME, TYPE 13; NPHS13
616894	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 3; DRS3
616896	MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14
616897	OSTEOCHONDRODYSPLASIA, COMPLEX LETHAL, SYMOENS-BARNES-GISTELINCK TYPE; OCLSBG
616898	CHROMOSOME 15q14 DELETION SYNDROME
616900	HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTIC FACIES 3; IHPRF3
616901	DEVELOPMENTAL DELAY WITH SHORT STATURE, DYSMORPHIC FEATURES, AND SPARSE HAIR; DEDSSH
616902	CHROMOSOME 11p13 DELETION SYNDROME, DISTAL
616903	THIOPURINES, POOR METABOLISM OF, 2; THPM2
616907	SPASTIC PARAPLEGIA 76, AUTOSOMAL RECESSIVE; SPG76
616910	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 3; ICF3
616911	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 4; ICF4
616913	BLEEDING DISORDER, PLATELET-TYPE, 20; BDPLT20
616914	MARFAN LIPODYSTROPHY SYNDROME; MFLS
616917	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 53; MRT53
616920	HEART AND BRAIN MALFORMATION SYNDROME; HBMS
616921	DYSKINESIA, LIMB AND OROFACIAL, INFANTILE-ONSET; IOLOD
616922	STRIATAL DEGENERATION, AUTOSOMAL DOMINANT 2; ADSD2
616924	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2CC; CMT2CC
616937	THROMBOCYTOPENIA 6; THC6
616938	COFFIN-SIRIS SYNDROME 5; CSS5
616939	CHOREA, CHILDHOOD-ONSET, WITH PSYCHOMOTOR RETARDATION; COCPMR
616941	AGAMMAGLOBULINEMIA 8, AUTOSOMAL DOMINANT; AGM8
616943	TRICHOTHIODYSTROPHY 6, NONPHOTOSENSITIVE; TTD6
616944	MENTAL RETARDATION, AUTOSOMAL DOMINANT 41; MRD41
616946	PREMATURE OVARIAN FAILURE 11; POF11
616947	PREMATURE OVARIAN FAILURE 12; POF12
616948	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 22; SCAR22
616949	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 23; SCAR23
616950	SPERMATOGENIC FAILURE 15; SPGF15
616954	YOU-HOOVER-FONG SYNDROME; YHFS
616959	RETINITIS PIGMENTOSA AND ERYTHROCYTIC MICROCYTOSIS; RPEM
616963	HYPERCALCEMIA, INFANTILE, 2; HCINF2
616968	DEAFNESS, AUTOSOMAL DOMINANT 70; DFNA70
616969	DEAFNESS, AUTOSOMAL DOMINANT 66; DFNA66
616973	MENTAL RETARDATION, AUTOSOMAL DOMINANT 42; MRD42
616974	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 30; COXPD30
616975	NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT ANOMALIES OF THE BRAIN, EYE, OR HEART; NEDBEH
616977	MENTAL RETARDATION, AUTOSOMAL DOMINANT 43; MRD43
616981	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 37; EIEE37
617004	POLYCYSTIC LIVER DISEASE 2 WITH OR WITHOUT KIDNEY CYSTS; PCLD2
617006	AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 2; ADMIO2
617008	CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 3; CPSQ3
617011	MACROCEPHALY, DYSMORPHIC FACIES, AND PSYCHOMOTOR RETARDATION; MDFPMR
617013	HYPERMANGANESEMIA WITH DYSTONIA 2; HMNDYT2
617014	NEUTROPENIA, SEVERE CONGENITAL, 7, AUTOSOMAL RECESSIVE; SCN7
617017	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T
617018	SPINOCEREBELLAR ATAXIA 43; SCA43
617020	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 38; EIEE38
617021	HYDROPS, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA; HLASA
617022	LETHAL CONGENITAL CONTRACTURE SYNDROME 10; LCCS10
617023	RETINITIS PIGMENTOSA 75; RP75
617024	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1H; CSNB1H
617025	NEVUS COMEDONICUS; NC
617026	PONTOCEREBELLAR HYPOPLASIA, TYPE 2F; PCH2F
617027	HYPERALDOSTERONISM, FAMILIAL, TYPE IV; HALD4
617028	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 54; MRT54
617030	MYOPATHY, DISTAL, 5; MPD5
617035	PATENT DUCTUS ARTERIOSUS 2; PDA2
617039	PATENT DUCTUS ARTERIOSUS 3; PDA3
617041	DUANE RETRACTION SYNDROME 3 WITH OR WITHOUT DEAFNESS; DURS3
617044	SHORT STATURE, DEVELOPMENTAL DELAY, AND CONGENITAL HEART DEFECTS; SDDHD
617046	SPASTIC PARAPLEGIA 77, AUTOSOMAL RECESSIVE; SPG77
617047	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 26; CMH26
617049	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 5; PFIC5
617050	HERMANSKY-PUDLAK SYNDROME 10; HPS10
617051	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 55; MRT55
617052	BONE MARROW FAILURE SYNDROME 3; BMFS3
617053	MIRAGE SYNDROME; MIRAGE
617054	STRIATONIGRAL DEGENERATION, CHILDHOOD-ONSET; SNDC
617055	CRISPONI/COLD-INDUCED SWEATING SYNDROME 3; CISS3
617056	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 4; HNFJ4
617061	MENTAL RETARDATION, AUTOSOMAL DOMINANT 44; MRD44
617062	OKUR-CHUNG NEURODEVELOPMENTAL SYNDROME; OCNDS
617063	MEIER-GORLIN SYNDROME 7; MGORS7
617065	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 40; EIEE40
617066	MUSCULAR DYSTROPHY, CONGENITAL, DAVIGNON-CHAUVEAU TYPE; MDCDC
617068	PORTAL HYPERTENSION, NONCIRRHOTIC; NCPH
617069	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3
617070	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4
617072	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Y; LGMD2Y
617073	TOOTH AGENESIS, SELECTIVE, 8; STHAG8
617075	NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 3; NPCA3
617080	SEIZURES, BENIGN FAMILIAL INFANTILE, 5; BFIS5
617082	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iaa; CDG1AA
617086	ENCEPHALOPATHY DUE TO DEFECTIVE MITOCHONDRIAL AND PEROXISOMAL FISSION 2; EMPF2
617087	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2A2B; CMT2A2B
617088	SHORT-RIB THORACIC DYSPLASIA 15 WITH POLYDACTYLY; SRTD15
617090	MICROCEPHALY 17, PRIMARY, AUTOSOMAL RECESSIVE; MCPH17
617091	CILIARY DYSKINESIA, PRIMARY, 34; CILD34
617092	CILIARY DYSKINESIA, PRIMARY, 35; CILD35
617093	GROWTH RETARDATION, INTELLECTUAL DEVELOPMENTAL DISORDER, HYPOTONIA, AND HEPATOPATHY; GRIDHH
617099	AUTOINFLAMMATION, PANNICULITIS, AND DERMATOSIS SYNDROME; AIPDS
617100	FAMILIAL ADENOMATOUS POLYPOSIS 4; FAP4
617101	INTELLECTUAL DEVELOPMENTAL DISORDER WITH PERSISTENCE OF FETAL HEMOGLOBIN
617102	SHORT-RIB THORACIC DYSPLASIA 16 WITH OR WITHOUT POLYDACTYLY; SRTD16
617105	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 41; EIEE41
617106	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 42; EIEE42
617107	THAUVIN-ROBINET-FAIVRE SYNDROME; TROFAS
617108	SESSILE SERRATED POLYPOSIS CANCER SYNDROME; SSPCS
617111	MACULAR DYSTROPHY, PATTERNED, 3; MDPT3
617113	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 43; EIEE43
617114	MYOPATHY, MYOFIBRILLAR, 7; MFM7
617115	PEELING SKIN SYNDROME 5; PSS5
617116	EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 2; FFEVF2
617118	EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 3; FFEVF3
617119	BARDET-BIEDL SYNDROME 20; BBS20
617120	JOUBERT SYNDROME 27; JBTS27
617121	JOUBERT SYNDROME 28; JBTS28
617123	RETINITIS PIGMENTOSA 76; RP76
617125	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 56; MRT56
617126	ALAZAMI-YUAN SYNDROME; ALYUS
617127	OROFACIODIGITAL SYNDROME XV; OFD15
617132	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 44; EIEE44
617133	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 24; SCAR24
617137	FRONTOMETAPHYSEAL DYSPLASIA 2; FMD2
617140	ZTTK SYNDROME; ZTTKS
617141	ANIRIDIA 2; AN2
617142	ANIRIDIA 3; AN3
617143	MYASTHENIC SYNDROME, CONGENITAL, 20, PRESYNAPTIC; CMS20
617145	NEURODEGENERATION WITH ATAXIA, DYSTONIA, AND GAZE PALSY, CHILDHOOD-ONSET; NADGP
617146	ARTHROGRYPOSIS, DISTAL, WITH IMPAIRED PROPRIOCEPTION AND TOUCH; DAIPT
617153	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 45; EIEE45
617156	MITOCHONDRIAL DNA DEPLETION SYNDROME 15 (HEPATOCEREBRAL TYPE); MTDPS15
617157	SHORT STATURE, BRACHYDACTYLY, INTELLECTUAL DEVELOPMENTAL DISABILITY, AND SEIZURES; SBIDDS
617158	MYOPATHY, DISTAL, WITH RIMMED VACUOLES; DMRV
617159	SIFRIM-HITZ-WEISS SYNDROME; SIHIWES
617162	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 46; EIEE46
617164	SHORT STATURE, RHIZOMELIC, WITH MICROCEPHALY, MICROGNATHIA, AND DEVELOPMENTAL DELAY; SRMMD
617166	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 47; EIEE47
617168	AORTIC ANEURYSM, FAMILIAL THORACIC 10; AAT10
617169	SOTOS SYNDROME 3; SOTOS3
617171	DYSKINESIA, SEIZURES, AND INTELLECTUAL DEVELOPMENTAL DISORDER; DYSEIDD
617173	INTELLECTUAL DEVELOPMENTAL DISORDER WITH CARDIAC ARRHYTHMIA; IDDCA
617174	EHLERS-DANLOS SYNDROME, PERIODONTAL TYPE, 2; EDSPD2
617175	RETINAL DYSTROPHY WITH OR WITHOUT EXTRAOCULAR ANOMALIES; RDEOA
617180	CHITAYAT SYNDROME; CHYTS
617182	LANGUAGE DELAY AND ATTENTION DEFICIT-HYPERACTIVITY DISORDER/COGNITIVE IMPAIRMENT WITH OR WITHOUT CARDIAC ARRHYTHMIA; LADCI
617183	HAREL-YOON SYNDROME; HAYOS
617184	MITOCHONDRIAL DNA DEPLETION SYNDROME 12A (CARDIOMYOPATHIC TYPE), AUTOSOMAL DOMINANT; MTDPS12A
617186	ENCEPHALOPATHY, PROGRESSIVE, EARLY-ONSET, WITH BRAIN EDEMA AND/OR LEUKOENCEPHALOPATHY; PEBEL
617187	SPERMATOGENIC FAILURE 16; SPGF16
617188	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 57; MRT57
617190	SHASHI-PENA SYNDROME; SHAPNS
617193	ENCEPHALOPATHY, PROGRESSIVE, EARLY-ONSET, WITH BRAIN ATROPHY AND THIN CORPUS CALLOSUM; PEBAT
617194	LETHAL CONGENITAL CONTRACTURE SYNDROME 11; LCCS11
617201	PERIVENTRICULAR NODULAR HETEROTOPIA 7; PVNH7
617205	HETEROTAXY, VISCERAL, 8, AUTOSOMAL; HTX8
617207	ENCEPHALOPATHY, PROGRESSIVE, WITH AMYOTROPHY AND OPTIC ATROPHY; PEAMO
617213	SEDOHEPTULOKINASE DEFICIENCY; SHPKD
617214	SPERMATOGENIC FAILURE 17; SPGF17
617217	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA6; AI2A6
617219	CHROMOSOME 19q13.11 DELETION SYNDROME, PROXIMAL
617222	SUDDEN CARDIAC FAILURE, INFANTILE; SCFI
617223	SUDDEN CARDIAC FAILURE, ALCOHOL-INDUCED; SCFAI
617225	SPASTIC PARAPLEGIA 78, AUTOSOMAL RECESSIVE; SPG78
617228	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 31; COXPD31
617232	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Z; LGMD2Z
617234	PREIMPLANTATION EMBRYONIC LETHALITY 2; PREMBL2
617235	MYOCLONUS, INTRACTABLE, NEONATAL; NEIMY
617236	CONE-ROD DYSTROPHY AND HEARING LOSS; CRDHL
617237	IMMUNODEFICIENCY 49; IMD49
617238	MYOPIA 25, AUTOSOMAL DOMINANT; MYP25
617239	MYASTHENIC SYNDROME, CONGENITAL, 21, PRESYNAPTIC; CMS21
617241	LUNG DISEASE, IMMUNODEFICIENCY, AND CHROMOSOME BREAKAGE SYNDROME; LICS
617243	FANCONI ANEMIA, COMPLEMENTATION GROUP V; FANCV
617244	FANCONI ANEMIA, COMPLEMENTATION GROUP R; FANCR
617247	FANCONI ANEMIA, COMPLEMENTATION GROUP U; FANCU
617248	3-METHYLGLUTACONIC ACIDURIA, TYPE VIII; MGCA8
617251	UNCOMBABLE HAIR SYNDROME 2; UHS2
617252	UNCOMBABLE HAIR SYNDROME 3; UHS3
617253	SECKEL SYNDROME 10; SCKL10
617255	LISSENCEPHALY 8; LIS8
617258	MYOPATHY, MYOFIBRILLAR, 8; MFM8
617260	GLOBAL DEVELOPMENTAL DELAY, ABSENT OR HYPOPLASTIC CORPUS CALLOSUM, AND DYSMORPHIC FACIES; GDACCF
617268	NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, SEIZURES, AND ABSENT LANGUAGE; NDHSAL
617270	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 58; MRT58
617271	NEPHRONOPHTHISIS 20; NPHP20
617272	GLAUCOMA 3, PRIMARY CONGENITAL, E; GLC3E
617275	TOOTH AGENESIS, SELECTIVE, 9; STHAG9
617276	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 48; EIEE48
617280	ATRIAL FIBRILLATION, FAMILIAL, 18; ATFB18
617281	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 49; EIEE49
617282	DYSTONIA, CHILDHOOD-ONSET, WITH OPTIC ATROPHY AND BASAL GANGLIA ABNORMALITIES; DYTOABG
617284	DYSTONIA 28, CHILDHOOD-ONSET; DYT28
617290	EPILEPSY, EARLY-ONSET, VITAMIN B6-DEPENDENT; EPVB6D
617294	EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED, WITH SCARRING AND HAIR LOSS; EBSSH
617296	SPASTIC PARAPLEGIA, INTELLECTUAL DISABILITY, NYSTAGMUS, AND OBESITY; SINO
617297	AMELOGENESIS IMPERFECTA, TYPE IJ; AI1J
617300	HYDROPS FETALIS, NONIMMUNE, AND/OR ATRIAL SEPTAL DEFECT, SUSCEPTIBILITY TO; HFASD
617301	GLYCINE ENCEPHALOPATHY WITH NORMAL SERUM GLYCINE
617302	OPTIC ATROPHY 11; OPA11
617303	MUCOPOLYSACCHARIDOSIS-PLUS SYNDROME; MPSPS
617304	RETINITIS PIGMENTOSA 77; RP77
617306	COLOBOMA, OSTEOPETROSIS, MICROPHTHALMIA, MACROCEPHALY, ALBINISM, AND DEAFNESS; COMMAD
617308	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 6; CBAS6
617315	ANTERIOR SEGMENT DYSGENESIS 6; ASGD6
617319	ANTERIOR SEGMENT DYSGENESIS 8; ASGD8
617320	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 12; ARCI12
617321	YAO SYNDROME; YAOS
617323	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 59; MRT59
617330	HYPOTONIA, ATAXIA, AND DELAYED DEVELOPMENT SYNDROME; HADDS
617333	INTELLECTUAL DEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND PTOSIS; IDDDFP
617336	NEMALINE MYOPATHY 11, AUTOSOMAL RECESSIVE; NEM11
617337	ECTODERMAL DYSPLASIA 12, HYPOHIDROTIC/HAIR/TOOTH/NAIL TYPE; ECTD12
617339	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 51; EIEE51
617341	CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS 2; CRMCC2
617343	HYPERPARATHYROIDISM 4; HRPT4
617347	HYPERLIPOPROTEINEMIA, TYPE III
617349	AORTIC ANEURYSM, FAMILIAL THORACIC 11, SUSCEPTIBILITY TO; AAT11
617350	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 52; EIEE52
617360	CONGENITAL HEART DEFECTS, DYSMORPHIC FACIAL FEATURES, AND INTELLECTUAL DEVELOPMENTAL DISORDER; CHDFIDD
617364	CONGENITAL HEART DEFECTS AND ECTODERMAL DYSPLASIA; CHDED
617370	PEROXISOME BIOGENESIS DISORDER 10B; PBD10B
617383	AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY, 2; ANFH2
617384	HYPERPHENYLALANINEMIA, MILD, NON-BH4-DEFICIENT; HPANBH4
617388	AUTOINFLAMMATION WITH ARTHRITIS AND DYSKERATOSIS; AIADK
617389	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 53; EIEE53
617391	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 54; EIEE54
617392	ECTODERMAL DYSPLASIA 13, HAIR/TOOTH TYPE; ECTD13
617393	NEURODEVELOPMENTAL DISORDER WITH EPILEPSY, CATARACTS, FEEDING DIFFICULTIES, AND DELAYED BRAIN MYELINATION; NECFM
617394	SCLEROSING CHOLANGITIS, NEONATAL; NSC
617395	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIq; CDG2Q
617396	ANAUXETIC DYSPLASIA 2; ANXD2
617397	PSEUDO-TORCH SYNDROME 2; PTORCH2
617402	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIC; ARCL2C
617403	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IID; ARCL2D
617404	MUSCULAR DYSTROPHY, CONGENITAL, WITH CATARACTS AND INTELLECTUAL DISABILITY; MDCCAID
617405	SHORT-RIB THORACIC DYSPLASIA 17 WITH OR WITHOUT POLYDACTYLY; SRTD17
617406	BARDET-BIEDL SYNDROME 21; BBS21
617408	DIAMOND-BLACKFAN ANEMIA 16; DBA16
617409	DIAMOND-BLACKFAN ANEMIA 17; DBA17
617412	BRACHYCEPHALY, TRICHOMEGALY, AND DEVELOPMENTAL DELAY; BTDD
617425	IMMUNOSKELETAL DYSPLASIA WITH NEURODEVELOPMENTAL ABNORMALITIES; ISDNA
617432	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 60; MRT60
617433	RETINITIS PIGMENTOSA 78; RP78
617435	LOPES-MACIEL-RODAN SYNDROME; LOMARS
617439	CRANIOSYNOSTOSIS 7; CRS7
617441	THROMBOCYTOPENIA, ANEMIA, AND MYELOFIBROSIS; THAMY
617442	PREMATURE OVARIAN FAILURE 13; POF13
617443	BLEEDING DISORDER, PLATELET-TYPE, 21; BDPLT21
617450	INTELLECTUAL DEVELOPMENTAL DISORDER WITH GASTROINTESTINAL DIFFICULTIES AND HIGH PAIN THRESHOLD; IDDGIP
617452	INTELLECTUAL DEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES, SEIZURES, AND DISTAL LIMB ANOMALIES; IDDFSDA
617460	RETINITIS PIGMENTOSA 79; RP79
617466	TOWNES-BROCKS SYNDROME 2; TBS2
617468	ARTHROGRYPOSIS MULTIPLEX CONGENITA, NEUROGENIC, WITH MYELIN DEFECT; AMCNMY
617475	SPECIFIC GRANULE DEFICIENCY 2; SGD2
617478	STRUCTURAL HEART DEFECTS AND RENAL ANOMALIES SYNDROME; SHDRA
617480	46,XX SEX REVERSAL 4; SRXX4
617481	NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, HYPOTONIA, AND VARIABLE BRAIN ANOMALIES; NMIHBA
617493	NEURODEVELOPMENTAL DISORDER WITH INVOLUNTARY MOVEMENTS; NEDIM
617506	NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR 2; NSLH2
617507	PEHO-LIKE SYNDROME; PEHOL
617514	IMMUNODEFICIENCY 52; IMD52
617516	STANKIEWICZ-ISIDOR SYNDROME; STISS
617519	NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, NEUROPATHY, AND DEAFNESS; NEDHND
617520	MICROCEPHALY 18, PRIMARY, AUTOSOMAL DOMINANT; MCPH18
617523	NEURODEVELOPMENTAL DISORDER WITH MIDBRAIN AND HINDBRAIN MALFORMATIONS; NEDMHM
617524	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 2; EKVP2
617525	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 3; EKVP3
617526	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 4; EKVP4
617527	NEURODEVELOPMENTAL DISORDER WITH PROGRESSIVE MICROCEPHALY, SPASTICITY, AND BRAIN ANOMALIES; NDMSBA
617532	INTELLECTUAL DEVELOPMENTAL DISORDER WITH NEUROPSYCHIATRIC FEATURES; IDDNPF
617537	RAHMAN SYNDROME; RMNS
617540	PITUITARY ADENOMA 5, MULTIPLE TYPES; PITA5
617542	GAZE PALSY, FAMILIAL HORIZONTAL, WITH PROGRESSIVE SCOLIOSIS, 2; HGPPS2
617547	RETINAL DYSTROPHY WITH OR WITHOUT MACULAR STAPHYLOMA; RDMS
617557	GABRIELE-DE VRIES SYNDROME; GADEVS
617560	SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY; SPAX8
617561	COHEN-GIBSON SYNDROME; COGIS
617562	MECKEL SYNDROME 13; MKS13
617563	OROFACIODIGITAL SYNDROME XVI; OFD16
617564	MEIER-GORLIN SYNDROME 8; MGORS8
617565	PERRAULT SYNDROME 6; PRLTS6
617571	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 14; ARCI14
617572	EXUDATIVE VITREORETINOPATHY 7; EVR7
617574	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 13; ARCI13
617575	NEPHROTIC SYNDROME, TYPE 14; NPHS14
617576	SPERMATOGENIC FAILURE 18; SPGF18
617577	CILIARY DYSKINESIA, PRIMARY, 37; CILD37
617584	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 25; SCAR25
617585	IMMUNODEFICIENCY 53; IMD53
617591	PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 3; PRAAS3
617592	SPERMATOGENIC FAILURE 19; SPGF19
617593	SPERMATOGENIC FAILURE 20; SPGF20
617595	BIRK-LANDAU-PEREZ SYNDROME; BILAPES
617596	MALEYLACETOACETATE ISOMERASE DEFICIENCY; MAAID
617598	MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 3; MVA3
617599	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 55; EIEE55
617600	MENTAL RETARDATION, AUTOSOMAL DOMINANT 45; MRD45
617601	MENTAL RETARDATION, AUTOSOMAL DOMINANT 46; MRD46
617602	CONGENITAL HEART DEFECTS AND SKELETAL MALFORMATIONS SYNDROME; CHDSKM
617604	MICROCEPHALY, SHORT STATURE, AND LIMB ABNORMALITIES; MISSLA
617605	DEAFNESS, AUTOSOMAL DOMINANT 71; DFNA71
617606	DEAFNESS, AUTOSOMAL DOMINANT 72; DFNA72
617607	AMELOGENESIS IMPERFECTA, TYPE IIIB; AI3B
617609	NEPHROTIC SYNDROME, TYPE 15; NPHS15
617610	POLYCYSTIC KIDNEY DISEASE 5; PKD5
617613	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 5; MMDS5
617616	SKRABAN-DEARDORFF SYNDROME; SKDEAS
617622	JOUBERT SYNDROME 30; JBTS30
617626	FIBROMATOSIS, GINGIVAL, 5; GINGF5
617629	SCHIZOPHRENIA 19; SCZD19
617633	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 26; SCAR26
617635	MENTAL RETARDATION, AUTOSOMAL DOMINANT 47; MRD47
617637	DEAFNESS, AUTOSOMAL RECESSIVE 106; DFNB106
617638	IMMUNODEFICIENCY 11B WITH ATOPIC DERMATITIS; IMD11B
617639	DEAFNESS, AUTOSOMAL RECESSIVE 107; DFNB107
617641	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT SYNDROME WITH OR WITHOUT HEARING LOSS, ABNORMAL EARS, OR DEVELOPMENTAL DELAY; CAKUTHED
617642	POLYDACTYLY, POSTAXIAL, TYPE A7; PAPA7
617643	CEREBELLAR ATROPHY, DEVELOPMENTAL DELAY, AND SEIZURES; CADEDS
617644	SPERMATOGENIC FAILURE 21; SPGF21
617654	DEAFNESS, AUTOSOMAL RECESSIVE 108; DFNB108
617660	VERTEBRAL, CARDIAC, RENAL, AND LIMB DEFECTS SYNDROME 1; VCRL1
617661	VERTEBRAL, CARDIAC, RENAL, AND LIMB DEFECTS SYNDROME 2; VCRL2
617662	JOINT LAXITY, SHORT STATURE, AND MYOPIA; JLSM
617664	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 32; COXPD32
617665	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 56; EIEE56
617666	FRASER SYNDROME 2; FRASRS2
617667	FRASER SYNDROME 3; FRASRS3
617668	ENCEPHALOPATHY, NEONATAL SEVERE, WITH LACTIC ACIDOSIS AND BRAIN ABNORMALITIES; NELABA
617669	ENCEPHALOPATHY, PROGRESSIVE, EARLY-ONSET, WITH BRAIN ATROPHY AND SPASTICITY; PEBAS
617671	HELIX SYNDROME; HELIX
617672	NEURODEGENERATION, CHILDHOOD-ONSET, WITH BRAIN ATROPHY; CONDBA
617675	MYOPATHY, MITOCHONDRIAL, AND ATAXIA; MMYAT
617681	BLEPHAROCHEILODONTIC SYNDROME 2; BCDS2
617682	PILAROWSKI-BJORNSSON SYNDROME; PILBOS
617686	PITUITARY ADENOMA 3, MULTIPLE TYPES; PITA3
617690	OVARIAN DYSGENESIS 5; ODG5
617691	SPINOCEREBELLAR ATAXIA 44; SCA44
617694	AL KAISSI SYNDROME; ALKAS
617695	PONTOCEREBELLAR HYPOPLASIA, TYPE 11; PCH11
617698	3-METHYLGLUTACONIC ACIDURIA, TYPE IX; MGCA9
617706	SPERMATOGENIC FAILURE 22; SPGF22
617707	SPERMATOGENIC FAILURE 23; SPGF23
617709	NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, ATAXIA, AND SEIZURES; NEDMAS
617710	NEURODEVELOPMENTAL DISORDER, MITOCHONDRIAL, WITH ABNORMAL MOVEMENTS AND LACTIC ACIDOSIS, WITH OR WITHOUT SEIZURES; NEMMLAS
617711	EPILEPTIC ENCEPHALOPATHY, INFANTILE OR EARLY CHILDHOOD, 1; IECEE1
617712	OOCYTE MATURATION DEFECT 3; OOMD3
617713	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 33; COXPD33
617717	AUDITORY NEUROPATHY AND OPTIC ATROPHY; ANOA
617718	PLATELET ABNORMALITIES WITH EOSINOPHILIA AND IMMUNE-MEDIATED INFLAMMATORY DISEASE; PLTEID
617719	EPIPHYSEAL DYSPLASIA, MULTIPLE, 7; EDM7
617721	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IX; HMN9
617729	GALLOWAY-MOWAT SYNDROME 3; GAMOS3
617730	GALLOWAY-MOWAT SYNDROME 4; GAMOS4
617731	GALLOWAY-MOWAT SYNDROME 5; GAMOS5
617732	FACIAL PALSY, CONGENITAL, WITH PTOSIS AND VELOPHARYNGEAL DYSFUNCTION; FPVEPD
617743	OOCYTE MATURATION DEFECT 4; OOMD4
617744	IMMUNODEFICIENCY, DEVELOPMENTAL DELAY, AND HYPOHOMOCYSTEINEMIA; IMDDHH
617746	SWEENEY-COX SYNDROME; SWCOS
617749	ACTN3 DEFICIENCY
617751	MENTAL RETARDATION, AUTOSOMAL DOMINANT 48; MRD48
617752	MENTAL RETARDATION, AUTOSOMAL DOMINANT 49; MRD49
617755	NEURODEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND DISTAL LIMB ANOMALIES; NEDDFL
617756	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 5; EKVP5
617757	JOUBERT SYNDROME 32; JBTS32
617760	MYOPATHY, CENTRONUCLEAR, 6, WITH FIBER-TYPE DISPROPORTION; CNM6
617761	JOUBERT SYNDROME 31; JBTS31
617762	LEUKODYSTROPHY, PROGRESSIVE, EARLY CHILDHOOD-ONSET; PLDECO
617763	SHORT STATURE, HEARING LOSS, RETINITIS PIGMENTOSA, AND DISTINCTIVE FACIES; SHRF
617765	IMMUNODEFICIENCY, COMMON VARIABLE, 14; CVID14
617767	JOUBERT SYNDROME 33; JBTS33
617768	KLEEFSTRA SYNDROME 2; KLEFS2
617769	SPINOCEREBELLAR ATAXIA 45; SCA45
617770	SPINOCEREBELLAR ATAXIA 46; SCA46
617771	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 57; EIEE57
617772	DEAFNESS, AUTOSOMAL DOMINANT 34, WITH OR WITHOUT INFLAMMATION; DFNA34
617773	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 61; MRT61
617780	COMBINED IMMUNODEFICIENCY AND MEGALOBLASTIC ANEMIA WITH OR WITHOUT HYPERHOMOCYSTEINEMIA; CIMAH
617781	RETINITIS PIGMENTOSA 80; RP80
617783	NEPHROTIC SYNDROME, TYPE 16; NPHS16
617784	FANCONI ANEMIA, COMPLEMENTATION GROUP W; FANCW
617787	MENTAL RETARDATION, AUTOSOMAL DOMINANT 50; MRD50
617788	MENTAL RETARDATION, AUTOSOMAL DOMINANT 51; MRD51
617796	MENTAL RETARDATION, AUTOSOMAL DOMINANT 52; MRD52
617798	MENTAL RETARDATION, AUTOSOMAL DOMINANT 53; MRD53
617799	MENTAL RETARDATION, AUTOSOMAL DOMINANT 54; MRD54
617800	MICROCEPHALY 19, PRIMARY, AUTOSOMAL RECESSIVE; MCPH19
617802	NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, SEIZURES, AND CORTICAL ATROPHY; NDMSCA
617804	NEURODEVELOPMENTAL DISORDER WITH SEVERE MOTOR IMPAIRMENT AND ABSENT LANGUAGE; NEDMIAL
617805	RENAL HYPODYSPLASIA/APLASIA 3; RHDA3
617807	NEURODEVELOPMENTAL DISORDER WITH ATAXIC GAIT, ABSENT SPEECH, AND DECREASED CORTICAL WHITE MATTER; NDAGSCW
617808	COFFIN-SIRIS SYNDROME 6; CSS6
617809	GELEOPHYSIC DYSPLASIA 3; GPHYSD3
617810	GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 15; GPIBD15
617816	GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 16; GPIBD16
617820	NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT HYPERKINETIC MOVEMENTS AND SEIZURES, AUTOSOMAL RECESSIVE; NDHMSR
617821	EHLERS-DANLOS SYNDROME, ARTHROCHALASIA TYPE, 2; EDSARTH2
617822	ALKURAYA-KUCINSKAS SYNDROME; ALKKUCS
617825	GLUCOCORTICOID DEFICIENCY 5; GCCD5
617827	IMMUNODEFICIENCY 55; IMD55
617829	EPILEPTIC ENCEPHALOPATHY, INFANTILE OR EARLY CHILDHOOD, 2; IECEE2
617830	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 58; EIEE58
617831	MENTAL RETARDATION, AUTOSOMAL DOMINANT 55, WITH SEIZURES; MRD55
617836	DEVELOPMENTAL DELAY AND SEIZURES WITH OR WITHOUT MOVEMENT ABNORMALITIES; DEDSM
617839	AMYOTROPHIC LATERAL SCLEROSIS 23; ALS23
617854	MENTAL RETARDATION, AUTOSOMAL DOMINANT 56; MRD56
617862	NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, EPILEPSY, AND BRAIN ATROPHY; NEDMEBA
617864	NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT SEIZURES AND GAIT ABNORMALITIES; NEDSGA
617865	NEURODEVELOPMENTAL DISORDER WITH MOVEMENT ABNORMALITIES, ABNORMAL GAIT, AND AUTISTIC FEATURES; NEDMAGA
617866	SHORT-RIB THORACIC DYSPLASIA 18 WITH POLYDACTYLY; SRTD18
617871	RETINITIS PIGMENTOSA 81; RP81
617872	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 34; COXPD34
617873	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 35; COXPD35
617874	POLYCYSTIC LIVER DISEASE 3 WITH OR WITHOUT KIDNEY CYSTS; PCLD3
617875	POLYCYSTIC LIVER DISEASE 4 WITH OR WITHOUT KIDNEY CYSTS; PCLD4
617877	SHORT STATURE, FACIAL DYSMORPHISM, AND SKELETAL ANOMALIES WITH OR WITHOUT CARDIAC ANOMALIES; SSFSC
617879	LEBER CONGENITAL AMAUROSIS WITH EARLY-ONSET DEAFNESS; LCAEOD
617882	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE G; CMTDIG
617883	FANCONI ANEMIA, COMPLEMENTATION GROUP S; FANCS
617885	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 19; BMIQ19
617892	AMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 24; ALS24
617895	SHORT-RIB THORACIC DYSPLASIA 19 WITH OR WITHOUT POLYDACTYLY; SRTD19
617898	MULTIPLE SYNOSTOSES SYNDROME 4; SYNS4
617899	LEUKODYSTROPHY, HYPOMYELINATING, 14; HLD14
617900	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 8; IIAE8
617903	NEURODEVELOPMENTAL DISORDER WITH POOR LANGUAGE AND LOSS OF HAND SKILLS; NDPLHS
617904	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 59; EIEE59
617907	ERYTHROCYTOSIS, FAMILIAL, 5; ECYT5
617911	DIAMOND-BLACKFAN ANEMIA-LIKE; DBAL
617912	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 5; CHTD5
617913	NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, CATARACTS, AND RENAL ABNORMALITIES; NEDMCR
617914	MICROCEPHALY 20, PRIMARY, AUTOSOMAL RECESSIVE; MCPH20
617915	HYPOTONIA, ATAXIA, DEVELOPMENTAL DELAY, AND TOOTH ENAMEL DEFECT SYNDROME; HADDTS
617916	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 7; NBIA7
617917	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 8; NBIA8
617920	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 3; PLCA3
617921	AMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 25; ALS25
617924	EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 10; EJM10
617925	SHORT-RIB THORACIC DYSPLASIA 20 WITH POLYDACTYLY; SRTD20
617926	OROFACIODIGITAL SYNDROME XVII; OFD17
617927	OROFACIODIGITAL SYNDROME XVIII; OFD18
617928	KERATOCONUS 9; KTCN9
617929	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 60; EIEE60
617930	CHROMOSOME 1p35 DELETION SYNDROME
617931	SPINOCEREBELLAR ATAXIA 47; SCA47
617933	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 61; EIEE61
617935	EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 4; FFEVF4
617936	BUTYRYLCHOLINESTERASE DEFICIENCY; BCHED
617938	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 62; EIEE62
617941	SHWACHMAN-DIAMOND SYNDROME 2; SDS2
617948	ELLIPTOCYTOSIS 3; EL3
617950	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 36; COXPD36
617951	LEUKODYSTROPHY, HYPOMYELINATING, 15; HLD15
617952	OSTEOGENESIS IMPERFECTA, TYPE XVIII; OI18
617954	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 6; MMDS6
617960	SPERMATOGENIC FAILURE 25; SPGF25
617961	SPERMATOGENIC FAILURE 26; SPGF26
617964	LEUKODYSTROPHY, HYPOMYELINATING, 16; HLD16
617965	SPERMATOGENIC FAILURE 27; SPGF27
617967	HYDROCEPHALUS, CONGENITAL, 3, WITH BRAIN ANOMALIES; HYC3
617971	METHEMOGLOBINEMIA, BETA TYPE
617973	METHEMOGLOBINEMIA, ALPHA TYPE
617974	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, DI ROCCO TYPE; SEMDDR
617976	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 63; EIEE63
617977	NEURODEVELOPMENTAL DISORDER WITH SPASTIC QUADRIPLEGIA AND BRAIN ABNORMALITIES WITH OR WITHOUT SEIZURES; NEDSBAS
617980	ERYTHROCYTOSIS, FAMILIAL, 6; ECYT6
617981	ERYTHROCYTOSIS, FAMILIAL, 7; ECYT7
617982	VERVERI-BRADY SYNDROME; VERBRAS
617983	MICROCEPHALY 21, PRIMARY, AUTOSOMAL RECESSIVE; MCPH21
617984	MICROCEPHALY 22, PRIMARY, AUTOSOMAL RECESSIVE; MCPH22
617985	MICROCEPHALY 23, PRIMARY, AUTOSOMAL RECESSIVE; MCPH23
617988	JABERI-ELAHI SYNDROME; JABELS
617991	DEVELOPMENTAL DELAY, INTELLECTUAL DISABILITY, OBESITY, AND DYSMORPHIC FEATURES; DIDOD
617992	DEAFNESS, CONGENITAL HEART DEFECTS, AND POSTERIOR EMBRYOTOXON; DCHE
617993	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 2; HFTC2
617995	IMPDH2 ENZYME ACTIVITY, VARIATION IN; IMPDH2V
618000	EHLERS-DANLOS SYNDROME, CLASSIC-LIKE, 2; EDSCLL2
618004	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 64; EIEE64
618005	CONGENITAL DISORDER OF GLYCOSYLATION WITH DEFECTIVE FUCOSYLATION; CDGF
618006	LEUKODYSTROPHY, HYPOMYELINATING, 17; HLD17
618007	NEURODEVELOPMENTAL DISORDER WITH BRAIN, LIVER, AND LUNG ABNORMALITIES; NEDBLLA
618008	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 65; EIEE65
618010	GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 17; GPIBD17
618011	HYPEREKPLEXIA 4; HKPX4
618012	EPILEPTIC ENCEPHALOPATHY, INFANTILE OR EARLY CHILDHOOD, 3; IECEE3
618013	DEAFNESS, AUTOSOMAL RECESSIVE 109; DFNB109
618014	PREMATURE OVARIAN FAILURE 14; POF14
618015	PROTOPORPHYRIA, ERYTHROPOIETIC, 2; EPP2
618018	DRUG METABOLISM, ALTERED, CYP2C8-RELATED
618019	PELGER-HUET ANOMALY WITH MILD SKELETAL ANOMALIES; PHASK
618021	TETRAAMELIA SYNDROME 2; TETAMS2
618022	HUMEROFEMORAL HYPOPLASIA WITH RADIOTIBIAL RAY DEFICIENCY; HHRRD
618027	COFFIN-SIRIS SYNDROME 7; CSS7
618031	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 4; PPCD4
618036	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2DD; CMT2DD
618048	PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 2; PRAAS2
618049	PARKINSONISM-DYSTONIA, INFANTILE, 2; PKDYS2
618050	MENTAL RETARDATION, AUTOSOMAL DOMINANT 57; MRD57
618056	NEURODEVELOPMENTAL DISORDER WITH CEREBELLAR ATROPHY AND WITH OR WITHOUT SEIZURES; NEDCAS
618057	DRUG METABOLISM, ALTERED, CES1-RELATED
618060	INTELLECTUAL DEVELOPMENTAL DISORDER WITH OR WITHOUT EPILEPSY OR CEREBELLAR ATAXIA; IDDECA
618061	POLYCYSTIC KIDNEY DISEASE 6 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD6
618063	CILIARY DYSKINESIA, PRIMARY, 38; CILD38
618065	PONTOCEREBELLAR HYPOPLASIA, TYPE 1D; PCH1D
618067	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 66; EIEE66
618074	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 6; FAME6
618075	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 7; FAME7
618076	NEURODEVELOPMENTAL DISORDER WITH SPASTICITY AND POOR GROWTH; NEDSG
618077	INFLAMMATORY BOWEL DISEASE 29; IBD29
618078	OVARIAN DYSGENESIS 6; ODG6
618079	LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 8; LDLCQ8
618084	PEELING SKIN SYNDROME 6; PSS6
618086	SPERMATOGENIC FAILURE 28; SPGF28
618087	SPINOCEREBELLAR ATAXIA 42, EARLY-ONSET, SEVERE, WITH NEURODEVELOPMENTAL DEFICITS; SCA42ND
618088	NEURODEVELOPMENTAL DISORDER WITH REGRESSION, ABNORMAL MOVEMENTS, LOSS OF SPEECH, AND SEIZURES; NEDAMSS
618089	INTELLECTUAL DEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND BEHAVIORAL ABNORMALITIES; IDDFBA
618090	NEURODEVELOPMENTAL DISORDER WITH EPILEPSY AND HYPOPLASIA OF THE CORPUS CALLOSUM; NEDEHCC
618091	SPERMATOGENIC FAILURE 29; SPGF29
618094	DEAFNESS, AUTOSOMAL RECESSIVE 110; DFNB110
618096	PREMATURE OVARIAN FAILURE 15; POF15
